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RIASSUNTO 
 
 
Acidi nucleici ricchi di guanine possono formare una particolare struttura secondaria nota 
come G-quadruplex, il quale è implicato nella regolazione di importanti processi biologici a 
livello del genoma umano, di procarioti e virus. 
Dato che il genoma dell’herpes simplex virus-1 (HSV-1) è notevolmente ricco in guanine, il 
nostro studio è stato mirato all’individuazione di sequenze virali in grado di foldare in G-
quadruplex e, in secondo luogo, alla possibilità di colpire selettivamente questa 
conformazione non-canonica con specifiche molecole chimiche, al fine di sviluppare una 
terapia antivirale innovativa. 
Il nostro studio dimostra la presenza di sei gruppi composti da sequenze altamente ripetute 
capaci di formare strutture G-quadruplex particolarmente stabili. Queste sequenze sono state 
individuate a livello delle regioni terminali del genoma di HSV-1 e all’interno di due regioni 
codificanti (geni ICP0 e UL36). Un cluster di sequenze G-quadruplex, inoltre, è situato nella 
regione promotoriale deputata all’espressione della proteina multifunzionale γ134.5. 
Il trattamento di cellule infettate con BRACO-19 e TMPyP4 ha mostrato una significativa 
inibizione di HSV-1 e una riduzione dell’espressione di alcuni trascritti virali. 
BRACO-19 si è dimostrato efficace nell’inibire l’elongazione di regioni G-quadruplex del 
genoma di HSV-1, da parte dell’enzima Taq; è stato in grado di diminuire il DNA virale 
intracellulare, opportunamente estratto da cellule infettate e trattate; inoltre, mentre nessun 
effetto è stato osservato sull’entry di HSV-1, l’ultimo step del ciclo virale inibito da BRACO-
19 corrisponde alla replicazione del DNA virale.  
Un diverso meccanismo d’azione è stato, invece, osservato in seguito al trattamento con 
TMPyP4. Nonostante questa porfirina sia riuscita ad inibire l’attività della Taq, non è riuscita, 
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al contrario, ad influenzare i livelli di DNA virali intracellulari. TMPyP4 sembra essere 
efficace nell’inibire la maturazione/uscita di HSV-1, attraverso un’induzione dell’autofagia. 
In una seconda parte dello studio, abbiamo esteso questa promettente strategia antivirale 
all’herpes virus umano 6 (HHV-6), il quale presenta una caratteristica molto peculiare. Ad 
entrambe le estremità del suo genoma (DR) contiene, infatti, numerose ripetizioni della 
sequenza telomerica umana (TTAGGG)n. Questa caratteristica è ritenuta responsabile 
dell’integrazione di HHV-6 in alcuni cromosomi umani (1-2% della popolazione). 
Ad oggi, la struttura G-quadruplex della sequenza telomerica è stata studiata in dettaglio e 
completamente caratterizzata. Abbiamo, quindi, testato BRACO-19 e TMPyP4 su cellule 
infettate sia con HHV-6A che HHV-6B, ottenendo anche in questo caso dei risultati molto 
incoraggianti. 
Infine, in una terza parte del lavoro, è stato possibile visualizzare per la prima volta G-
quadruplex virali a livello del DNA in cellule infettate, grazie all’impiego di anticorpi ad alta 
affinità per questa struttura. La specificità di segnale è data dal fatto che l’incremento di 
fluorescenza è avvenuto nel corso della replicazione virale in cui il DNA è presente come 
singolo filamento. 
Questo lavoro, oltre a mostrare l’esistenza di estese regioni G-quadruplex in siti chiave del 
genoma di HSV-1 e HHV-6, mette in luce le potenzialità del G-quadruplex come target 
innovativo in terapie antivirali nuove e mirate, basate sull’impiego di leganti specifici per 
questa particolare conformazione secondaria del DNA. 
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ABSTRACT 
 
Guanine-rich nucleic acids can fold into G-quadruplexes, four-stranded secondary structures 
which are implicated in important regulatory functions at the genomic level in humans, 
prokaryotes and viruses. Because the herpes simplex virus-1 (HSV-1) genome is remarkably 
rich in guanines, we aimed at investigating both the presence of G-quadruplex forming 
sequences at the viral genome level and the possibility to target them with G-quadruplex 
ligands to obtain anti-HSV-1 effects with novel mechanisms of action.  
Here we show that HSV-1 displays six clusters of repeated sequences that form very stable G-
quadruplexes. These sequences are located in the inverted repeats and in two gene-coding 
regions (ICP0 and UL36) of the HSV-1 genome. One G-quadruplex repeat is located in the 
promoter region of the multifunctional protein γ134.5.  
Treatment of HSV-1 infected cells with the G-quadruplex ligands BRACO-19 and TMPyP4 
induced significant inhibition of virus production and reduction of viral transcripts. BRACO-
19 was able to inhibit Taq polymerase processing at G-quadruplex forming sequences in the 
HSV-1 genome, and caused a decreased intracellular viral DNA in infected cells. The last step 
targeted by BRACO-19 was viral DNA replication, while no effect on virus entry in the cells 
was observed. A different TMPyP4-mediated mechanism of action was on the contrary 
observed. Despite its capability to affect Taq polymerase processing, TMPyP4 did not inhibit 
intracellular viral DNA and it appeared to prevent HSV-1 maturation/egress by stimulating 
the autophagy process. 
As a second part of the study, we extended this innovative antiviral approach to human herpes 
virus-6 (HHV-6). One of the main HHV-6 features is the presence of tandem repeats of the 
telomeric sequence (TTAGGG)n at the genome termini (DR). This peculiarity is thought to be 
responsible for the viral integration in specific human chromosomes, occurring in the 1-2% of 
the world population. To date, the telomeric G-quadruplex structure had been extensively 
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characterized. We showed that BRACO-19 and TMPyP4 displayed a great antiviral activity 
against both HHV-6A and HHV-6B. 
In the third part of this study, by using specific DNA G-quadruplex-interacting antibodies, for 
the first time we visualized viral DNA G-quadruplexes in infected cells at crucial time points 
for the viral replication cycle, in which viral DNA is likely in a single-stranded state.  
This work, besides presenting the first evidence of extended G-quadruplex sites in key regions 
of the HSV-1 and HHV-6 genomes, points out G-quadruplexes as innovative potential 
antiviral targets in novel therapeutic interventions, based on the use of G-quadruplex ligands. 
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1  INTRODUCTION 
 
1.1 G-QUADRUPLEX 
The predominant structure adopted by the DNA is the double-helix, in which two 
complementary strands are held together by Watson–Crick base pairs (Figure 1.1.1a). 
However, DNA sequences can not only fold into the canonical duplex helix (B-DNA) but 
they can also form more than ten different types of non-B DNA structures under particular 
conditions, such as left-handed hairpin, Z-DNA, A-motif, triplex, tetraplex as G-quadruplex 
and i-motif (Zhang, et al., 2014). 
G-Quadruplexes are non-canonical higher-order nucleic acid secondary structures formed 
from G-rich DNA and RNA sequences. Although the unusual ability of guanine-rich DNA 
solutions to form gelatinous aggregates was first noted in 1910 (Bang, 1910), their exact 
nature was not discovered until 1962. In fact, the first proof of the guanine (G) self-
association called G-quadruplex was reported by Davies and co-worker in 1962 (Gellert, et 
al., 1962).  
The existence of G-quadruplex was confirmed in several organisms such as bacteria, yeasts, 
in human telomere and genome as well as viruses. Most importantly, in the recent years their 
biological functions, presence in mammalian living cells and their stabilization by G-
quadruplex ligands have been extensively demonstrated (Biffi, et al., 2013), (Henderson, et 
al., 2013). The formation of these particular structures can interfere with the biology that is 
crucial to sustain cellular homeostasis and metabolism via mechanisms that include 
transcription, translation, splicing, telomere maintenance and DNA recombination (Di 
Antonio, et al., 2012). Thus, the prospect of using G-quadruplex structures as novel targets for 
drug design, in the treatment of various disorders such as cancer and viral infections, is very 
attractive.  
 
1.1.1 G-quadruplex general features 
Guanine-rich nucleic acids can fold into non-canonical DNA secondary structures called G-
quadruplexes. Guanine bases display the capability to self-associate through Hoogsteen 
hydrogen bonds to form planar G-quartets (also named G-tetrads), which are the building 
block of G-quadruplex (Figure 1.1.2a,b). Two or more G-quartets can stack on top of each 
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other to form the tetraplex G-quadruplex structure (Figure 1.1.1b). The sequences intervening 
between successive G-tracts, serving as links between G-quartets, are known as loops. 
 
 
Figure 1.1.1 Representation of a) duplex DNA and b) G-quadruplex DNA structures (Ou, et al., 2008). 
 
The formation of such guanine based supramolecular assemblies is particularly favored under 
physiological conditions, with respect to pH and the presence of alkali cations (Na
+
 and K
+
) 
(Di Antonio, et al., 2012). In fact, there is a strong negative electrostatic potential created by 
the guanine O6 oxygen atoms, which form a central channel of the G-tetrad stack, with the 
cations located within this channel (Figure 1.1.2a,e).  
Cations, such as Na
+
 and K
+
, can neutralize the electrostatic repulsions in the G-4 core. 
Moreover, because of their different size, the precise location of cations between the tetrads is 
dependent on the nature of the ion: Na
+
 ions are positioned mainly in the plane of the G-
tetrads, whereas K
+
 ions are usually tetrad plane-equidistant, consequently forming a 
tetragonal bipyramidal configuration (Figure 1.1.2e) (Burge, et al., 2006).  
Introduction 
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Figure 1.1.2 Representation of a G‐quartet. a, b) A G‐quartet structure formed by four coplanar guanines, each 
guanine is shown as a rectangle. c, d) Guanines in anti (pentoses as a grey ellipse) and syn (pentoses as a white 
ellipse) glycosidic conformations. (Zhang, et al., 2014). e) Monovalent cation location (K
+
) in a G‐quadruplex 
ion channel. (Ou, et al., 2008). 
 
1.1.2 G-quadruplex polymorphism and topologies 
G-quadruplex structures exhibit extensive structural diversity and polymorphism. In general, 
structural polymorphism arises mostly from the following factors: number of strands and 
orientation, G-tetrads number and composition, anti/syn glycosidic torsion of guanines, 
dimension of the four grooves and nature of the loops (Ou, et al., 2008) (Zhang, et al., 2014). 
 
 
Figure 1.1.3 Different G-quadruplex topologies depending on the number of strands involved in the G-
quadruplex formation: tetramolecular, bimolecular and monomolecular G-quadruplexes are represented. 
 
First, depending of the number of strands three principal categories of quadruplex 
arrangement are possible (Zhang, et al., 2014) (Figure 1.1.3): 
1. Monomolecular (or unimolecular or intramolecular): composed by one strand 
which forms four consecutive G-tracts 
2. Bimolecular: formed by two strands, each normally having two G-tracts 
Introduction 
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3. Tetramolecular: given by four separate strands associating together, in which each 
strand shows a minimum of one G-tract. 
Second, each G-quadruplex displays four parallel- or antiparallel- stranded G-tracts (or legs, 
Figure 1.1.4a–d). The orientation of adjacent legs may be parallel or antiparallel, this feature 
is related to the conformation of the guanine glycosidic torsion angles. Parallel G-
quadruplexes have all guanines in an anti conformation, which implies that the four strands 
are parallel to each other (Figure 1.1.4a); antiparallel G-quadruplexes have both syn and anti 
guanines, consequently at least one of the four legs is antiparallel to the others (Figure 1.1.4b–
d) (Zhang, et al., 2014).  
 
 
Figure 1.1.4 Scheme of four different G‐quartets and three types of loops. a) Parallel G‐quartet with an external 
loop. b) Hybrid/mixed G‐quartet (3+1) and a lateral loop. c, d) Antiparallel G‐quartets showing a diagonal loop 
(c) or a lateral loop (d). Arrows indicate 5′ to 3′ direction; N, M, and W represent narrow, medium, and wide 
grooves, respectively (Zhang, et al., 2014). 
 
Each G-quadruplex contains a G-tetrad core that consists of at least two stacked G-tetrads. 
Based on the strand orientation, G-quartets show four possible conformations (Zhang, et al., 
2014): 
 Four strands in the same direction, and all guanines in an anti conformation 
(parallel G-quartet, Figure 1.1.4a) 
 Three strands in the same direction and the fourth leg in an opposite direction, thus 
G-tetrads adopt anti-anti-anti-syn and syn-syn-syn-anti alignments (3+1 G-quartet, 
alternatively known as hybrid/mixed G-tetrad core) (Figure 1.1.4b) 
 Two adjacent strands in the same direction and the remaining two legs in the 
opposite direction; all G-tetrads adopt a syn-syn-anti-anti conformation (Figure 
1.1.4c) 
 Two diagonally opposite strands in the same direction and the two other diagonally 
opposite legs in the opposite direction; all G-quartet adopt an anti-syn-anti-syn 
alignment (Figure 1.1.4d). 
Moreover, loop regions can arrange in a number of distinct ways, so that a variety of 
quadruplex topologies can be formed. The loops can be classified into three major types 
(Zhang, et al., 2014):   
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 External loop (also named double-chain-reversal loop or propeller-type loop), 
which connects adjacent parallel strands (Figure 1.1.4a)  
 Lateral loop (or edgewise loop), which connects adjacent antiparallel strands 
(Figure 1.4b,d)  
 Diagonal loop, which connects diagonally opposite antiparallel strands (Figure 
1.1.4c)  
An additional structural feature differentiating between G-quadruplex and double helix DNA 
is represented by the four grooves (Figure 1.1.5a,b). In a G-quartet, there are at most three 
dimensions of grooves formed from two adjacent guanines (Zhang, et al., 2014):  
 Medium grove: formed by two anti or two syn guanines (Figure 1.1.5a)  
 Narrow groove: given by an anti and a syn guanine which is perpendicular to the 
anti guanine (Figure 1.1.5a,b)  
 Wide groove: formed by an anti guanine perpendicular to a syn guanine (Figure 
1.1.5a,b). 
 
 
Figure 1.1.5 Scheme of different groove types within G-quartets. a) G-quartet formed from two pairs of adjacent 
parallel strands, having a narrow, a wide and two medium grooves. b) G-tetrad core composed by two pairs of 
diagonally opposite antiparallel strands, showing two narrow and two wide grooves. (Zhang, et al., 2014). 
 
1.1.3 G-quadruplex as a drug target  
In recent years, mounting evidence has indicated that G-quadruplexes formed in telomeric 
ends and oncogenic promoter regions play an important role in DNA replication, 
transcriptional regulation, and genome stability. These studies suggest that G-quadruplexes 
have a potential as drug targets. Hence, many scientists have refocused their research on 
seeking small molecular inducers and stabilizers of G-quadruplexes (Zhang, et al., 2014).   
A structure-based design and synthesis approach has been generally adopted to develop new 
G-quadruplex-interacting lead compounds. In fact, the particular geometry of the G-
quadruplex structure is thought to allow specific recognition by small ligands through various 
Introduction 
10 
 
binding modes in a manner analogous to that of double-helical DNA intercalators (Ou, et al., 
2008). One of these G-4 peculiarities is the wide aromatic planar ring exhibited by G-quartets, 
in addition this wide aromatic surface generally possesses sites that can be protonated, thus 
improving the water solubility of the G-quadruplex ligands. 
To date, numerous groups of compounds were identified and their binding to G-quadruplex 
extensively studied (Han, et al., 2001),  however the exact interaction mode remained in some 
cases undefined in vitro (Ou, et al., 2008). Several interactions occurring between G-
quadruplex and G-4-ligand have been identified (Figure 1.1.6): 
 intercalation between G-tetrads  
 stacking on the terminal G-tetrads (known as external stacking) 
 groove binding mode 
 combination of two or more of the previous binding modes.  
Ligands with a wide planar aromatic surface interact with the G-quadruplexes mainly through 
π-π stacking on the terminal G-quartets and less through intercalating into the G-tetrads. The 
intercalation on the outer planes of G-quartets is poorly favored because of the highly stable 
and rigid G-quadruplex structure, which disruption requires an extremely high energy. 
Electrostatic interactions between cationic ligands and the anionic central backbone of G-
quadruplex are very important to improve their binding affinity (Ou, et al., 2008). Ligands 
containing amino groups and (or) side chains can interact with the grooves, loops, and the 
negatively charged phosphate backbone of the G-quadruplexes. In fact, the amino groups 
become positively charged by protonation or methylation, which may result in better 
recognition and stronger binding to the grooves as well as to the negatively charged phosphate 
backbone through electrostatic interactions (Ou, et al., 2008) (Zhang, et al., 2014).  
G-quadruplex ligands are differently classified depending on their chemical features: 
 Anthraquinons 
 Acridine analogues 
 Porphyrins 
 Quindoline and quinacridine analogues 
 Telomestatin 
 Naphthalene diimmides 
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Figure 1.1.6 G-quadruplex ligand binding mode representation: on the left, an external stacking on the surface of 
the terminal quartet; in the middle, an intercalation between the tetrads and a groove binding mode on the right 
(Ou, et al., 2008). 
 
1.1.3.1 Anthraquinones 
The first developed anthraquinone was BSU-1051 (Figure 1.1.7), a 2,6-disubstituted 
aminoalkylamido anthraquinone with a telomerase inhibitory value (
tel
IC50) of 23 µM. This 
group of G-quadruplex ligands interacts with the G-tetrads through π- π stacking. A series of 
2,7-fluorenone (2,7-FO) analogues (Figure 1.1.7)were designed to reduce the cytotoxicity and 
improve the inhibitory effect against telomerase. The most potent compounds showed an 
tel
IC50 of 8-12 µM, with a 2-10 fold cytotoxicity decrease on several human-tumor-derived 
cell lines (Ou, et al., 2008). 
 
 
Figure 1.1.7 Chemical structures of anthraquinone analogues.  
 
1.1.3.2 Acridines 
The complementarity between negative electrostatic potential of G-quadruplexes and 
positively charged ring of small molecules was the impetus for the discovery of a new series 
of chromophore better known as acridines. 3,6-disubstituted and 3,6,9-trisubstituted acridines 
were developed. 
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Figure 1.1.8 Chemical structures of some acridine analogues. a) the 3,6,9-trisubstituted acridine BRACO-19, b) 
the pentacyclic acridine RHPS4 and c) BSU-6039. 
 
The 3,6-disubstituted analogues show approximately the same binding constant for duplex 
and quadruplex DNA. Furthermore, because of the weak basicity of the ring nitrogen atom for 
the poor electron-donating effect of the 3,6-bisamido groups, disubstituted acridines do not 
exhibit a higher inhibitory activity toward telomerase in comparison with the analogous 2,7-
bisamidoanthraquinones (Ou, et al., 2008). On the contrary, the 3,6,9-trisubstituted acridines 
display a telomerase inhibitory activity in the range of 10–20 nM and they selectively bind to 
quadruplex DNA with 30–40-fold greater affinity over the duplex. BRACO-19 and RHPS4 
are probably  the most renown trisubstitued acridine, both entered in a preclinical 
development stage (Figure 1.1.8a,b) (Ou, et al., 2008). 
Acridines mainly interact with the G-quadruplex grooves: the two substituent amido chains 
lies in the two widest grooves, the anilino group at the 9-position of the acridine fits into a 
third groove in this model, and the 9-substituent enhances the basicity of the acridine central 
ring nitrogen atom.  
RHPS4 (Figure 1.1.8b), a pentacyclic acridine 3,11-difluoro-6,8,13-trimethyl(8H)-
quino[4,3,2-kl]acridinium methylsulfate, is a potent telomerase inhibitor, it inhibits cell 
proliferation within 2-3 weeks at non-cytotoxic concentrations with an 
tel
IC50 of 0.33 µM.  
BRACO-19 (Figure 1.1.8a), a 9-[4-(N,N-dimethylamino)phenylamino]-3,6-bis(3-
pyrrolodino-propionamido) acridine, efficiently stabilizes telomeric G-quadruplexes and acts 
as a strong telomerase inhibitor (Kim, et al., 1994), (Burger, et al., 2005). 
The novel acridine derivative BSU-6030 (Figure 1.1.8c) interacts with the G-quadruplex in a 
1:1 stoichiometry, showing a 70-100 fold greater selectivity than  BRACO-19 (Figure 1.1.8a). 
The acridine ring stacks on one terminal G-tetrad of the G-quadruplex and interacts with the 
T4 loop of the sequence d(G4T4G4) by forming intermolecular hydrogen bonds with the 
thymine residues of the loop (Zhang, et al., 2014).  
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1.1.3.3 Telomestatin 
Telomestatin (SOT-095) (Figure 1.1.9a) is the most interesting neutral macrociclyc G-
quadruplex ligand, it is one of the most efficient in vitro telomerase inhibitor with an 
tel
IC50 
value of 5 nM.  
 
 
Figure 1.1.9 Chemical structures of some G-quadruplex ligands. a) Telomestatin, two telomestatin-analogues b) 
HXDV and c) bistrioxazole acetate. d) The perylene derivative PIPER. 
 
Telomestatin is a natural small molecule consisting of seven oxazole rings and one thiazoline 
ring, normally isolated from the actinomycete Streptomyces anulatus 3533-SV4. It appears to 
interact preferentially with intramolecular G-quadruplexes rather than intermolecular 
quadruplexes, in addition it shows a 70-fold stronger binding affinity for G-quadruplex over 
duplex DNA (Ou, et al., 2008).  
The main disadvantage of this G-quadruplex ligand is related to the very hard synthesis that 
has been recently reported (Doi, et al., 2006). Since then, some synthetic derivatives of 
telomestatin such as macrocyclic hexaoxazole (HXDV) (Figure 1.1.9b) and bistrioxazole 
acetate have been developed (Figure 1.1.9c). 
 
1.1.3.4 Perylenes 
PIPER is a polycyclic compound showing a perylene skeleton (Figure 1.1.9d). PIPER is an 
effective telomerase inhibitor, with an 
tel
IC50 value which lies in the low-µM range. It binds to 
a variety of G-quadruplex structures with ligand/G-quadruplex stoichiometries of 1:2, 1:1, 
and 2:1, depending on the sequence of the G-4 DNA. PIPER appears to be able to perform 
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chaperone-like functions, capable of accelerating the assembly of G-quadruplex structures in 
a cell-free system (Ou, et al., 2008).  
As mentioned above, the G-quadruplex is an extremely stable and rigid structure. The 
distortion of its integrity, necessary for intercalation of ligands within G-tetrads, should 
involve a very high energy cost (Hurley, 2000). For this reason, stacking of PIPER on the 
outer planes of G-quartets appears to be an energetically more plausible alternative. 
 
1.1.3.5 Porphyrins 
N-Methylated ligands, with a central aromatic ring in which four methylated nitrogen groups 
are located at the four corners of the aromatic surface, have been extensively used as G-
quadruplex ligands. Their lower electron density improves the water solubility and π-stacking 
capability. TMPyP4, a (tetra-(N-methyl-4-pyridyl) porphyrin (Figure 1.1.10a), is 
representative of porphyrins family, it can inhibit telomerase activity and down-regulate the 
expression of oncogenes such as c-myc.  
It has been extensively demonstrated that the planar arrangement of the aromatic rings in 
porphyrins bind to G-quadruplexes by stacking externally on the G-quartets, rather than by 
intercalating between G-tetrads. Porphyrins bind to and stabilize both parallel and antiparallel 
G-quadruplex structures, but with only twofold greater affinity for G-quadruplex over duplex 
DNA.  
TMPyP4 was proved to inhibit telomerase by interacting with G-quadruplexes: the ligand/G-
quadruplex binding occurs by stacking either on part of the external TTA loop structure in the 
telomere or at 5’ region of the stacked quadruplex. The stacking interactions of TMPyP4 with 
the quadruplex involve the hydrogen bonded base pairs that are not involved in the formation 
of G-tetrads, thus precluding direct ligand interactions with the G-tetrads. This is consistent 
with the lower selectivity of TMPyP4 for quadruplex DNAs over duplex DNA (Ou, et al., 
2008).  
A complex between TMPyP4 and a parallel G-quadruplex formed in the c-myc promoter 
revealed that TMPyP4  stacks on one terminal G-tetrad of the G-quadruplex (Zhang, et al., 
2014).  
Differently the TMPyP4 conformational isomer, TMPyP2, a (tetra-(N-methyl-2-pyridyl) 
porphyrin with a N-methyl groups in the sterically hindered 2-position (Figure 1.1.10b), 
shows very weak activity (Ou, et al., 2008). Therefore, TMPyP2 is commonly considered a 
porphyrin with a much lower G-quadruplex binding affinity. Comparative studies using tumor 
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cell lines demonstrated that TMPyP4 has a greater slowing effect on cell growth than 
TMPyP2. TMPyP4 also induces anaphase chromosomal bridges in sea urchins, whereas 
TMPyP2 does not. This result indicates that G4-interactive compounds might target the 
telomeres directly inside cells (Han & Hurley, 2000). 
 
 
Figure 1.1.10 Porphyrin and derivatives. a) TMPyP4, b) TMPyP2, c) Mn(III) porphyrin and d) Se2SAP. 
 
To overcome the restricted selectivity and better differentiate between G-4 over duplex DNA, 
a Mn(III) porphyrin composed by a central porphyrin ring and four flexible arms carrying 
methylated nitrogen groups was designed to target G-quadruplexes (Figure 1.1.10c). Mn(III) 
porphyrin exhibited both high affinity and excellent selectivity for G-quadruplexes. The 
complex between Mn(III) porphyrin and the human G-quadruplex telomere showed that the 
porphyrin ring was stacked on the terminal G-tetrads and the four flexible arms interacted 
with the grooves (Zhang, et al., 2014).  
To achieve higher therapeutic selectivity for G-quadruplexes, it is necessary to design drugs 
that can discriminate different types of G-quadruplexes. To this end, a core-modified 
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expanded porphyrin analogue, Se2SAP (5,10,15,20-[tetra(N-methyl-3-pyridyl)]-26,28-
diselenasapphyrin chloride), was synthesized (Ou, et al., 2008) (Figure 1.1.10d). 
 
1.1.3.6 Other G-quadruplex ligands 
Other small molecules can efficiently bind to G-quadruplex structures and further stabilize 
them. As described above, the size and shape of grooves discriminate between quadruplex and 
duplex DNA. These differences, resulting in a different binding site for the ligands, are used 
for a rational design of new selective compounds. 
Non-planar alkaloids may represent a new class of G-quadruplex binders and, more 
importantly, that planar aromatic systems may not be essential groups for G-quadruplex 
ligands in some cases. This evidence is suggested by two novel G-quadruplex ligands, 
peimine (Figure 1.1.11a) and peiminine (Figure 1.1.11b), with non-planar aromatic structures. 
This new family of ligands displays high affinity for the grooves of parallel G-quadruplexes 
and also high selectivity for G-quadruplexes over duplex DNA. Both peimines and 
peiminines bind to the grooves through electrostatic interactions with a stoichiometry of 2:1.  
 
 
Figure 1.1.11 Chemical structures of a) peimine, b) peiminine and c) a naphthalene diimmide core. 
 
A promising class of G-quadruplex ligands is represented by naphthalene diimmides (NDI) 
(Figure 1.1.11c). Among the 1,4,5,8-naphthalene tetracarboxylic diimides analogues, tri- and 
tetra-substituted NDIs show interesting G-quadruplex binding properties (Cuenca, et al., 
2008). The chemical synthesis of NDIs permits to introduce up to four different side chains 
within the ND core, resulting in the design and development of new topology-selective G-
quadruplex ligands. Moreover, NDIs with an extended core fused to 1,4-dihydropyrazine-2,3-
dione, figured out as promising G-quadruplex ligands with an anticancer activity against 
different human telomerase-positive cell lines (Doria, et al., 2012). 
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1.1.4 The biological role of G-quadruplex 
G-quadruplexes have been extensively studied in vitro and increasing evidences suggest a key 
biological role of the tetraplex structures in vivo (Biffi, et al., 2013), (Henderson, et al., 2013).  
It has been estimated that more than 300,000 distinct sites in the human genome have 
potential to fold in a G-quadruplex structure, suggesting an important role of these structures 
in regulating crucial biological processes (Huppert & Balasubramanian, 2005).  
 
 
Figure 1.1.12 The six hallmarks of cancer, first proposed by Hanahan and Weinberg (Hanahan & Weinberg, 
2000), here shown in association with the G-quadruplexes found in the promoter regions of these genes (Brooks, 
et al., 2010). 
 
G-quadruplex DNA is a dynamic structure. Theoretically, the folding of a G-quadruplex DNA 
may initiate either from duplex or from single-stranded DNA, although it can mostly form in 
single-stranded G-rich sequences (Lopes, et al., 2011). Therefore, its formation depends on 
denaturation of the duplex, as occurs during replication, transcription or recombination 
(Maizels, 2006).  
When DNA replication occurs, a replicative helicase divides the leading and lagging strands, 
this allows the DNA synthesis. During this process, there is a transient single-stranded DNA, 
which provides opportunities for a G-quadruplex formation (Figure 1.1.13a). Moreover, it has 
been reported that the G-quadruplex formation occurs mainly in the lagging strand template, 
that it is discontinuously replicated, triggering fork pausing and instability (Lopes, et al., 
2011). A large number of natural proteins have been found to specifically interact with G-
quadruplex structures (Wu & Brosh, 2010).   
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In vitro several DNA helicases, such as the mammalian BLM (Bloom syndrome protein) and 
WRN (Werner’s syndrome protein) RecQ orthologues, PIF1, and FANCJ (Fanconi anaemia 
group J protein) unwind G-quadruplex structures (Maizels, 2006). PIF1 helicases was 
reported to specifically bind to G-quadruplex and efficiently unwind it (Figure 1.1.13b) 
(Sanders, 2010), (Mirkin, 2013). 
 
 
Figure 1.1.13 a) During DNA replication, replicative DNA helicases unwind the two strands into a leading- and 
a lagging-strand template to form a replication fork. b) PIF1 helicases was reported to efficiently unwind G-
quadruplexes, allowing replication to progress past this obstacle (Mirkin, 2013). 
 
The first biologically relevant G-quadruplex formation was observed in telomeric DNA (Yang 
& Okamoto, 2010). G-quadruplex potential folding sequences also occur in different regions 
of the human genome, such as oncogene promoters (Figure 1.1.12), ribosomal DNA, mini-
satellites and the immunoglobulin heavy chain switch region (Ou, et al., 2008). Therefore, G-
quadruplex is considered a very interesting innovative target in selective anticancer strategies. 
 
1.1.4.1 Telomeres and cell proliferation potential 
Telomeres, first described by Hermann Muller in 1938, are very unique structures. Muller 
coined the term “telomere” which comes from Greek, telos meaning end and meros meaning 
part (Bailey & Murnane, 2006).  
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Figure 1.1.14 Human telomeres consist of (TTAGGG)n hexanucleotide repeats, with a G-rich leading strand and 
a C-rich lagging strand. The G-rich strand extends in the 3’ direction, forming the G-tail. The shelterin complex 
is also shown (O'Sullivan & Karlseder, 2010). 
 
Telomeres are non-coding DNAs located at the termini of linear eukaryotic chromosomes. 
They serve multiple functions in preserving chromosome stability, including protecting the 
ends of chromosomes from degradation and preventing chromosomal end fusion. In fact, the 
broken ends of chromosome can fuse end to end, leading to ring, dicentric or other unstable 
chromosome forms (Blackburn, 1991). 
 
 
Figure 1.1.15 Mechanism of DNA replication of telomeric ends A) Semi-conservative replication of lagging 
strand B) Telomerase drives the synthesis of the G-rich tandem repeats at telomeric G-overhangs by using an 
RNA template (hTERC) (O'Connor, 2008). 
B
A
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Telomeres are characterized by different sequences depending on the organism. Human 
telomeres comprise tandem repeats of the short G-rich DNA motif (TTAGGG), oriented 5’ to 
3’ towards the end of chromosomes, and an array of telomeric proteins better known as 
shelterin proteins. Telomeres consist of 9-15 kilobases (kb) long double stranded DNA and a 
3’ single-stranded overhang tail that ranges in length from ~50 to 300-400 nucleotides (nt) 
(Figure 1.1.14).  
The shelterin complex consists of the double stranded telomeric repeat binding factors TRF1 
and TRF2, the TRF2 interacting factor RAP1, the bridging molecules TIN2 and TPP1 and the 
telomeric protection factor POT1, together covering the double and single stranded repeats 
(Figure 1.1.14). Shelterin members interact with a large number of other factors that 
transiently localize to telomeres, frequently in a cell-cycle dependent manner. These factors 
aid in the generation of a protective structure at chromosome ends, here referred to T-loop 
(O'Sullivan & Karlseder, 2010). In fact, T-loop destabilization, resulting in the exposure of 
the 3’ end, is recognized as a DNA damage signal by the cell, which starts a senescence 
process leading to the cell death (Li, et al., 2003). The T-loop is generated by invasion of the 
single stranded G-overhang into the double stranded TTAGGG repeats. The looped structure 
protects telomeres on several levels (Figure 1.1.14). Invasion effectively sequesters the G-tail, 
and allows distinction of natural chromosome ends from double stranded breaks (O'Sullivan 
& Karlseder, 2010). 
During each cell cycle, 50–100 bp of telomeric DNA is lost because of the “end-replication 
problem” (Figure 1.1.15). This progressive shortening has been attributed to the inability of 
DNA polymerase to completely replicate the ends of chromosomal DNA during each S phase 
(Hanahan & Weinberg, 2000), (Phatak & Burger, 2007) (Levy, et al., 1991). When normal 
cells reach a critical telomere length called Hayflick limit, they exit the cell cycle, enter M2 
phase (mortality stage) and undergo senescence. This mechanism is thought to be the clock 
that determines human life span (Phatak & Burger, 2007).  
This is the reason why telomeres are thought to be essential in cellular aging and cancer, 
chromosome stability and genomic integrity (O'Sullivan & Karlseder, 2010). A stringent 
control of telomere length is important for cell cycle control, cellular immortalization, and 
tumorigenesis (Figure 1.1.16) (Ou, et al., 2008). Different cell types have different telomere 
dynamics. In normal somatic cells the average available telomere length is 10 kb, then their 
telomeres erode resulting in senescence. Stem cells of renewal tissues have an average 
telomere length of 12 kb, which shorten at reduced rates, whereas germ cells and fetal tissues 
have 15-20 kb. The average telomere length of cancer cells however, is only 5 kb (range 2-9 
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kb). During early tumorigenesis telomeres erode, but in the great majority of cases they are 
maintained at a stable length through the reactivation of telomerase (Phatak & Burger, 2007). 
Telomere shortening is thought to lead to the loss of structural integrity of the telomere 
nucleoprotein, thus resulting in the activation of p53 and Rb tumor suppressor pathways and 
cellular senescence, which is an important tumor suppressor mechanism. Telomere-induced 
senescence is as effective as apoptosis in decreasing cancer incidence, particularly in 
preventing oncogene-expressing cells from progressing to malignancy (Ou, et al., 2008).  
 
 
Figure 1.1.16 Structure and biological roles of telomeres. Repair mechanisms or telomerase reactivation is be 
triggered by telomere shortening or damage. While repair or reactivation in excess would induce or trigger 
tumorigenesis, G-quadruplex ligands could induce or stabilize the G-quadruplex structure in this region and thus 
block telomerase from binding to the terminal single-stranded end of telomeres (Ou, et al., 2008). 
 
Telomerase, first identified by Carol Greider and Elisabeth Blackburn in 1985 (Greider & 
Blackburn, 1985), is a RNA-dependent DNA polymerase, almost universally conserved in 
eukaryotes. It allows cells to overcome one of the fundamental limitations to mammalian cell 
immortality, the progressive loss of telomeric DNA (Ou, et al., 2008). 
Telomerase is a ribonucleoprotein reverse transcriptase, mainly composed of two distinct 
components: a human telomerase RNA component (hTERC or hTR), which acts as a template 
for addition of new telomeric repeats, and the catalytic subunit human telomerase reverse 
transcriptase (hTERT) (Figure 1.1.15). Cell populations that continue dividing throughout 
life, such as germ and stem cells, require the addition of new telomeres to their chromosomes 
to replace sequences lost during cell division. Differently cancer cells, which have acquired a 
high proliferative potential, surpass replicative senescence by activation of the telomerase 
(Phatak & Burger, 2007). This mechanism, termed alternative lengthening of telomeres 
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(ALT), can solve the end-replication problem, mentioned above. Telomerase is thought to be 
overexpressed in ~85-90% of cancer cells and primary tumors, but not in normal somatic cells 
(Balasubramanian & Neidle, 2009), (Ou, et al., 2008). 
 
1.1.4.2 G-quadruplex at the telomeric ends 
The single-stranded G-rich telomeric sequence can fold into G-quadruplex, which coexists 
with the T-loop structure in a dynamic equilibrium. 
 
 
Figure 1.1.17 Anticancer effect induced by G-quadruplex ligands. 
 
The folding and stabilization of a variety of G-quadruplexes in G-rich sequences at the end of 
telomeres may affect telomere length and hence the normal regulation of telomeres in the cell 
cycle, moreover the G-quadruplex formation can also inhibit the telomerase activity. In fact, 
as mentioned above, the physiological substrate for the enzyme is the single-stranded G-
overhang of telomeres, which is recognized by the RNA template component of the 
telomerase complex (Figure 1.1.16, 1.1.17) (Ou, et al., 2008), (Balasubramanian & Neidle, 
2009). This was first demonstrated using a disubstituted anthraquinone derivative (Ou, et al., 
2008).  
In addition, human POT1, a highly conserved telomeric protein that binds to the 3′ end of 
single-stranded telomeric DNA and plays an important role in telomere end-capping and 
protection, was shown to disrupt telomeric G-quadruplexes presumably by trapping the 
single-stranded form of telomeric DNA, thus allowing telomerase extension.  
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The effects of these structure stabilization by small ligands have been extensively studied over 
the past decade. The interactions of G-quadruplexes with ligands give rise to various effects 
on telomere functions (Ou, et al., 2008). Compounds that stabilize the DNA G-quadruplexes 
formed in the human telomeric sequence have been shown to inhibit the activity of 
telomerase, disrupt telomere capping and maintenance, induce senescence as well as cell 
growth and shortening of telomere length (Figure 1.1.17). Therefore, the human telomeric 
DNA G-quadruplex has become an attractive target for cancer therapeutic intervention and 
structural information of its topology under physiological conditions are fundamental for a 
structure-based rational drug design (Ou, et al., 2008), (Balasubramanian & Neidle, 2009). 
The human telomeric G-quadruplex was extensively studied both in the presence of Na
+ 
and 
K
+
, which is biologically more relevant because of its prevalence in physiological conditions.  
 
 
Figure 1.1.18 Schematic structures of intramolecular G-quadruplexes formed by the human telomeric sequences 
d[AGGG(TTAGGG)3]: a) in Na
+
 solution; b) in a K
+
-containing crystal; c) in K
+
 solution (natural-Form 1) and 
d) d[TAGGG(TTAGGG)3TT] in K
+
 solution (natural-Form 2). Loops are in red; anti and syn Gs are in cyan and 
magenta, respectively. W, M and N denote wide, medium, narrow groove, respectively (Phan, et al., 2007). 
 
In 1993, the first four-repeat human telomere sequence, d[AGGG(TTAGGG)3] in Na
+
 
solution, was characterized by a NMR-based solution structure. This sequence forms an 
intramolecular antiparallel G-quadruplex, which involves three stacked G-tetrads with anti-
anti-syn-syn glycosidic orientations around each tetrad (Figure 1.1.18a). Three connecting 
TTA loops adopt successive edgewise, diagonal and edgewise alignments, such that each 
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strand has both parallel and antiparallel adjacent strands (Figure 1.1.18a) (Wang & Patel, 
1993), (Phan, et al., 2007). 
In 2002, a very different G-quadruplex structure of the same sequence was observed in a K
+
- 
containing crystal by Stephen Neidle group. In this structure, all four strands are parallel, the 
connecting TTA loops are double-chain-reversal, and all guanines adopt anti glycosidic 
conformations. Subsequent studies from many laboratories indicated the presence of a 
mixture of multiple G-quadruplex forms for human telomere sequences in physiological K
+
 
solution conditions (Figure 1.1.18b)  (Parkinson, et al., 2002), (Phan, et al., 2007). 
In 2006, further studies showed that four-repeat human telomere sequences form at least two 
intramolecular G-quadruplexes of the (3+1)-type in K
+
 solution (form 1 and 2 in Figure 
1..1.18c,d), with one double-chain-reversal and two edgewise loops (Phan, et al., 2007). 
 
1.1.4.3 G-quadruplex in gene promoters 
Given the promising results of research on telomeric G-quadruplexes and the cellular 
consequences of targeting them with small molecules that stabilize these structures, interest in 
the more general therapeutic significance of G-quadruplexes has expanded during the past 
decade to include G-quadruplexes in gene promoters as targets (Balasubramanian, et al., 
2011). An altered expression of these oncogenes is recognized as hallmarks of cancer, this 
evidence supports the therapeutic potential of targeting G-quadruplex for the treatment of 
human diseases, primarily cancer (Figure 1.1.19).  
The most representative among these genes are c-myc (Siddiqui-Jain, et al., 2002), c-kit  
(Rankin, et al., 2005), KRAS, RET, bcl-2 (Dexheimer, et al., 2006), pRb, VEGF (Sun, et al., 
2002), hTERT (Palumbo, et al., 2009) and PDGF-A  (Qin & Hurley, 2008)  (Figure 1.1.12). 
 
 
Figure 1.1.19 Schematic of the promoter-G-quadruplex hypothesis. G-quadruplex-forming sequence motifs in 
the upstream (promoter) region (in green) of genes (in red) may fold into G-quadruplex structures. The formation 
of G-quadruplex, rather than duplex, DNA structure in the promoter is associated with an altered state of 
transcription. This hypothesis would suggest that any molecule capable of interacting with the specific G-
quadruplex could modulate the transcriptional activity of the associated gene (Balasubramanian & Neidle, 2009). 
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Promoters in each of these genes can form G-quadruplexes with vast diversity in their folding 
patterns and loop lengths, making them putatively amenable to specific drug targeting 
(Brooks, et al., 2010).  
These G-quadruplexes include different numbers of tetrads, most commonly three, sometimes 
two or four. They also vary in their loop directionality, being parallel, antiparallel or mixed 
parallel/antiparallel. Most often the tetrads are continuously connected, but a snap-back 
configuration has been confirmed in at least one naturally occurring G-quadruplex formation, 
c-kit . The greatest variability among these secondary structures is found in loop lengths and 
constituent bases. Although the G-tetrad stacks are almost exclusively formed from guanines, 
there are no such limitations on bases in the loops. In these oncogenes, the loops are mainly 
1–9 bases long. Shorter loops, especially in double-chain reversals, help stabilize the G-
quadruplex. However, loop lengths have been seen to vary from only 1 base (the minimum 
required) to as many as 26 (forming their own secondary loop–stem structure in the hTERT 
promoter) (Brooks, et al., 2010).  
Because of the diversity of G-quadruplex forming sequences in promoter elements, in 2010 
Brooks and coworkers categorized promotorial G-quadruplexes in four distinct classes, 
summarized as follow (Brooks, et al., 2010): 
 Class I: represented by a single G-quadruplex, in which many loop isomers are 
possible and loop sizes may vary. The c-myc G-quadruplex is the prototypical 
member of this class (Figure 1.1.20a) 
 Class II: made of two distinctly different G-quadruplexes separated by about three 
turns of DNA. C-kit  is the only example of this category (Figure 1.1.20b) 
 Class III: including a pair of G-quadruplexes, but sufficiently close to form tandem 
G-quadruplexes, and together these tandem structures are more stable than the 
individual G-quadruplexes. Thus there are intermolecular interactions between the 
two adjacent G-quadruplexes. The two examples are c-myb and hTERT promoters 
(Figure 1.1.20c) 
 Class IV: multiple overlapping G-quadruplexes exist in a dynamic equilibrium. 
The greatest example of this class is bcl-2 (Figure 1.1.20d) 
All these genes and their promotorial regions have a role in tumorigenesis. For example, the 
human bcl-2 gene is a proto-oncogene with a GC-rich region upstream of the P1 promoter, 
which is critical for the regulation of bcl-2 gene expression. bcl-2 oncogenic property arises 
from decreasing the rate of cell death (Ou, et al., 2008). 
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Figure 1.1.20 Four classes of G-quadruplexes found in eukaryotic promoter regions (Brooks, et al., 2010). 
 
The aberrant overexpression of c-myc is associated with a variety of malignant tumors 
including those of breast, colon, cervix, small-cell lung, osteosarcomas, glioblastomas, and 
myeloid leukemia. In particular, c-myc has been identified as one of the main activating 
factors for the human telomerase reverse transcriptase (hTERT) catalytic domain of the 
telomerase enzyme.   
 
 
Figure 1.1.21 Structure and biological roles of c-myc (Ou, et al., 2008). 
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The nuclear hypersensitivity element III1 (NHE III1) upstream of the P1 promoter of c-myc is 
a G-rich strand containing a 27-base-pair sequence (Pu27). This sequence contains more than 
four consecutive G-strands, resulting in the formation of a dynamic mixture of four parallel 
G-quadruplex loop (Figure 1.1.21). The NHE III1 region of c-myc controls 85–90% of 
transcriptional activation. The specific G-quadruplex structure formed in this region functions 
as a transcriptional repressor element. Stabilization of G-quadruplexes in this region by small 
molecular ligands can suppress c-myc transcriptional activation, down-regulate c-myc 
expression, inhibit cell proliferation, and induce delayed apoptosis of leukemia cells (Figure 
1.1.21) (Ou, et al., 2008).  
As a third example, two G-rich sequences (c-kit  native and c-kit 21) within the promoter 
region of the human c-kit  gene have been identified, and biophysical studies showed that 
these sequences can form G-quadruplexes. In the c-kit native sequence, 87-base-pairs 
upstream of the transcription start site of c-kit , a single intramolecular G-quadruplex structure 
forms in K
+
 solution, as mentioned above. The proto-oncogene c-kit  encodes a membrane 
bound glycoprotein of the family of growth factor receptors with tyrosine kinase activity, and 
it constitutes a cell signaling system that can stimulate cell proliferation, differentiation, 
migration, and survival. c-kit  is closely related to the cell division regulation, thus its activity 
plays a very crucial role in human neoplasm (Ou, et al., 2008). c-kit  expression is linked to 
several human solid tumors such as ovarian and breast carcinomas, lung cancer, 
gastrointestinal stromal tumors, mast and germ cell tumors, neuroblastoma and malignant 
melanomas. 
 
1.1.4.4 G-quadruplex in viruses 
Beside human genome, evidences of putative G-quadruplex forming sequences have been 
found in key regions of several organisms, such as other vertebrates (Verma, et al., 2008), 
bacteria as E. coli and yeasts such as Saccharomyces cerevisiae (Hershman, et al., 2008). 
Similarly to the human genome, in a number of organisms a computational analysis showed 
an analogous G-quadruplex motif distribution within the genome, and most importantly in 
promoter regions (Huppert & Balasubramanian, 2005).  
Differently, to date little information about G-quadruplexes in viruses is available, therefore 
this area of research appears to be very promising. In 1992, for the first time Sundquist and 
Heaphy demonstrated a role of G-quadruplex during the dimerization of HIV-1 genome 
(Sundquist & Heaphy, 1993). Extensive recent studies, carried out by Prof. Richter’s research 
group, strongly suggested the presence of putative G-quadruplex sequences within the HIV 
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genome (Perrone, et al., 2013a), (Perrone, et al., 2013b), and an antiviral activity induced by 
the G-quadruplex-interacting compound BRACO-19 against the virus was proved (Perrone, et 
al., 2014).  
The Epstein Barr virus (EBV) encodes for the EBV nuclear antigen 1 (EBNA1), which is a 
virus-encoded protein that is critical for the replication and maintenance of the genome during 
latency in proliferating cells. In 2009, BRACO-19 was demonstrated to inhibit EBNA1-
dependent stimulation of viral DNA replication and preferentially blocked proliferation of 
EBV-positive cells relative to EBV-negative cell lines. BRACO-19 treatment also disrupted 
the ability of EBNA1 to tether to metaphase chromosomes, suggesting that maintenance 
function is also mediated through G-quadruplex recognition. These findings suggest that the 
EBNA1 replication and maintenance function uses a common G-quadruplex binding capacity 
of the two EBNA1 linking region LR1 and LR2, which may be targetable by small-molecule 
inhibitors (Norseen, et al., 2009). 
Moreover, highly conserved G-rich sequences showing a strong G-quadruplex folding 
propensity have been discovered within the human Papillomavirus (HPV) genome. Although 
the stability of these G-quadruplex structures, implications for a medical treatment of the 
HPV infection remain undefined so far (Tluckova, et al., 2013). 
Overall, the presence and the biological roles of G-quadruplex in viruses remain elusive, 
making necessary further investigations in this promising research area. In the present study, 
the interest was focused on the herpesvirus family, with special attention to herpes simplex 
virus-1 and human herpes virus-6 (HHV-6). 
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1.2 HERPESVIRUSES 
Herpesviruses are common causes of infections in humans, resulting in a spectrum of illness 
ranging from asymptomatic to life-threatening disease (Stewart, et al., 1995). The 
Herpesviridae family consists of large DNA viruses, which have been grouped together based 
on common biological features and virion. This family comprises three subfamilies 
designated Alphaherpesvirinae, Betaherpesvirinae and Gammaherpesvirinae. The first 
subfamily, Alphahersvirinae, includes herpes simplex virus type 1 and 2 (HSV-1 and HSV-2, 
respectively) and varicella-zoster virus (VZV or HHV-3). The Betaherpesvirinae subfamily 
includes human cytomegalovirus (HCMV or HHV-5) and human herpesvirus type 6 and 7 
(HHV-6 and HHV-7, respectively). Whereas Epstein-Barr virus (EBV or HHV-4) and 
Kaposi's sarcoma-associated herpesvirus (KSHV or HHV-8) are part of the 
Gammaherpesvirinae subfamily (Figure 1.2.1a). 
All herpesviruses exhibit a common virion structure, which is composed of four distinct 
elements: a core comprising the large double-stranded linear DNA, an icosahedral capsid, a 
tegument and an external envelope (Figure 1.2.1b).  
 
 
Figure 1.2.1 a) Herpesviruses, which belong to the Herpesviridae family, are shared into three different 
subfamilies: Alphahersvirinae (HSV-1, HSV-2, VZV), Betaherpesvirinae (HHV-5, HHV-6, HHV-7) and 
Gammaherpesvirinae subfamily (EBV and KSHV). b) Herpesviruses consist of core, containing the large 
double-stranded DNA, capsid, tegument and envelope with important glycoproteins. 
 
The primary infection of herpesviruses starts by the interaction of viral envelope 
glycoproteins (g) with receptors at the plasma membrane of host cells. Entry consequentially 
occurs by fusion of the virion envelope with the cellular plasma membrane, a process which is 
still unclear at the molecular level, although several virally-encoded envelope glycoproteins 
have been shown to play essential roles in penetration. These glycoproteins include gB, gH, 
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and gL which are conserved throughout the Herpesviridae subfamilies. Subsequently, part of 
the tegument dissociates from the nucleocapsid and tegument proteins modulate the host cell 
to create an environment, which is beneficial for virus replication. Herpesviruses are 
transported along microtubuli to the nuclear pore and genomic viral DNA is released into the 
nucleus. Here viral genome transcription occurs in a cascade-like fashion resulting in 
immediate-early, early, and late viral mRNAs (Figure 1.2.6) (Mettenleiter, 2004). Therefore, 
viral DNA is replicated and assembled into nucleocapsids that egress by budding into the 
perinuclear cisterna, where they become enveloped. Thereafter, a de-envelopment during 
passing of the outer nuclear membrane occurs (Ahlqvist, et al., 2006). At this stage of 
maturation the tegument is formed around the now naked nucleocapsids (Mettenleiter, 2004). 
This is followed by a re-envelopment in the cytoplasm in close vicinity to the stacks of the 
Golgi apparatus, followed by egress of mature virions (Figure 1.2.6) (Ahlqvist, et al., 2006). 
Interestingly, although the wide variety of tissue tropisms and the way of interaction with 
their natural hosts, all herpesviruses share a common mechanism by which they replicate their 
genomes during the lytic phase of the replication cycle. Moreover, in every herpesvirus the 
lytic DNA replication occurs by generating a long head-to-tail concatemers of viral genomes, 
that are cleaved to unit-length genomes during the process of encapsidation. This common 
replication mode reflects a conserved set of viral genes, encoding the basic components of the 
replication machinery.  
 
 
Figure 1.2.2 HSV-1 life cycle. Image from www.bio.davidson.edu. 
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Another common feature of herpesvirus biology is the capacity to remain latent in the infected 
host, but, unlike the case with lytic DNA replication, the mechanism by which the viral 
genomes are maintained during latency apparently differs considerably among the 
herpesviruses. After the primary infection all herpesviruses share the common ability to 
establish a lifelong infection by undergoing latency in their host. During latency, viral DNA is 
detectable in infected cells but no replication is observed, although the expression of some 
viral proteins. Upon stimuli not clearly defined, herpes viruses can reactivate and restart a 
lytic infectious cycle. Therefore, all of them have developed specific mechanisms to bypass 
the immune responses of the host to persist in it (Figure 1.2.2) (Vandevenne, et al., 2010). 
 
1.2.1 Herpes simplex virus-1 (HSV-1)  
1.2.1.1 General features and epidemiology 
Herpes simplex viruses (HSV) are among the most ubiquitous of human pathogens, that 
evolved to use the human skin epithelium and mucous membrane epithelia as their port of 
entry into the human body (Stewart, et al., 1995). Human HSV infections were first 
documented in ancient Greece. Greek scholars, particularly Hippocrates, used the word 
“herpes” to describe spreading lesions. The classification now in use came into being in the 
late eighteenth century, although the vesicular nature of lesions associated with herpetic 
infections was previously well characterized, person-to-person transmission of HSV 
infections was recognized only in 1893 (Whitley, et al., 1998). 
HSV-1 is the prototypical member of the Herpesviridae family and also the defining example 
of the Alphaherpesvirinae, the neurotropic subfamily of herpesviruses (Smiley, 2004). The 
frequency of HSV (HSV-1, HSV-2) infection is generally measured by testing various 
populations for the presence of antibodies. Worldwide, the global incidence of HSV-1 is 
~90%, with a prevalence of 65% in the USA and 52–67% in northern Europe (Xu, et al., 
2002). In the developing Countries HSV-1 is almost universal, and usually acquired from 
intimate contact with family in early childhood (Whitley, et al., 1998). After childhood, the 
HSV-1 prevalence rates increase minimally with age. Moreover, rates of HSV-1 infection are 
similar for men and women. The majority of infections are oral, although most are 
asymptomatic (Arvin, et al., 2007). 
As previously mentioned, HSV-1 virion consists of four components: 1) an electron-dense 
core containing viral DNA, 2) an icosadeltahedral capsid, ~125 nm in diameter, 3) an 
amorphous, at times eccentric layer of proteins, designated tegument and 4) an envelope 
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(Figure 1.2.1). The capsid consists of 162 capsomeres and is surrounded by the tightly 
adhering tegument. The envelope surrounds the capsid-tegument structure and consists of at 
least 10 glycosylated and several nonglycosylated viral proteins, lipids, and polyamines 
(Whitley, et al., 1998). HSV-1 is a large double-stranded DNA virus characterized by a 
genome of approximately 152 kb, which encodes for more than 80 proteins and possesses 
complex transcriptional regulation mechanisms (Figure 1.2.3).  
 
 
Figure 1.2.3 Scheme of the HSV-1 genome and episomal form of the virus after circularization. 
 
The variability in size is due chiefly to the variation in the number of reiterations of specific 
terminal and internal sequences (Whitley, et al., 1998). A very particular HSV-1 genome 
feature is the high G+C content (68%) (Ouyang, et al., 2012). The genome of HSV-1 consists 
of two covalently linked components, designated as long (L) and a short (S) segment, each of 
which is composed of unique sequences (UL and US, respectively), flanked by inverted 
repetitions (TRL, IRL, TRS and IRS) (Figure 1.2.3). The inverted repeat sequences flanking UL 
are named ab and b’a’, whereas those flanking US are a’c’ and ca. (Figure 1.2.3). 
 
1.2.1.2 Primary infection of HSV-1 and entry 
The initial step in HSV-1 entry begins with virus binding to heparan sulfate receptors on the 
cell surface membrane, followed by entry of the virus into host cells (Figure 1.2.4).  
It was generally believed that HSV-1 entry into cells occurs by direct fusion of the virion 
envelope with the outer plasma membrane. Recently it has been reported, however, that at 
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least three different pathways are implicated in HSV-1 entry, depending on the cell types 
susceptible to infection: 1) via direct fusion with the plasma membrane, 2) via fusion within 
an acidic endosome, and 3) via fusion within a neutral endosome (Reske, et al., 2007). 
The entry process is mediated by five viral surface glycoproteins, gB, gC, gD, gH, gL, and at 
least one cellular receptor for gD (Spear, 1993). These include a member of the TNF-receptor 
family named herpesvirus entry mediator (HVEM), a member of the immunoglobulin 
superfamily commonly known as nectin-1, and 3-O sulfated heparan sulfate (3-OS HS). gB 
and gC independently interact with heparan sulfate proteoglycans (HSPGs) to promote the 
initial attachment to the cell surface, in fact gC is not essential for viral entry and its absence 
decreases the overall viral binding to cell surfaces. gD is, then, required for entry of the virus 
into cells. Since gD does not have the characteristics of a fusion protein, it is assumed that the 
central fusion machinery involves gB and the heterodimer gH/gL. Therefore, the binding of 
gD to one of its potential entry receptors induces conformational changes in gD, that 
mobilizes a fusion active multi-glycoprotein complex involving gB, gD, gH and gL (Figure 
1.2.4).  
 
 
Figure 1.2.4 Scheme of HSV-1 entry into host cells. a) Host cell and HSV-1 representation. b) gB and gC bind 
to HSPG or an unknown gB receptor, in a HS-independent mechanism, allowing virus-cell attachment. c) gD 
binding to a cell surface receptor induces a gD conformational change. d) gB and gH/gL hypothetically form the 
fusion machinery (Reske, et al., 2007).  
 
The fusion of the viral envelope with the cellular membrane is followed by the release of the 
viral nucleocapsid and tegument proteins into the host cytoplasm (Akhtar & Shukla, 2009), 
(Reske, et al., 2007). Thereafter, HSV-1 nucleocapsids dissociate with tegument proteins, the 
capsid is transported to the nuclear pores through a minus-end-directed microtubule motor 
protein dynein (Reske, et al., 2007), (Copeland, et al., 2009). During entry and transit to the 
nucleus, much of the tegument dissociates from the capsid, although at least two tegument 
proteins, VP1/2 and UL37, remain associated. Such partially tegumented capsids bind to the 
host nuclear pore complex (NPC), where the viral DNA is released, a process termed 
uncoating. The HSV-1 capsid remains on the cytoplasmic side of the NPC, while the DNA 
enters the nucleus by translocating through the pore (Copeland, et al., 2009). 
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The key events in viral replication that occur in the nucleus include transcription, DNA 
synthesis, capsid assembly, DNA packaging, and envelopment (Figure 1.2.6). 
 
1.2.1.3 HSV-1 replication cycle 
1.2.1.3.1 The DNA replication functional machinery 
During the life cycle of HSV-1, the genome exists in at least three different states: linear, 
circular, and concatemeric, which may influence the outcome of infection. Within the virion, 
HSV-1 DNA normally exists in a linear double-stranded physical state, and it presumably 
assumes a circular form (“endless genomes”) after entry into host cells. Although the kinetics 
of this genome circularization have not been fully established, the conversion from linear to 
circular form, also known as θ replication mode, has generally been assumed to be essential 
for replication (Poffenberger & Roizman, 1995). In 2003, however, Jackson and Deluca 
proved that θ replication does not occur during productive infection. The circular form of the 
viral genome, differently, is preferred for the establishment of latency, especially in the cells 
characterized by a low ICP0 expression (Jackson & DeLuca, 2003). 
HSV-1 lytic infection involves the temporally regulated expression of three classes of viral 
genes: immediate early genes (α or IE), early genes (β or E) and late genes (γ or L). IE-genes 
are the first to be transcribed between 2 and 4 hours post infection (h.p.i.), followed by the 
early-genes which are transcribed between 5 and 7 hours after infection. Subsequently the 
expression of late-genes occurs between 12 and 17 hours post infection.  
IE-promoters contain an enhancer element that responds to cellular factors but whose activity 
is greatly increased by a component of the virus particle known as virion protein (VP) VP16 
(Everett, 1984). VP16 activates transcription by binding, along with the cellular factors Oct1 
and host cell factor (HCF), to the TAATGARAT elements present in all IE promoters 
(Samaniego, et al., 1998). The expression of IE proteins, the infected-cell polypeptide ICP0 
(α0 gene), ICP4 (α4 gene), ICP22 (α22 gene), ICP27 (α27 gene) and ICP47 (α47 gene), does 
not require prior viral protein synthesis. However, functional IE proteins are required for the 
optimal expression of both E and L gene products (Post, et al., 1981), (Everett, 1984), 
(Sampath & DeLuca, 2008). ICP4 is the principal regulatory protein of the virus, it plays a 
role as a transcriptional repressor or activator and it is necessary for the transition of viral 
gene transcription from the IE to the E phase.  Binding to an array of cellular protein and not 
DNA, ICP0 acts as a potent transactivator of viral and cellular promoters, providing for 
efficient viral gene expression and growth in vitro and in vivo. Moreover, it is required both in 
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lytic viral growth and the efficient reactivation of the virus from the latent state (Whitley, et 
al., 1998), (Samaniego, et al., 1998). ICP0 has also been shown to interact with ND10 nuclear 
structures and components of the transcription, translation, cell cycle, and proteolytic 
machinery of the cell. Therefore, it has the potential to affect many aspects of host cell 
metabolism (Samaniego, et al., 1998). ICP27 regulates the processing of viral and cellular 
mRNAs, and it modulates ICP4 and ICP0 activities. ICP27 is required for an optimal viral 
DNA synthesis, in fact it increases the early-gene expression levels. Furthermore it 
contributes to an efficient late-gene expression, as well as ICP22. ICP22 has many other 
functions in viral proliferation. It mediates the formation of a novel phosphorylated form of 
RNA polymerase II (pol II), it regulates the longevity as well as the splicing pattern of the 
ICP0 mRNA. ICP47 may help the virus escape immune surveillance on the basis of its ability 
to block the presentation of antigenic peptides to CD8
+
 cells (Whitley, et al., 1998) 
(Samaniego, et al., 1998). 
The HSV-1 genome contains three origins of replication: OriS is present in two copies within 
the repeated c region of HSV-1, and OriL is present in UL (Figure 1.2.3, 1.2.5c). OriL and OriS 
sequences are closely related, both contain an extensive inverted repeat sequence, the central 
18 bp of which are exclusively AT base pairs (Figure 1.2.5c).  Morever, both of them are 
located in the promoter-regulatory regions of divergently transcribed genes. OriL, the 
sequence of which comprises a 144-bp perfect palindrome, is located between the gene ICP8 
(UL29) encoding a single-stranded DNA-binding protein, and the gene UL30 encoding the 
catalytic subunit of the polymerase (Pol) (Figure 1.2.3, 1.2.5c). OriS is located between genes 
encoding immediate early proteins such as ICP4 and either ICP22 and ICP47 (Weller & 
Coen, 2012), (Challberg, 1996). The significance of having three origins of replication in the 
HSV genome is not clear. Mutant viruses lacking OriL or one or both copies of OriS have been 
isolated and have no obvious growth defect either in cultured cells or in animal models. Thus, 
OriL and OriS serve as essential cis-acting functions during the replication of viral DNA in 
vivo (Igarashi, et al., 1993) (Poffenberger & Roizman, 1995), (Challberg, 1996). OriS is 
mainly composed of two components: the core origin containing UL9-binding sites showing 
several similarity with OriL, and flanking sequences that increase the efficiency of replication 
by 50-fold or more. The flanking sequences contain a number of consensus binding sites for 
transcriptional activator proteins such as SP1 and NFI, and the available evidence suggests 
that the binding of one or more of these transcriptional regulators to sites in close 
juxtaposition to the core sequence may be critical for enhancing DNA replication (Challberg, 
1996). The core of OriS can be divided in at least five functional domains, essential for an 
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efficient replication of HSV-1 DNA: 1, 2) two high-affinity UL9-binding sites named site I 
and site II, which are separated by 3) an AT-rich region, 4) a sequence homologous to site I 
characterized by a lower affinity for UL9, known as site III, and 5) a binding site for an as-
yet-uncharacterized cellular protein(s) called OF-1 (Challberg, 1996). It has been 
demonstrated that mutations in one or more of these functional domains lead to a significant 
less-efficient DNA replication. An interesting example of this evidence is the substitution of 
some AT pairs in the central AT-rich region of OriS with GC pairs (Lockshon & Galloway, 
1988), (Werstuck, et al., 1990). 
HSV-1 encodes seven essential replication proteins. Six of these play “core” replication roles 
at the replication fork and are conserved in all known herpesviruses: the single-strand DNA-
binding protein ICP8 (or UL29), the two-subunit DNA polymerase (catalytic subunit Pol and 
processivity subunit UL42), and a three-subunit helicase/primase complex (H/P: UL5, UL8, 
and UL52). The remaining HSV-encoded protein is the origin-binding protein UL9 (Figure 
1.2.5). Given the higher complexity of the replication origins in β and γ herpesviruses, UL9 
homologs have never been identified.  
 
 
Figure 1.2.5 a) Organization of the HSV-1 replication fork: two heterotrimeric complexes of the helicase-
primase (H/P) (dark gray spheres with white centers); the polymerase (white shapes with gray centers in which 
UL30, or Pol, is shown as an oval and UL42 as a crescent); a RNA primer depicted as hatched bars on the 
lagging strand of DNA; the ssDNA-binding protein ICP8 (uniformly dark gray circles). b) Coupled leading- and 
lagging-strand synthesis (Weller & Coen, 2012). c) Structure of the HSV-1 origins of replication, OriS and OriL 
(Lehman & Boehmer, 1999). 
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Therefore, although the similarities of the DNA replication cycle among all herpesviruses, the 
initiation of viral DNA synthesis may differ among the three herpesvirus subfamilies (Weller 
& Coen, 2012). 
ICP8, an abundant HSV-induced protein of about 130 kD, is a particular helix-destabilizing 
proteins. It binds more tightly to single-stranded DNA than to double-stranded DNA, in a 
sequence-independent manner. The binding to the HSV-1 singl-stranded DNA (ssDNA), 
formed at the replication fork by the unwinding of the parental duplex DNA, favors the 
synthesis of the DNA templates by the DNA polymerase. 
The polymerase is a heterodimeric complex composed of the catalytic subunit Pol (140 kD) 
and UL42 (52 kD), a phosphoprotein that binds tightly to double-stranded DNA. Pol contains 
an intrinsic 3’-5’ exonuclease activity and a 5’-3’ exonuclease/RNase H activity. The first one 
seems to increase the fidelity of DNA synthesis, while the second activity cooperates with the 
alkaline exonuclease UL12 in the removal of primers from the Okazaki fragments made on 
the lagging strand during semi-discontinuous synthesis (Figure 1.2.5) (Challberg, 1996). 
 
1.2.1.3.2 HSV-1 DNA synthesis 
Once the entry of viral genome into the nucleus occurs, HSV-1 infection determines a 
reorganization of the infected cell nucleus involving relocalization of cellular proteins and the 
ordered assembly of replication compartments, in which gene expression, DNA replication, 
and cleavage/packaging are thought to occur (Figure 1.2.5) (Weller & Coen, 2012).  
HSV-1 DNA synthesis is believed to initiate at one of the three viral origins of replication, in 
which UL9 and ICP8 determine a distortion in the AT-rich origin spacer region. Hence, the 
helicase/primase complex unwinds the duplex DNA and synthesizes short RNA primers to 
start the DNA replication. The combinatory activity of the RNA primer and the H/P complex, 
which undergoes a conformational change, appears indispensable to recruit the two-subunit 
polymerase to the replication fork, thus promoting the synthesis of the viral leading and 
lagging strands. The recruitment of polymerase to the fork has been shown to involve direct 
interactions between the UL8 subunit of H/P and/or UL5 with Pol (Marsden, et al., 1996). 
Coupled leading- and lagging-strand DNA synthesis has now for the first time been 
reconstituted on synthetic minicircular DNA templates with the H/P, ICP8, and the viral 
polymerase (Pol/UL42) (Stengel & Kuchta, 2011). 
Following the synthesis, HSV-1 DNA accumulates in the nucleus of infected cells as end-to-
end long concatamers. The packaging machinery recognizes signals within the DNA to 
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generate unit length monomers, which are inserted into preformed capsids (Baines & Weller, 
2005).  
 
 
Figure 1.2.6 Replication cycle of herpesviruses. Following viral attachment/entry into host cells, 1) the viral 
genome circularize and the transcription of IE-genes occurs. 2) IE-proteins stimulate the transcription of E-
genes. 3) E-proteins promote DNA replication and the formation of a concatemeric DNA, which is processed 
during cleavage/packaging, and DNA molecules are pre-encapsidated. Nuclear egress and maturation result in 
mature herpes virions. 
 
1.2.1.3.3 Cleavage and packaging of HSV-1 DNA 
The mechanism of cleavage and packaging of DNA is likely to be highly conserved among all 
herpesviruses. The terminally redundant a regions, containing several cis-acting sequences, 
are essential to successfully accomplish cleavage and packaging of the viral genomes. In 
HSV-1, these regions are 250-500 bp long, depending on the virus strain, for example in the 
strain F of HSV-1 the length is 391 bp long. The a sequence is in the same orientation at both 
termini of the genome, whereas it is present in inverted orientation at the L/S junction 
(indicated as a’): a single copy is detectable at the S terminus, differently one or more copies 
are present at the end of the L component. The a sequences are arranged as DR1-Uc-(DR4)m-
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(DR2)n-Ub-DR1. Direct repeats DR1 (17-20 bp) flank each a sequence, with single copies of 
DR1 separating tandem a sequences. The core of the a segment comprises multiple repeats of 
one or two short sequences named DR2 and DR4 (not ubiquitously present), whereas very 
unique sequences are located between DR1 and either side of the DR2/DR4 repeats.  
 
 
Figure 1.2.7 Scheme of the cleavage/packaging mechanism in HSV-1 (Baines & Weller, 2005). 
 
These sequences, adjacent to the S and L components, known as Ub and Uc or pac1 and pac2 
respectively, represent the signals to initiate DNA cleavage. The pac1 and pac2 domains 
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contain characteristic sequence motifs, also conserved among all herpesviruses. The T-rich 
element, within pac1, is one of the most conserved motif and, interestingly, it is flanked on 
each side by short GC-rich tracts. In pac2, the conserved T-rich element, frequently 
associated with the consensus motif CGCGGCG (from the proximal and distal GC-rich 
regions), is crucial to start the cleavage and packaging of DNA.  
Genomic termini are generated by a cleavage event toward one end of DR1, and 
circularization of infecting genomes restores a complete a sequence. The cis-acting, 
sequences necessary for DNA packaging, are located within the approximately 200-bp 
fragment Uc-DR1-Ub, generated upon fusion of the genomic ends. 
Cleaved viral genomes are not detected in cells infected with viruses that fail to assemble 
capsids, suggesting that capsids contain essential parts of the cleavage/packaging machinery 
(Baines & Weller, 2005). Four types of intracellular capsids have been identified by sucrose 
gradient sedimentation and electron microscopic analysis: procapsid (containing internal 
scaffold proteins), A capsids (empty), B capsids (containing scaffold protein) and C capsids 
(with DNA). The procapsid is the precursor of all capsid types, its shell is morphologically 
distinct from all other capsids and appears porous and roughly spherical. Differently, A, B and 
C capsids are more angularized icosahedrons of approximately 125 nm in diameter. The shells 
of all capsid types contain similar structural components such as VP5 (major capsid protein), 
VP19C, VP23, VP24 and VP26, differently VP21 and VP22 (UL26) are present in procapsid 
and B-type capsid only (Baines & Weller, 2005).  
At least seven genes, UL6, UL15, UL17, UL25, UL28, UL32 and UL33, encode proteins that 
are required for the DNA cleavage/packaging process. Six of them, UL6, UL15, UL17, UL28, 
UL32, UL33, are required for the DNA cleavage, while UL25 performs a later function. 
Packaging, consisting in two distinct DNA cleavages, proceeds from pac2 toward the pac1 
terminus. The putative terminase, composed of UL15 and UL28 proteins, binds viral DNA 
through a UL28-protein subunit, and dock with procapsids primarily through an interaction 
mediated by the UL6 protein (Baines & Weller, 2005). Interestingly, the UL28 component of 
the HSV-1 terminase enzyme is reported to binds to a specific conformation adopted by the 
region comprising the T element and G tracts, and this interaction is likely to be crucial for 
cleavage (Tong & Stow, 2010). The DNA concatemer is scanned by the capsid-associated 
terminase for the first pac2 in proper orientation. Therefore, the first cleavage occurs at a 
fixed distance from pac2, which normally occurs within the upstream DRl, leaving a 18 bp 
truncated element and a single-base 3’ overhang (Us end) (Figure 1.2.7). The first one, formed 
L-terminus with 18 bp of DRl followed by the rest of the a sequence, is inserted into the 
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capsid, on the contrary the cleaved Us end is presumably degraded (Baines & Weller, 2005). 
Deletion, but not substitution, of the pac2 GC element and unconserved region impaired DNA 
packaging, suggesting that the relative spacing of the cleavage site, T element and distal 
motifs, is crucial (Tong & Stow, 2010). The second cleavage is dependent on pac1 domain, it 
occurs between the pac1 T-element and the flanking G tracts. As a result, the terminus of the 
unpackaged concatemeric DNA is identical to the end to be packaging after the first DNA 
cleavage, and should therefore be able to initiate a subsequent round of packaging (Figure 
1.2.7) (Baines & Weller, 2005).  
 
1.2.1.3.4 Primary and secondary envelopment 
Once completely assembled, nucleocapsids must be translocated through the nuclear 
membrane in the cytoplasm of the host cell, in which herpes virions mature. Both nuclear 
egress and the final maturation, also named primary and secondary envelopment respectively, 
involve different subcellular compartments and viral proteins. The first budding step in 
herpesvirus maturation occurs at the inner nuclear membrane, which provides the 
nucleocapsid with a first primary envelope (Mettenleiter, 2004).  
 
 
Figure 1.2.8 Scheme of the primary and secondary envelopment of HSV-1. Nuclear egress may involve  the 
proteins UL34, UL31 and US3. The secondary envelopment is thought to require the cooperation of a number of 
HSV-1 late proteins, most importantly UL36 and UL37, and glycoproteins. Solid lines between gene products 
(rectangles) represent physical interaction, whereas arrows indicate functional effects (Mettenleiter, 2002). 
 
Cooperating with two crucial protein, UL31 and UL34, conserved among all herpesviruses, 
nucleocapsids approach the inner nuclear membrane, bud into the perinuclear space and thus 
produce vesicular intermediates (Figure 1.2.8, 1.2.9). Upon fusion of these intermediates with 
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the outer nuclear membrane, capsids are released into the cytosol of infected cells and de-
enveloped close to the Golgi area. Also the secondary envelopment process takes place in the 
cytoplasm of the cells and it produces intravesicular enveloped virus particles (Figure 1.2.9). 
Therefore, egress of virus progeny occurs by exocytosis of virus-containing vesicles (Figure 
1.2.9) (Granzow, et al., 2001). 
The molecular mechanism of this fusion process is unknown, moreover it is also unclear 
whether the UL34 protein, so far the only membrane protein unequivocally identified as a 
component of primary virions, is capable of mediating this fusion event either alone or in 
combination with other viral proteins such as UL31. Only one virally encoded protein, the 
product of the US3 genes, conserved exclusively in alphaherpesviruses, has been identified 
which plays a role in this fusion process. In the betaherpesviruses, other tegument 
components may also be added during primary envelopment, although it is not clear if they 
are retained or reacquired after de-envelopment (Mettenleiter, 2004), (Mettenleiter, 2002).  
 
 
Figure 1.2.9 Scheme of the proposed pathway of herpesvirus egress (Mettenleiter, 2002). 
 
After translocation into the cytosol, the alphaherpesvirus nucleocapsid has to collect more 
than 15 tegument proteins prior to acquisition of a lipid envelope, containing more than 10 
viral glycoproteins. The betaherpes virion contains even more different proteins. Only a few 
of the components of the mature tegument and envelope are conserved, makes it difficult to 
propose a general pathway of virion formation for all herpesviruses. (Mettenleiter, 2004). 
In fact, tegumentation requires an intricate network of protein-protein interactions  
(Mettenleiter, 2002). During the secondary envelopment, the UL36 gene product, the largest 
herpesvirus protein with more than 2000 amino acids, exhibits a crucial role in the 
tegumentation. In fact, the interaction between UL36 protein with the UL37 and UL19 gene 
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product is fundamental to the virus maturation (Figure 1.2.8). Two tegument components 
UL36 and UL37 are conserved among all herpesvirus subfamilies, therefore it is reasonable to 
assume that complex formation between UL36 and UL37 may also be a conserved property.  
In the absence of the UL36 protein, virion morphogenesis of HSV-1 is totally blocked and no 
infectious progeny arises. Lack of the UL37 protein yielded a similar effect in HSV-1 
(Mettenleiter, 2004). Additional tegument-capsid interactions may occur, mediated by viral 
proteins (UL13, US3, UL41, UL46, UL47, UL49) and glycoproteins (gE/gI, gM/gN) but, 
unfortunately, these subsequent steps in tegumentation are still largely undefined (Figure 
1.2.8, 1.2.9) (Mettenleiter, 2002). 
 
1.2.1.4 HSV-1 pathogenesis and latency 
The pathogenesis of human HSV-1 disease depends on intimate, personal contact between a 
susceptible seronegative individual and an individual who is excreting HSV-1. Virus must 
come in contact with mucosal surfaces or abraded skin for infection to be initiated (Whitley & 
Roizman, 2001). However, a great variability exists in the clinical symptomatology of 
primary HSV-1 infections, therefore asymptomatic infection is the rule rather than the 
exception (Whitley & Roizman, 2001). The most common manifestation of the HSV-1 
disease comprises vesicular lesions affecting the mucous membranes principally of the mouth, 
nose, or eyes, and an increasing proportion of genital infections. HSV-1 is the cause of severe 
encephalitis and keratitis. Moreover, in 1979 HSV-1 has been also related to Alzheimer’s 
disease (Itzhaki, et al., 1997), (Pyles, 2001). 
A fascinating attribute of HSV-1 is its ability to enter a quiescent state and establish a lifelong 
latent infection (Kramer, et al., 2003). The latency of HSV-1 has been biologically recognized 
since the beginning of the century. Following entry and primary infection, HSV-1 is 
transported by retrograde movement to the nuclei of sensory ganglia (Figure 1.2.2). In the 
majority of the neurons, the viral genome remains in an episomal state for the entire life of the 
individual.  The virus can later reactivate, generating a new virus progeny that is transported 
axonally back to the periphery and causes recurrent disease. Reactivation occurs following  a 
variety of local or systemic stimuli, such as physical or emotional stress, fever, exposure to 
ultraviolet light, tissue damage and immunosuppression (Whitley & Roizman, 2001), and 
pathways such as the hormonal regulation of the thyroid hormone T3 (Bedadala, et al., 2010). 
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1.2.2 Human herpes virus-6 (HHV-6) 
1.2.2.1 General features 
In 1986, a new virus was isolated in the USA from patients affected by the acquired 
immunodeficiency syndrome (AIDS) as well as lymphoproliferative disorders. Initially 
designated human B-lymphotropic virus (HBLV), the virus was renamed human herpesvirus 
6 (HHV-6), following herpesvirus nomenclature guidelines (Lusso & Gallo, 1995), (Ablashi, 
et al., 1987). To date, a number of strains were isolated from various geographic regions and 
clinical settings, included in two well-defined groups, HHV-6A and HHV-6B.  
Historically, HHV-6A and HHV-6B have been treated as the same virus, mainly due to the 
lack of serological assays able to distinguish between the two variants (Ahlqvist, et al., 2006). 
However, these two variants showed different in vitro tropism for selected T cell lines, 
specific and conserved interstrain variations in their DNA sequences, specific immunological 
reactivity with monoclonal antibodies and distinct patterns of restriction endonuclease sites. 
As new evidence continued to accrue, several authors have suggested that the two variants be 
recognized as distinct viruses (Ablashi, et al., 2014). In fact, genomic sequencing confirmed 
distinctions between HHV-6A and HHV-6B and relationships to the herpesvirus family 
overall. Moreover, although the co-linear genome identity of 90%, HHV-6A and HHV-6B 
differ in some immediate-early gene functions, splicing patterns, specific amino acid 
signatures, biological and immunological properties, epidemiology and related diseases. 
Therefore, in 2012 the International Committee on Taxonomy of Viruses classified HHV-6A 
and HHV-6B as distinct viruses. 
 
 
Figure 1.2.10 Genome of the human herpes virus type 6 (Braun, et al., 1997). 
 
The HHV-6 genome is a linear double-stranded DNA molecule, 160 to 162 kb in size. It is 
composed of a ~145 kb long and A+T-rich unique (U) region, flanked by two identical G+C-
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rich terminal direct repeats (DR) of ~9 kp, named DRL (direct repeat left) and DRR (direct 
repeat right) (Figure 1.2.10) (Morissette & Flamand, 2010), (De Bolle, et al., 2005), (Gompels 
& Macaulay, 1995). The terminal DR region are interrupted by three intermediate repeats, 
designated R1, R2, and R3, in the immediate-early A (IE-A) region (De Bolle, et al., 2005). 
Similarly to other herpesviruses, the G+C content across the genome is not uniform. The G+C 
content within the U region is estimated around 40-44%, whereas DRL and DRR are 
composed by a higher G+C composition ~59% (Gompels & Macaulay, 1995), (Martin, et al., 
1991). The DRs contain the cleavage-packaging motifs, pac-1 and pac-2, and reiterations of 
the hexanucleotide (TTAGGG)n, which is a characteristic sequence of the telomeres of 
vertebrate chromosomes (De Bolle, et al., 2005), as abundantly described above. It has been 
suggested that one role of these repeats is to participate in the DNA packaging, in a manner 
analogous to the terminal repeats in HSV-1 (Figure 1.2.11) (Gompels & Macaulay, 1995), 
(Flint, et al., 2003). It is presumed that through homologous recombination between the 
telomeric repeat sequences (TRS) present within the HHV-6 genome and the telomeres, the 
HHV-6 genome, or part of it, gets integrated within human chromosomes. In fact, all 
integration sites identified to date (1q44, 9q34.3, 10q26, 11p15.5, 17p13.3, 18p11.3, 18q23, 
19q13.4, and 22q13.3) have been localized in the telomeric regions (Figure 1.2.11) 
(Morissette & Flamand, 2010). The protein U94 was shown to enable the establishment 
and/or maintenance of latent infection, it is expressed at low levels during lytic replication but 
is a major transcript during latent infection (Figure 1.2.11) (De Bolle, et al., 2005). 
 
 
Figure 1.2.11 Genome structure of HHV-6, composed by a single unique long component (UL) flanked by two 
identical direct repeats (DRR and DRL) (Morissette & Flamand, 2010). 
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1.2.2.2 The replication cycle of HHV-6 
The entry of both HHV-6A and HHV-6B occurs via interaction through the human cellular 
receptor CD46, located on the membrane of all nucleated cells, and a number of 
glycoproteins, such as gH, gL, gM, gN, gQ and gB, are involved in the primary infection of 
HHV-6. However, the modality and affinity of the interaction between CD6 and glyproteins 
differ between the two viruses.  
In the case of HHV-6A, the complex between the glycoproteins gH, gL and gQ (encoded by 
the genes U48, U82, and U100, respectively) serves as the viral ligand for CD46. The HHV-6 
gB (encoded by U39 gene) is involved in viral attachment and fusion process as well, through 
an as-yet-undefined mechanism (Figure 1.2.12).  
After the fusion of the viral envelope to the cell membrane, nucleocapsids is transported 
through the cytoplasm, most likely by association with the microtubule network, to nuclear 
pore complexes, where the viral DNA genome is released into the nucleus. The cytosolic 
transport mechanisms have not been investigated in detail for HHV-6, but they probably show 
strong similarity to those described for HSV-1 and HCMV (De Bolle, et al., 2005). 
Subsequently, similarly to HSV-1, the transcription of three kinetic classes of viral genes, IE-
genes, E-genes and L-genes, are required for the viral DNA metabolism and replication.  
 
 
Figure 1.2.12 Scheme of HHV-6 DNA replication (De Bolle, et al., 2005). 
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HHV-6 DNA replication requires multiple virally encoded factors. First, the protein U73 
binds to the origin of replication oriLyt, thus denaturing a portion of the circular viral DNA 
genome. This gap is maintained by the helicase/primase complex, consisting of the U43, U74, 
and U77 gene products, which also provides RNA primers for the lagging-strand DNA 
synthesis (Nicholas, 1994). The single-stranded DNA is stabilized by the major DNA binding 
protein U41, therefore HHV-6 DNA synthesis can be catalyzed by the DNA polymerase U38, 
driven by a processivity factor protein U27. The four proteins encoded by the U79 and U80 
genes of HHV-6 are suspected of being involved in DNA replication as well, although their 
role is not yet understood. As the new strand grows, the circular replication structure is nicked 
to form a rolling circle intermediate. Long concatameric strands of progeny DNA are 
encapsidated by the interaction of cleavage and packaging proteins with specific packaging 
(pac) signals at the end of the viral genomes (Deng & Dewhurst, 1998). It is of interest that 
oriLyt and pac sequences are different for the A and B variants of HHV-6 (De Bolle, et al., 
2005). The mature capsids bud out of the nucleus (thereby temporarily acquiring an 
intermediate membrane devoid of glycoproteins) into the cytoplasm, where they acquire a 
tegument and a secondary spiked viral envelope at the Golgi complex or at annulate lamellae, 
where viral glycoproteins accumulate (Cardinali, et al., 1998). These are sequentially 
glycosylated in transport vesicles prior to release of the mature virus particle into the 
extracellular space by exocytosis. The HHV-6 maturation pathway is different from that of 
the other herpesviruses in that no viral glycoproteins are detectable in the cell membrane of 
infected cells (De Bolle, et al., 2005).  
 
1.2.2.3 HHV-6 primary infection, epidemiology and latency 
HHV-6 is ubiquitous in general populations and it is normally acquired at a very early age 
(Braun, et al., 1997). Given that HHV-6 is most frequently detected in saliva and salivary 
glands, the transmission via saliva is considered the main route of infection, either from 
mother to child or between children. Remarkably, HHV-6B is usually isolated from saliva, 
whereas the detection of HHV-6 DNA in cord blood specimens of healthy newborns in the 
absence of serum immunoglobulin M (IgM) and in fetuses following spontaneous abortion 
supports the possibility of intrauterine transmission. The incidence of vertical HHV-6 
transmission is about 1 to 2% of all births (De Bolle, et al., 2005). 
In the USA, UK and Japan, 97-100 % of primary infections are caused by HHV-6B and occur 
between the ages of 6 and 12 months. HHV-6B primary infection normally causes acute 
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febrile illness and exanthem subitum (ES), also known as roseola infantum or sixth disease. 
Less is known about the epidemiology of HHV-6A. One report has indicated that HHV-6A 
infection is acquired later in life and that primary infection is typically without clinical 
symptoms (Ablashi, et al., 2014). HHV-6 has been associated also to several other diseases: 
epilepsy (Donati, et al., 2003), HIV/AIDS progression (Lusso & Gallo, 1995), chronic fatigue 
syndrome (CFS) (Watt, et al., 2012), cancer (Lacroix, et al., 2007), endocrine and 
autoimmune disorders (Caselli, et al., 2012), heart diseases, transplant complications, multiple 
sclerosis and, very recently, to Alzheimer disease (Carbone, et al., 2014). 
Like other herpesviruses, HHV-6 can establish a latent or persistent infection which remains 
for the lifetime of the host and can reactivate during immunosuppression, under a number of 
stimuli. Whereas salivary glands and brain tissue are suspected of harboring persistent HHV-6 
infection, candidate sites for latency are monocytes and early bone marrow progenitor cells. 
Low levels of HHV-6 DNA are also found in PBMCs from healthy individuals (De Bolle, et 
al., 2005). 
 
1.2.3 Current antiviral treatments against HSV-1 and HHV-6 
The nucleoside analogues represent the compound of choice to treat herpesvirus symptoms. 
However, herpesviruses remains in the body for life and can reactivate from time to time, 
since no cure, able to completely eradicate these viruses, has been developed so far. The most 
common compound for the prophylaxis and treatment of HSV-1 infection is acyclovir (ACV), 
a (9-[2-hydroxyethoxymethyl] guanine, that selectively inhibits viral DNA replication with a 
very low host-cell toxicity. Several nucleoside analogues, sharing the same mechanism of 
action, are currently used, such as ganciclovir (GCV), penciclovir (PCV), valacyclovir 
(VACV), famciclovir (FCV), foscarnet (PFA) (Figure 1.2.13). 
HHV-6 infections in immunocompetent children are self-limiting and do not require 
treatment. In immunocompromised individuals, however, reactivation of latent virus may 
cause life-threatening complications. No controlled trials of antiviral therapy against HHV-6 
have been conducted, and no compounds have been formally approved for the treatment of 
HHV-6 infections. Therefore, the drugs clinically used against HHV-6 are the nucleoside 
analogs GCV and valganciclovir, less frequently also ACV, VACV, cidofovir, and PFA 
(Figure 1.2.13) (De Bolle, et al., 2005). 
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Figure 1.2.13 Chemical structures of the some nucleoside analogues. 
 
The uptake of nucleoside analogs by infected cells is followed by phosphorylation of the drug 
to the monophosphate form, which occurs via HSV-encoded thymidine kinase (TK). 
Subsequently, the conversion to the triphosphate metabolite is catalysed by host cell enzymes. 
The triphosphate metabolites preferentially inhibit viral DNA polymerase, by competition 
with the natural substrate dGTP, over cellular DNA polymerase (Figure 1.2.14) (Snoeck, 
2000). Unlike alpha- and gammaherpesviruses, betaherpesviruses do not express a TK 
enzyme but encode a phosphotransferase, which is capable of converting nucleoside analogs 
to their monophosphate (De Bolle, et al., 2005). 
An emerging problem, which becomes particularly serious in immunocompromised patients, 
is related to increasing mutations within the gene TK. Therefore, new antiviral approaches 
able to suppress both lytic and possibly also latent infections are highly required. 
 
 
Figure 1.2.14 Diagram of the mechanism of action of nucleoside analogs as ganciclovir or acyclovir. 
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2 AIM OF THE STUDY 
 
G-quadruplex structures are widespread within key regions of the human genome, such as 
telomeres and oncogene promoters. The additional stabilization of G-quadruplex structures by 
interacting with rationally-designed small molecules was proved to interfere with crucial 
biological mechanisms as replication and transcription. Therefore, this non-canonical 
secondary conformation of DNA has become an interesting therapeutic target in oncology.  
Increasing evidences of putative G-quadruplex sequences in viruses, such as HIV, EBV and 
HPV, make G-quadruplex emerge also as a novel and very attractive antiviral target. 
In the present study, efforts were focused on the family of herpesviruses with a particular 
attention to herpes simplex virus-1 (HSV-1) and human herpes virus-6 (HHV-6). 
The main purposes of this study were:  
1. Identification of putative and conserved G-quadruplex folding region in the genome 
of HSV-1 and HHV-6, and their ability to effectively fold in G-quadruplex in the 
absence or presence of G-quadruplex inducing/stabilizing small molecules in vitro. 
2. Evaluation of the antiviral properties of commercially available G-quadruplex ligands 
on both HSV-1 and HHV-6 infected cells.  
3. Study of the G-quadruplex ligand mechanism of action involved in the antiviral effect 
against these viruses. 
4. Visualization of viral DNA-related G-quadruplex structures in infected cells. 
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3 MATERIALS AND METHODS 
 
3.1 HSV-1 STUDY: MATERIALS AND METHODS 
3.1.1 Selection of putative G-quadruplex sequences in HSV-1 genome 
HSV-1 genome from the Pubmed database (http://www.ncbi.nlm.nih.gov/nuccore) was 
analyzed by QGRS Mapper (http://bioinformatics.ramapo.edu/QGRS/index.php). The 
following restrictions were applied to identify the putative G-quadruplex sequences: i) 
maximum oligonucleotide length of 30 nucleotides (nt), ii) minimum G-group size of 2-3 nt, 
iii) loop size from 0 to 20 nt. Oligonucleotide sequences are reported in Table 1 and Table 2.  
 
Oligonucleotide Sequence (5’→3’) 
gp054a GGGGTTGGGGCTGGGGTTGGGG 
gp054b GGGGTTGGGGTTGGGGTTGGGG 
gp054c GGGGTTGGGGTTGGGGCTGGGG 
gp054d GGGGCTGGGGCTGGGGCTGGGG 
gp054e GGGGCTGGGGCTGGGGTTGGGG 
gp054f GGGGCTGGGGTTGGGGTTGGGG 
un1 GGGGGAGAGGGGAGAGGGGGGGAGAGGGG 
un2 GGGGGCGAGGGGCGGGAGGGGGCGAGGGG 
un3 GGGAGGAGCGGGGGGAGGAGCGGG 
Table 1 Oligonucleotide sequences selected through the analysis the HSV-1 genome. 
 
HSV-1 packaging sequences (Adelman, et al., 2001) were provided by IDT (Integrated DNA 
Technologies, Belgium). The oligonucleotide un1 was purchased from Invitrogen (Monza, 
Italy), whereas all other oligonucleotides were from Sigma-Aldrich (Milan, Italy). 
 
Oligonucleotide Sequence (5’→3’) 
HSV-1 pac1 CCCCC GGGGGG TGTGTTT  CGGGG GGGG 
mut L-poly G CCCTA CCATGG  TGTGTTT  CGGGG GGGG 
mut T-rich CCCCC GGGGGG TGCGCCC CGGGG GGGG 
mut R-poly G CCCCC GGGGGG TGTGTTT  CCCAT  GGGG 
Table 2 Wild-type and mutated HSV-1 (strain F) packaging sequences. 
 
3.1.2 G-quadruplex ligands and other drugs 
TMPyP4 and BRACO-19 were purchased from Calbiochem (Merck Millipore, Darmstadt, 
Germany) and ENDO-Therm (Saarbrücken, Germany), respectively. TMPyP2 was provided 
by Livchem Logistics GmbH (Frankfurt, Germany). Acyclovir (ACV), phosphonoacetic acid 
(PAA) and 3-methyl adenine (3-MA) were from Sigma Aldrich. 
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3.1.3 Circular dichroism and UV spectroscopy 
Polarized light spectroscopy offers the possibility to characterize nucleic acid conformations 
and their complexes with proteins and other ligands. Circular dichroism (CD) is a useful 
indicator of G-4 folding topology and it can also provide structure information on its 
quadruplex-ligand complexes (Ou, et al., 2008). Circular dichroism spectra were recorded on 
a JASCO-810 spectropolarimeter and Chirascan
TM
 CD Spectrometer (Applied PhotoPhysics, 
United Kingdom), both equipped with a temperature controller (Peltier Jasco PTC-4235), 
using a 0.5 cm-path length quartz cuvette. DNA oligonucleotides (Table 1 and Table 2) were 
diluted to the final concentration of 4 μM in a buffer containing lithium cacodylate (10 mM, 
pH 7.4) and 0, 20, 50 or 100 mM KCl. All samples were denatured by heating at 95°C for 5 
minutes, gradually cooled to room temperature and measured after 24 h with Nanodrop 1000 
Spectrophotometer (Thermo Scientific, Illkirch Cedex, France). BRACO-19, TMPyP4 or 
TMPyP2 were added after DNA folding at a final concentration of 16 μM. CD experiments 
were performed using the following parameters: speed scanning 50-100 nm/min, response 
time 4 seconds, accumulation 2, wavelengths from 230-320 nm or 230-600 nm in the 
presence of compounds. CD spectra were baseline-corrected for signal contributions due to 
the buffer and obtained ellipticity (mdeg) was converted into molar ellipticity  ((θ) = deg × 
cm
2
 × dmol
−1
) based on sample concentration. Spectra were recorded at 20°C or over a 
temperature range of 20-95°C with temperature increase of 5°C.  
UV spectra were carried out using a Lambda25 UV/Vis spectrometer (PerkinElmer) equipped 
with a Peltier temperature controller, and a quartz cell of 10-mm optical path length. 
Oligonucleotides were diluted to a final concentration of 4 μM in a lithium cacodylate (10 
mM, pH 7.4) and KCl (0 mM or 100 mM) buffer. UV spectra were recorded at 295 nm over a 
temperature range of 20-95°C, with temperature increase of 5°C. A 5 min equilibration period 
at each measurement was allowed to ensure homogeneous sample temperature. 
 
3.1.4 Electrophoretic mobility shift assay (EMSA) 
All oligonucleotides were gel-purified before use and prepared in desalted/lyophilised form 
(Table 1). Oligonucleotides were 5’-end-labelled with [γ- 32P]ATP by T4 polynucleotide 
kinase and purified by MicroSpin G-25 columns (GE Healthcare Life Sciences, Europe). 
They were next resuspended (1.8 µM final concentration) in lithium cacodylate 10 mM, pH 
7.4, with or without 100 mM KCl, heat-denatured and folded. To check for the presence of 
oligomers, 
32
P-labeled oligonucleotides (10 pmoles) were heat denatured and folded in the 
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presence of increasing amounts of cold oligonucleotides (10-290 pmoles), with or without 
KCl (100 mM), to a final concentration of 1.5-25 µM. All samples were loaded on 16% non-
denaturing polyacrylamide gels, with or without 100 mM KCl, run for ~16 hours at 40 volts. 
Gels were visualized by phosphorimaging (Thyphoon FLA 7000, GE Healthcare Life 
Sciences, Europe). 
 
3.1.5 Cell lines and Viruses 
Vero cells (African green monkey from ATCC, CCL-81) were propagated in Dulbecco’s 
modified Eagle’s medium (DMEM GIBCO, Life Technologies, Monza, Italy or Corning 
Cellgro, Manassas, VA, USA) supplemented with 10% fetal bovine serum (FBS, GIBCO Life 
Technologies, Monza, Italy or Sigma Aldrich, Canada) supplemented with non-essential 
amino acids (Sigma-Aldrich), HEPES, sodium pyruvate (Multicell Wisent Inc., St-Bruno, 
Québec, Canada) and plasmocin 5 g/ml (InvivoGen, San Diego, CA, USA) or PenStrep 1X 
(Life Technologies). Cell culture incubator was normally set at 37°C and 95% humidity, in an 
atmosphere of 5% CO2.  
The HSV-1 strain F was kindly provided by Dr. B. Roizman (University of Chicago, Illinois 
USA) and ATCC (VR-733).  
 
3.1.6 Cytotoxicity 
Cytotoxicity of the compounds was investigated by a 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. Vero cells were plated at a density of 1 ×10
4
 
cells/well in 96-well tissue culture plates to a final volume of 100 l and were grown 
overnight. Cells were treated with increasing concentrations of compounds, previously diluted 
in the appropriate solvent. Each sample was tested in triplicate. At 48 h post treatment cell 
survival was evaluated: 10 l of freshly dissolved MTT solution (5 mg/ml in sterile PBS 1X, 
Sigma Aldrich) were added, cells were subsequently incubated for 4 h at 37°C, CO2 5%. 100 
l/well of a SDS-HCl solution (sodium dodecyl sulphate 10%, HCl 0.01 M) were then added, 
cells were then incubated overnight at 37°C and absorbance was determined at 620 nm 
(Sunrise Tecan Spectrophotometer). Cell growth was also monitored by count: Vero cells 
were plated and treated with increasing compound concentrations every 24 h. Cell growth was 
assessed by counting cell number every 24 h (Cellometer Auto T4, Nexcelom Bioscience). 
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3.1.7 Viral titration assay 
Vero cells were seeded at a density of 2.5×10
5
 cells per well in 6-well tissue culture plates, 
pre-treated with BRACO-19, TMPyP4 or TMPyP2 (0.04 µM-25 µM) for 16 h, infected with 
HSV-1 strain F at a multiplicity of infection (MOI) of 1 Plaque Forming Units (PFUs). After 
1 h infection at 37°C, cells were washed twice with PBS 1X and maintained in culture 
medium supplemented or not with G-quadruplex ligands (0.04 µM-25 µM). At 24 h post 
infection (h.p.i.), supernatants were collected, cleared by centrifugation at 300 rcf and stored 
at -80°C until assayed.  
To test the autophagy hypothesis, 3-methyladenine was added at the final concentration of 1 
mM, from -1 h.p.i. up to supernatant collection (24 h.p.i.). 
Virus plaque assay was performed using confluent Vero cells in 24-well culture plates (1×10
5
 
cells/well). Cells were infected with 250 µl of serially-diluted (10-fold) supernatants. Every 
dilution was tested in triplicate. At 1 h.p.i., Vero cells were washed and incubated with 500 µl 
of DMEM supplemented with 2% FBS and 0.6% methyl cellulose (Sigma-Aldrich). Viral 
plaques were counted at 48 h.p.i. by fixing the cell monolayer with 1 ml/well of formaldehyde 
5% (in PBS 1X) and crystal violet 0.8% (in ethanol 50%).  
 
3.1.8 Time of addition and early-entry viral assay 
Vero cells were seeded in 24-well at a density of 9×10
4
 cells per well tissue culture plates. 
After 24 hours, to assess whether BRACO-19 had an impact on viral entry or fusogenic 
events, cells were treated at various time points (at -1, 0, 1, 2 h) relative to infection with 
HSV-1 strain F at a MOI of 1 PFU/cell. After 1 h at 37°C, cells were washed with PBS 1X 
and maintained in culture medium. Alternatively, to identify when G-quadruplex ligands 
mediate their effect within the HSV-1 replicative cycle, infected cells were treated every two 
hours (from 0 h.p.i. up to 12 h.p.i. and at 24 h.p.i.) with BRACO-19 (25 µM), or ACV (10 
µM) as reference drug. At 30 h.p.i. supernatants were collected and titrated as described 
above. 
 
3.1.9 Transmission electron microscopy (TEM) 
Vero cells were infected with HSV-1 strain F and treated with BRACO-19 (5 and 25 µM) and 
TMPyP4 (1, 5, 25 µM), as described above. At 24 h.p.i., cells were washed twice with PBS 
1X, detached with trypsin and collected by centrifugation at 300 rcf for 5 minutes at room 
temperature. Pellets were carefully resuspended with 2.5% glutaraldehyde (Sigma Aldrich) in 
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PBS 1X and incubated at room temperature for 4 hours, then stored at 4°C until processing 
and analysis with transmission electron microscopy (FEI Tecnai™). 
 
3.1.10  Real-time PCR 
Total HSV-1 intracellular DNA and RNA were collected from confluent Vero cells, similarly 
to the procedure used to collect viral supernatants, as described above. HSV-1 intracellular 
DNA was collected at 3 or 20 h.p.i. Infected and treated Vero cells were detached with trypsin 
(Wisent Inc.), centrifuged at 300 rcf and resuspended in 200 µl of PBS 1X. DNA extraction 
was performed using QIAamp DNA blood Mini Kit (QIAgen, Toronto, Canada), according to 
the manufacturer’s instructions. RNA was isolated at 24 h using TRIzol reagent (Life 
Technologies), according to the manufacturer’s instructions. All RNA samples were treated 
with RNase-free DNase I (Ambion Turbo DNA free, Life Technologies), resuspended in 
DEPC water (Sigma Aldrich) and stored at -80°C.  
Reverse transcription was carried out using 1 µg of total RNA in a reaction mixture composed 
of buffer 1X, MgCl2 3 mM, dNTPs 0.5 mM, random hexamers 2 μM, RNase inhibitor 0.5 
U/μl, MuLv 1.5 U/μl and DEPC water. Reverse transcription was performed under the 
following conditions: 10 minutes at 25°C, 60 minutes at 48°C and 5 minutes at 95°C using the 
Thermo Cycler Verity 96 (Applied Biosystem, Life Technologies, Monza, Italy). 
Forward/reverse primers and FAM-TAMRA fluorescent probes, used to perform TaqMan 
real-time PCR, were designed within conserved HSV-1 gene sequences, using Primer Express 
3 (Applied Biosystem) (Table 3).  
 
TaqMan real-time/sybr green primer sequences 
Gene Name Primers (5’3’) Probe (5’-FAMTAMRA-3’) Amplicon 
length (bp) 
-genes  US1 GGCCCGGAGTGTGATCTTAG 
GGTGGCATCGGAGATTTCAT 
AGATTCATCTCAGCGCGAC
AAGCGA 
70 
US12 CAACGGGTTACCGGATTACG 
TTGGGTGTGGCACATCGA 
ACTGTCGGTCACGGTCCCG
CC 
68 
UL54 ACATTGCATCCTTCGTGTTTGT 
AAGGGTCGCGTAGTCGATCTC 
TTCTGGCCAGGCTCGCCAA
CC 
86 
-gene UL30 TTCGACTTTGCCAGCCTGTA 
CAGGGAGAGCGTGCTGAAG 
AGCATCATCCAGGCCCAC
AACCTG 
69 
-genes UL36 TCCGTCTCCCGAATGACATC 
GCACGTGCTGGACGAAAACT 
ACAAGGATCAGCTTCGCC
AGCGC 
87 
UL37 CGGCTAACGGACGAAACG 
GTATGGATTGGTTACTGATGAA
CGA 
AAGCGCGAAACACGCCGT
CG 
81 
Housekeeping 
gene 
-actin TCACTGAGCGCGGCTACA 
CCTTAATGTCACGCACGATTTC 
TCACCACCACGGCCGAGC
G 
69 
Table 3 Primer sequences designed to perform TaqMan and SYBR
®
 green real-time PCR. 
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All oligonucleotides (Table 3) were purchased from Sigma-Aldrich, and were tested for 
potential cross-reactivity with unrelated viral or other microbial sequences using BLAST 
alignment software (http://blast.ncbi.nlm.nih.gov/).  
Each real-time PCR mixture contained: master mix 2X (Applied Biosystem), forward/reverse 
primer mixture 900 nM, probe 200 nM, sterile water and 5 µl of a 10-fold diluted 
complementary DNA (cDNA). Each sample was analyzed in triplicate. β-actin was used as 
housekeeping gene, whereas non-treated retro-transcribed HSV-1 RNA as a negative control. 
Real-time PCR experiments were performed in ABI 7900 HT – FAST Real Time PCR 
System under the following conditions: 2 minutes at 50°C (1 cycle), 10 minutes at 95°C (1 
cycle), followed by 50 cycles of 15 seconds at 95°C and 1 minute at 60°C. Differently, 
isolated HSV-1 intracellular DNAs were analyzed by real-time PCR using SYBR
®
 green as 
the detection reagent. The reaction was performed in a final volume of 20 µl containing 
SYBR
®
 green fast 2X (QIAgen), forward and reverse primers at 500 nM (Table 3) (IDT, 
Coralville, USA) and isolated viral DNA at 100 nM. Data were collected using a Rotor Gene 
Q thermo cycler (QIAgen) with the following cycling conditions: 95°C for 5 minutes, 
followed by 40 cycles of 5 seconds at 95°C and 10 seconds at 60°C. 
 
3.1.11  Taq-polymerase stop assay 
Taq-polymerase stop assay was initially carried out using synthesized DNA oligonucleotides 
(Table 4). T4 polynucleotide kinase was from Invitrogen (Paisley, UK), [-32P]ATP from 
Perkin Elmer (MA, USA). Primer (HSV Taq primer, Table 4) was 5’-end labelled with [γ-
32
P]ATP using T4 polynucleotide kinase at 37°C for 30 min. The labelled primer (final 
concentration 72 nM) was annealed to the template (final concentration 36 nM) in lithium 
cacodylate buffer (10 mM, pH 7.4). Where specified, samples were incubated with KCl 10 
mM in the presence or absence of BRACO-19 (0.5 µM, 1 µM) at room temperature. Primer 
extension was accomplished with 2 U of AmpliTaq Gold DNA polymerase (2 U/reaction, 
Applied Biosystem, Carlsbad, California, USA) at 60°C for 30 minutes. Reactions were 
stopped by ethanol (EtOH) precipitation, primer extension products were separated on a 15% 
denaturing gel, and finally visualized by phosphorimaging (Typhoon FLA 9000). 
In addition, Taq polymerase stop assay was performed on the full length HSV-1 DNA 
previously extracted from semi-confluent Vero cells infected with HSV-1 strain F. At 90% 
cytopathic effect (CPE), the cell monolayer was lysed with repeated freeze/thaw cycles, the 
HSV-1-containing supernatant was collected and cleared by centrifugation at 11000 rcf. HSV-
Materials and Methods 
 
59 
 
1 DNA was isolated by incubation at 56°C for 10 minutes with 500 μl Lysis buffer 
(Biomerieux) and 20 μl proteinase K, following extraction on easyMAG (Biomerieux). An 
appropriate volume of a 10-fold diluted HSV-1 DNA was denatured at 95°C for 10 min and 
gradually cooled to room temperature. After 90 minutes, increasing concentrations of 
BRACO-19 or TMPyP2 were added and samples stored overnight at 4°C. DNA amplification 
was achieved both by standard PCR, stained with GelRed in 1% agarose gel and visualized 
with Typhoon FLA 9000, and real-time PCR and detected with SYBR
®
 green. Standard PCR 
was performed using Verity 96 Thermo Cycler under the following conditions: 95°C for 5 
minutes followed by 35 cycles of 1 minutes at 94°C, 30 seconds at 58°C, 1 minutes at 72°C 
and finally 3 minutes at 72°C. PCR mixtures were composed of buffer 1X, MgCl2 2 mM, 
dNTPs 0.2 mM, primers 0.2 µM, sterile water and 5 µl of HSV-1 DNA treated with 
increasing compound concentrations (500 nM-16 µM, 1:2 dilutions) or sterile water. PCR 
reagents were provided by Fermentas (Milan, Italy). Real-time PCR was performed using 
ABI 7900 HT – FAST Real Time PCR System with the following conditions: 95°C for 10 
minutes followed by 40 cycles of 30 seconds at 95°C and 30 seconds at 58°C, 1 minutes at 
72°C. The mixtures were composed of SYBR
®
 green PCR Master Mix 2X (Applied 
Biosystem), primers 0.18 µM, sterile water and 5 µl of HSV-1 DNA treated with increasing 
compound concentrations (250 nM-4 µM, 1:2 dilutions). All primer sequences were 
synthesized by Sigma Aldrich (Table 4). 
 
Taq polymerase stop assay (on designed oligonucleotide templates for sequencing) 
Oligonucleotide 
name 
Oligonucleotide 
function 
Oligonucleotide sequence (5’3’) Amplicon 
length (bp) 
HSV Taq primer  primer GGCAAAAAGCAGCTGCTTATATGCAG - 
HSV Taq non-
G4 control 
template TTGTCGTTAAAGTCTGACTGCGAGCTCTCAGATCCT
GCATATAAGCAGCTGCTTTTTGCC 
60 
un2 template TTTTTGGGGGCGAGGGGCGGGAGGGGGCGAGGGGT
TTTTCTGCATATAAGCAGCTGCTTTTTGCC 
65 
un3 template TTTTTGGGAGGAGCGGGGGGAGGAGCGGGTTTTTCT
GCATATAAGCAGCTGCTTTTTGCC 
60 
gp054a template TTTTTGGGGTTGGGGCTGGGGTTGGGGTTTTTCTGCA
TATAAGCAGCTGCTTTTTGCC 
58 
gp054d template TTTTTGGGGCTGGGGCTGGGGCTGGGGTTTTTCTGC
ATATAAGCAGCTGCTTTTTGCC 
58 
Taq polymerase stop assay primer sequences (for full length HSV-1 DNA) 
un primer 
 
GTGTCACGGGGAAAGAGCA 
CCAAGTGTTTGCCCAGTAACAC 
288 
gp054 primer AGGGAGGATGCCCACGAA 
GACCGTCAGCCGCCTGTC 
357 
non-G4 control primer AGGGAGGATGCCCACGAA 
TCCGCGTCTTCCACAAATC 
68 
 
Table 4 Primer and template sequences of oligonucleotides used to perform Taq-polymerase stop assays. 
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3.2 HHV-6 STUDY: MATERIALS AND METHODS 
3.2.1 Analysis of the HHV-6 genome 
The genome of both HHV-6A (GS and U1102 strains) and HHV-6B (Z29 and HST strains), 
from the Pubmed database (http://www.ncbi.nlm.nih.gov/nuccore), were analyzed by QGRS 
Mapper (http://bioinformatics.ramapo.edu/QGRS/index.php). As described above for HSV-1, 
the following restrictions were applied to study the leading and lagging strands of the viruses: 
i) maximum oligonucleotide length of 30 nucleotides (nt), ii) minimum G-group size of 2-3 
nt, iii) loop size from 0 to 20 nt.  
 
3.2.2 Cell lines and Viruses 
Molt-3 (ATCC, CRL-1552), HSB-2 (ATCC, CCL-120.1) and pheripheral blood mononuclear 
cells (PBMCs) were propagated in RPMI-1640 medium (Corning Cellgro) containing 10% 
FBS (Sigma-Aldrich) and supplemented with HEPES and plasmocin 5 g/ml (InvivoGen). 
PBMCs were isolated from blood samples using a lymphocyte separation medium (Wisent 
Inc.). Cell lines were normally grown at 37°C and 95% humidity, in an atmosphere of 5% 
CO2. 
HHV-6B (Z29 strain) was provided by the HHV-6 Foundation, HHV-6A (GS strain) was 
purchased from the NIH AIDS Repository. 
 
3.2.3 G-quadruplex ligands and other drugs 
TMPyP4 was purchased from Calbiochem, whereas BRACO-19 from Sigma-Aldrich. 
TMPyP2 was provided by Livchem Logistics GmbH. 
 
3.2.4 Cytotoxicity studies 
Cytotoxicity of TMPyP4, BRACO-19 and TMPyP2 was investigated by a 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, following the cell 
growth every 24 hour post treatment. HSB-2, Molt-3 and PBMCs were plated in 96-well 
tissue culture plates (final volume of 100 μl/well), at a density of 3.5×104 cells/well, 2.5×104 
cells/well and 5×10
4
 cells/well, respectively. Therefore, cells were treated with increasing 
concentrations of these compounds (concentration range from 1 nM up to 1 mM), and 
incubated at 37°C. At 48 hours post incubation, cells were treated a second time. Every 
sample was tested in triplicate. Cell survival was evaluated at 96 h post treatment, by adding 
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12 μl/well of MTT solution (TACS TMM cell proliferation assay, R&D systems), 
subsequently cells were incubated for 4 hours at 37°C, CO2. 110 μl/well of a SDS-HCl 
solution (sodium dodecyl sulphate 10%, HCl 0.01 M) were then added and cells were 
incubated overnight at 37°C. The absorbance was determined at 620 nm (Tecan 
Spectrophotometer).  
Cell growth was also monitored by count: the cells were plated at a density of 5x10
4
 in 96-
well tissue culture plates (final volume 200 μl), and treated with increasing concentrations of 
compounds at 0 and 48 hours (day 1 and 3, respectively). Cell growth was assessed by 
counting the cell number every 24 h (Cellometer Auto T4, Nexcelom Bioscience). Cell 
viability was also assessed monitoring the cell growth by counting the cells every 24 h.p.t 
with Cellmeter Auto T4 (Nexcelom Bioscience).  
 
3.2.5 Antiviral activity studies against HHV-6 and nucleic acid isolation 
The different cell tropism of HHV-6A and HHV-6B required distinct procedures to properly 
investigate the activity of TMPyP4, BRACO-19 and TMPyP2 against the viruses. Molt-3 
cells were infected with HHV-6B (strain Z29) at a MOI of 0.5 in complete RPMI-1640, for 4 
hours at 37°C. After the infection, cells were washed twice in PBS 1X, resuspended in the 
appropriate volume of complete medium and distributed at a confluence of 5×10
5 
cells/ml in 
6-well tissue culture. The cells were treated with increasing concentrations of TMPyP4 (2-
fold dilutions from 1 M to 0.125 M or 10-fold dilutions from 1 M to 0.01 M), BRACO-
19 (2-fold dilutions from 2 M to 0.25 M or 2-fold dilutions from 3 M to 0.1875 M) or 
TMPyP2 (2-fold dilutions from 1 M to 0.125 M) at 0 h.p.i. (day 1 p.i.), 48 h.p.i. (day 3 
p.i.), 96 h.p.i.  (day 5 p.i.) and eventually 144 h.p.i. (day 7 p.i.). Aliquots of supernatants and 
cells, previously centrifuged at 300 rcf for 3 minutes,  were collected at 48 h.p.i. (day 3 p.i.), 
96 h.p.i. (day 5 p.i.), 144 h.p.i. (day 7 p.i.), and eventually 192 h.p.i. (day 9 p.i.). 
HSB-2 cells were infected with HHV-6A (strain GS) at a MOI of 0.5 or 1 in complete RPMI-
1640, for 6 hours at 37°C. After the infection, cells were washed in PBS 1X, resuspended in 
complete medium at a confluence of 7.5×10
5
 cells/ml and grown in flasks, to increase the 
infection rate. At 48 h.p.i., cells were distributed in 24-well tissue culture plates and treated 
with increasing concentrations of TMPyP4 (2-fold dilutions from 1 M to 0.125 M or 10-
fold dilutions from 1 M to 0.01 M) or TMPyP2 (2-fold dilutions from 1 M to 0.125 M) 
at 48 h.p.i. (day 3 p.i.), 96 h.p.i.  (day 5 p.i.), 144 h.p.i. (day 7 p.i.), and eventually 192 h.p.i. 
(day 9 p.i.). Aliquots of supernatants and cells, previously centrifuged at 300 rcf for 3 
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minutes,  were collected at 96 h.p.i. (day 5 p.i.), 144 h.p.i. (day 7 p.i.), 192 h.p.i. (day 9 p.i.), 
and eventually 240 h.p.i. (day 11 p.i.). 
PBMCs were isolated from blood samples of donors aged between 18 and 50 years old, in 
accord to the CHU de Quebec ethics committee. PBMCs were extracted by centrifuging 
venous blood samples over a Ficoll gradient, cells were then washed with PBS 1X, counted 
and stimulated for 48 h with PHA-P (10 μg/mL) (Sigma-Aldrich). After this time, PBMCs 
were infected with HHV6-B (strain Z29) or HHV-6A (strain GS) at a MOI of 0.5 or 1, as 
described for Molt-3 and HSB-2. 
In all cases, collected pellets and supernatants were stored at -80°C until DNA isolation. 
Infected and treated cell growth was monitored by counting the cells every 48 h, using an 
automatic cell counter (Cellmeter Auto T4, Nexcelom Bioscience). 
 
3.2.6 HHV-6 DNA isolation 
Intracellular HHV-6 DNAs were isolate using QIAamp DNA blood mini kit (QIAgen), in 
accord to the manufacturer’s instructions.  
Differently, viral DNA from supernatants was isolated as follow: each supernatant was treated 
with 20 µl DNAse buffer 10X (Tris 100 mM, pH=7.5, MgCl2  25 mM, CaCl2  5 mM), 5 µl of 
DNAse (Roche) and incubated at 37°C for 30 minutes, followed by a further incubation at 
70°C for 10 minutes in the presence of 7.5 µl/sample of EDTA (200 mM). Viral DNA 
extraction was completed with QIAamp DNA blood Mini Kit, in accord to the manufacturer’s 
instructions. Before DNA elution, 1x10
6 
copies/sample of a GAPDH-containing plasmid were 
added, as a control to normalize data. 
 
3.2.7 Q-PCR experiments 
The Q-PCR mixture was composed of multiplex mix 2X (Invitrogen, Life Technologies), 
forward/reverse/probe primers (Table 5) at a final concentration of 500 nM, sterile water and 
4-5 µl viral DNA isolated from supernatants or a total of 100 ng of DNA extracted from cells. 
The housekeeping gene GAPDH  used as control.  
Primer sequences were purchased from IDT. Q- PCR experiments were recorded with Rotor 
Gene Q thermo cycler (QIAgen) under the following conditions: 5 minutes at 95°C (1 cycle), 
followed by 40 cycles of 15 seconds at 95°C and 15 seconds at 60°C. 
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Primers Forward/Probe/Reverse primer sequences (5’3’) 
U65-U66 
GACAATCACATGCCTGGATAATG 
56FAM / AGCAGCTGGCGAAAAGTGCTGTGC / 3BHQ_1 
TGTAAGCGTGTGGTAATGGACTAA 
GAPDH 
AAATGAGCCCCAGCCTTC 
5HEX / CGACGTACT / ZEN / CAGCGCCAGCATC / 3IABkFQ 
AATCCCATCACCATCTTCCAG 
Table 5 Forward/probe/reverse primer sequences adopted to perform Q-PCR experiments with HHV-6. 
 
3.2.8 Circular dichroism 
Circular dichroism spectra were recorded with a Chirascan
TM
 CD Spectrometer (Applied 
PhotoPhysics), equipped with a temperature controller, using a 0.5 cm-path length quartz 
cuvette. HHV-6 packaging sequences (Table 6) (Thomson, et al., 1994) were diluted to the 
final concentration of 4 μM in a buffer containing lithium cacodylate (10 mM, pH 7.4) and 0 
or 100 mM KCl. All samples were measured with Nanodrop 1000 Spectrophotometer 
(Thermo Scientific) and denatured by heating at 95°C for 5 minutes, gradually cooled to room 
temperature. CD experiments were performed using the parameters mentioned above. CD 
spectra were baseline-corrected for signal contributions due to the buffer and obtained 
ellipticity (mdeg) was converted into molar ellipticity based on sample concentration. Spectra 
were recorded over a temperature range of 20-90°C, with temperature increase of 5°C.  
 
Oligonucleotide Sequence (5’→3’) 
HHV-6A pac1 CCCC CGGGGGG GCT AAAAAA AGGGGG GTAA 
HHV-B  pac1 CCCC GGGGGGG TTA AAAAAA GGGGGG TAT 
Table 6 HHV-6A (U1102 strain) and HHV-6B (Z29 strain) packaging sequences. 
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3.3 VIRAL G-QUADRUPLEX VISUALIZATION: MATERIALS 
AND METHODS 
3.3.1 Antibodies 
The plasmid pSANG-BG4, used to produce BG4, was kindly provided by Prof. S. 
Balasubramanian (Cambridge, UK) (Biffi, et al., 2013). 1H6 antibody was kindly provided by 
Prof. P. M. Lansdorp (University of Groningen, The Netherlands) (Henderson, et al., 2013). 
 
3.3.2 BG4 production and purification 
BL21DE3-RIL (Cml
R
) competent cells were transformed with the plasmid pSANG-BG4, 
plated in the presence of Luria-Bertani (LB) agar medium, supplemented with kanamycin (50 
g/ml) and chloramphenicol (25 g/ml), and incubated overnight at 37°C. 5 ml of a single-
colony LB preculture were inoculated in 500 ml of LB with kanamycin (50 g/ml) and 
chloramphenicol (25 g/ml), and incubated at 37°C, 250 rpm. When the OD600 reached 0.4-
0.5, the inoculum was induced with isopropyl β-D-1-thiogalactopyranoside (IPTG) 0.3 mM, 
then incubated overnight at 20°C, 250 rpm. The culture was centrifuged at 6000 rpm for 15 
minutes, at 4°C. The pellet was resuspended in binding buffer (sodium phosphate 20 mM, pH 
7.4, NaCl 0.5 M, imidazole 20 mM), sonicated for 2-3 minute in water/ice and spun down 
again at 12000 rpm for 10 minutes at 4°C. Subsequently, the supernatant was filtered and 
BG4 was purified on HisTrap column (Qiagen) using an elution buffer with an imidazole-
increasing gradient (sodium phosphate 20 mM, pH 7.4, NaCl 0.5 M, imidazole 500 mM). 
Dialysis in 4 liters of PBS 1X at room temperature for 4 h was performed to remove salts 
(3500 as molecular weight cut-off of the membrane), followed by BG4 quantification with 
both Bradford assay and bovine serum albumin (BSA) curve. 
 
3.3.3 ELISA assay 
The binding affinity and specificity of both BG4 and 1H6 for G-quadruplex DNA was 
assessed using enzyme-linked immunosorbent assay (ELISA). 96-well plates (NUNC
TM
 
medi-sorp surface, Thermo Scientific) were coated with 100 l/well of an avidin solution (5 
g/ml) (Life Technologies) and incubated overnight at 37°C.  
Biotinylated G-quadruplex folding oligonucleotides (Table 7) were diluted at 2 pmoles/60 l 
in annealing buffer(Tris-HCl 10 mM, pH=7.5; KCl 100 mM) and denatured by heating at 95°C 
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for 10 minutes, gradually cooled to room temperature overnight, and bound (2 pmoles/60 l) 
to the avidin-coated plates by incubation at 37°C for 1 h, followed by repeated washing in 
PBS-T (0.1% Tween 20 in PBS 1X). After a 1 h incubation with BSA 3% (in PBS-T) to 
prevent aspecific interactions, biotinylated oligonucleotides were incubated with BG4 (0-200 
nM, 2-fold dilutions) or 1H6 (0-40 ng/µl, 2-fold dilutions) for 1 or 2 h respectively, and 
washed. In the case of BG4, an additional incubation of 1 h in the presence of an anti-mouse 
α-flag secondary antibody (dilution 1/2500 in PBS-T) (Anti-D Tag, abm) was performed. The 
binding between G-4 structures and BG4 or 1H6 was detected with an anti-mouse horseradish 
peroxidase (HRP) antibody (dilution 1/20000 in PBS-T)  (Jackson ImmunoResearch, USA), 
by incubating the plates in the dark for 1 h. Subsequently, 100 l/well of TMB (3,3’,5,5’-
tetramethylbenzidine, HRP substrate, BD OptEIA
TM
, Thermo Scientific) were added, 
followed by addition of 50 l/well of H2SO4 2N to stop the reaction. Plates were read with 
TECAN at λ=450 nm, using a  reference wavelength of λ=570 nm. 
 
HSV-1 sequences (5’→3’) 
gp054a TTTTTGGGGTTGGGGCTGGGGTTGGGGTTTTT 
un2 TTTTTGGGGGCGAGGGGCGGGAGGGGGCGAGGGGTTTTT 
un3 TTTTTGGGAGGAGCGGGGGGAGGAGCGGGTTTTT 
HHV-6 sequence (5’→3’) 
hTELO TCGAGGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAG
GGTTAC 
HIV sequences (5’→3’) 
LTRII+III+IV TTTTTGGGGACTTTCCAGGGAGGCGTGGCCTGGGCGGGACTGGGGAGT
GGTTTTT 
LTRIII+IV  TTTTTGGGAGGCGTGGCCTGGGCGGGACTGGGGAGTGGTTTTT 
LTRIII+IV M5  TTTTTGGGAGGCGTGGCCTGGGCGTGACTGGGGAGTGGTTTTT 
LTRIII+IV M4+5 TTTTTGGGAGGCGTGGCCTGTGCGTGACTGGGGAGTGGTTTTT 
Reference sequences (5’→3’) 
c-myc GGCATAGTGCGTGGGCG 
Negative control sequences (5’→3’) 
ss-DNA GGCATAGTGCGTGGGCG 
ss-DNA long ACTACTACTGGCATAGTGCGTGGGCGTGAGGGTAG 
ss-DNA high G-content ACTACTACTGGGTGTGTGGTGTGTGTGTGGGTGTG 
TERC DNA GTGGCCATTTTTTGTCTAACCCTAACTGAGAAGGGCGTAG 
H6 TRS CTAACCCTAACCCTAACCCTAGGCCCTAACCCTAACCCTAGGTCTAAC
CCT 
Table 7 Sequence of biotinylated oligonucleotides (biotin at 5’ end) used to perform ELISA assay. ss-DNA 
sequence was reported by Biffi, et al (Biffi, et al., 2013). hTELO is the telomeric sequence. 
 
3.3.4 Circular dichroism 
Negative control sequences (TERC DNA, H6 TRS, ss-DNA, ss-DNA long, ss-DNA high G-
content) (Table 7), used to perform ELISA assay, were analyzed by circular dichroism to 
assess their capability to fold into G-quadruplex. Circular dichroism spectra were recorded 
with a JASCO-815 spectropolarimeter, using a 0.5 cm-path length quartz cuvette. As 
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described above, DNA oligonucleotides were diluted to the final concentration of 4 μM in a 
buffer containing lithium cacodylate (10 mM, pH 7.4) and KCl 100 mM. All samples were 
measured with TECAN, denatured by heating at 95°C for 5 minutes and gradually cooled to 
room temperature. CD spectra were recorded at 20°C, under the following parameters: speed 
scanning 100 nm/min, response time 4 seconds, accumulation 2, wavelengths from 230-320 
nm. CD spectra were baseline-corrected for signal contributions due to the buffer and 
obtained ellipticity (mdeg) was converted into molar ellipticity  ((θ) = deg × cm2 × dmol−1) 
based on sample concentration. All oligonucleotides were purchased from IDT. 
 
3.3.5 Cell lines and Viruses 
As mentioned above, Vero cells (ATCC, CCL-81) were propagated in Dulbecco’s modified 
Eagle’s medium (Life Technologies or Corning Cellgro) supplemented with 10% FBS (Life 
Technologies or Sigma Aldrich) supplemented with non-essential amino acids (Sigma-
Aldrich), HEPES, sodium pyruvate (Multicell Wisent Inc.) and plasmocin 5 g/ml 
(InvivoGen) or PenStrep 1X (Life Technologies). The HSV-1 strain F was purchased  from 
ATCC (VR-733), whereas the GFP-expressing recombinant virus V41 was kindly provided 
by Professor P. O’Hare (La Boissière, et al., 2004). 
Molt-3 (ATCC, CRL-1552) were propagated in RPMI-1640 medium (Corning Cellgro) 
containing 10% FBS (Sigma-Aldrich) and supplemented with HEPES and plasmocin 5 g/ml 
(InvivoGen). HHV-6B (Z29 strain) was provided by the HHV-6 Foundation. 
 
3.3.6 Immunofluorescence 
For HSV-1 G-quadruplex visualization, Vero cells were seeded at 5-7x10
4 
cells/well in 8-well 
plates (8-well cultureslide, BD Falcon
TM
) and grown overnight at 37°C. The cells were 
infected with the GFP-expressing recombinant virus V41 at a MOI of 0.5 (occasionally also 
0.2, 1 or 4) for 1 h at 37°C, then washed with PBS 1X and incubated at 37°C in complete 
DMEM. Cells were also treated with PAA (400 µg/ml), or ACV (200 µM), as control.  
At different time post infection (2, 4, 6, 8, 9, 12, 14, 16, 18 and 20 h.p.i.), cells were fixed in 
4% paraformaldehyde (Sigma Aldrich) in PBS and then permeabilized with 0.5% tween 20 in 
PBS 1X for 50-60 minutes at room temperature. At this step, cells were eventually treated 
with 40 µg/ml of RNase A in PBS 1X (Thermo Scientific) or 0.12 U/µl of DNAse I 
(Fermentas) in buffer 1X (Ambion Turbo DNA free, Life Technologies) for 1 h at 37°C. 
Subsequently, Vero cells were blocked with 5% normal FBS (Life Technologies) in PBS 1X 
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for 12 h at 4°C. Cells were then incubated with 1H6 (diluted to 1 µg/ml in PBS 1X), for 2 h at 
room temperature. Cells were washed with 0.2% PBS-T, and incubated in the dark for 1 h at 
room with alexa Fluor-546 anti-mouse IgG (Life Technologies). Following repeated washing 
in 0.2% PBS-T and PBS 1X, the nuclear staining for DNA was obtained by incubating the 
cells in the dark with DRAQ5
®
 at a dilution of 1:1000 (Cell Signaling Technologies), for 5 
minutes at room temperature. Cells were washed and mounted in Dako mounting medium 
(Dako, Denmark). Slides were analyzed using a confocal microscope Nikon A1R+. 
Although the many similarities, some different working conditions were necessary to test 
BG4 on infected Vero cells: the blocking step was performed by incubating the cells for 1 h 
with 3% BSA. BG4 was diluted to 1/100 in 3% BSA (stock concentration 520 ng/µl) and cells 
were incubated for only 1 h at room temperature. BG4 also required a further incubation of 1 
h with an anti-mouse α-flag secondary antibody, diluted to 1/500 or 1/1000 in PBS 1X (stock 
concentration 100 μg/μl). Moreover, detection was reached by incubating the cells, in the 
dark, for 1 h with alexa Fluor-488 anti-mouse IgG or alexa Fluor-568 anti-mouse IgG (Life 
Technologies). Slides were mounted using the slow-fade, containing DAPI for the DNA 
nuclear staining (Life Technology). Slides were analyzed with an Olympus BX-51 upright 
microscope, using a 40x or 60x UPlan Apo objective and processed with ImagePro 4.5.1 
software (Media Cybernetics, Silver Spring, MD). 
To detect G-quadruplex structures within the genome of HHV-6, Molt-3 cells were infected 
and treated as described above. Cells were centrifuged, counted and resuspended in order to 
distribute 10
5
 cell/10 µl in each well of multitest slides (MP Biomedicals, LLC., Germany). 
Cells were fixed in cold acetone 100% at -20°C for 10 minutes, and re-hydrate in PBS 1X for 
5 minutes. An additional permeabilization in 0.5% tween 20 in PBS 1X was eventually 
performed to improve the interaction with 1H6. The remaining consecutive steps were carried 
out as described above for BG4. 
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4 RESULTS AND DISCUSSION 
 
4.1 HSV-1: RESULTS AND DISCUSSION 
4.1.1 Analysis of herpes simplex virus-1 genome 
Following the observation that GC content of the HSV-1 genome is extremely high (68%, 
with peaks of 84.7% in simple sequence repeats) (Ouyang, et al., 2012), we initially 
investigated the theoretical possibility of G-quadruplex folding by an online algorithms-based 
software for recognition and mapping of putative Quadruplex forming G-Rich Sequences 
(QGRS) (http://bioinformatics.ramapo.edu/QGRS/index.php) (Kikin, et al., 2006), on both the 
leading and lagging strands.  
Among several hits, we selected nine regions that presented highly repeated putative QGRS 
(Table 1, Table 8 and 9). Six of them (named gp054a-f) were mainly found in the leading 
strand of the gp054 gene (positions 71.527-71.728 bp, Gene Bank Accession Number 
GU734771.1) (Figure 4.1.1) which encodes UL36, the largest viral protein and essential viral 
tegument component (McNabb & Courtney, 1992). Two repeats of gp054b were additionally 
identified in the leading and lagging strand of the gene encoding the ubiquitin E3 ligase ICP0 
(RL2) (Table 9).  
 
Name Sequence (5’→3’) G-score* 
gp054a GGGGTTGGGGCTGGGGTTGGGG 63 
gp054b GGGGTTGGGGTTGGGGTTGGGG 63 
gp054c GGGGTTGGGGTTGGGGCTGGGG 63 
gp054d GGGGCTGGGGCTGGGGCTGGGG 63 
gp054e GGGGCTGGGGCTGGGGTTGGGG 63 
gp054f GGGGCTGGGGTTGGGGTTGGGG 63 
un1 GGGGGAGAGGGGAGAGGGGGGGAGAGGGG 62 
un2 GGGGGCGAGGGGCGGGAGGGGGCGAGGGG 62 
un3 GGGAGGAGCGGGGGGAGGAGCGGG 36 
Table 8 The analysis of HSV-1 genome allowed to select nine putative G-quadruplex forming sequences named 
gp054 (a-f) and un (1-3). DNA sequences and G-scores are shown. *G-score: propensity of a sequence to fold 
into unimolecular G-quadruplex assigned by the QGRS software. 
 
The gp054 series sequences displayed the G4XTG4XTG4XTG4XT common motif, where X 
was either a T or a C base. All gp054 sequences were highly conserved among four reference 
HSV-1 strains. On the whole, gp054 sequences were repeated 13-14 times and covered about 
220 bps. Three more putative QGRS were found clustered at the terminal and internal repeats 
(both long and short) of the HSV-1 genome (Figure 4.1.1 and Table 8, 9). The exact role of 
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these regions is as yet unknown and thus the QGRS in these positions were named “un”. In 
the leading strand, un1 and un2 sequences were located in segments b of TRL and c of TRS, 
respectively; un3 laid in segment a of both TRL and TRS. Identical “un” sequences were also 
found in the lagging strand: un1 was found in segment b’ of IRL, un2 and un3 in segments c’ 
of IRS and a’ of IRS/IRL, respectively (Figure 4.1.1 and Table 9). Each “un” sequence was 
highly repeated (5-18 times) and conserved among different HSV-1 strains (Table 9). On the 
whole, the un sequences covered about 900 bps in the leading strand and 700 bps in the 
lagging strand.  
 
Name Strains Positions Repeats and genes 
  Leading strand (5’3’) Lagging strand 
(5’3’) 
Leading strand Lagging 
strand 
gp054a F 
17 
H129 
KOS 
71527-71620 
71612-71705 
71561-71654 
71580-71757 
- 
- 
- 
- 
4 UL36 
4 UL36 
4 UL36 
4 UL36 
- 
- 
- 
- 
gp054b F 
17 
H129 
KOS 
4121-4142/71587-71608 
4138-4159/71672-71693 
4114-4135/71621-71642 
71616-71637 
30075-30096 
29987-30008 
29892-29913 
- 
1 UL36, 1 TRL (RL2) 
1 UL36, 1 TRL (RL2) 
1 UL36, 1 TRL (RL2) 
1 UL36 
1 IRL (RL2) 
1 IRL (RL2) 
1 IRL (RL2) 
- 
gp054c F 
17 
H129 
KOS 
71593-71632 
71678-71717 
71627-71666 
71574-71661 
- 
- 
- 
- 
1 UL36 
1 UL36 
1 UL36 
2 UL36 
- 
- 
- 
- 
gp054d F 
17 
H129 
KOS 
71623-71722 
71708-71807 
71657-71756 
71652-71739 
- 
- 
- 
- 
4 UL36 
4 UL36 
4 UL36 
3 UL36 
- 
- 
- 
- 
gp054e F 
17 
H129 
KOS 
71707-71728 
71792-71813 
71741-71762 
71562-71745 
- 
- 
- 
- 
1 UL36 
1 UL36 
1 UL36 
2 UL36 
- 
- 
- 
- 
gp054f F 
17 
H129 
KOS 
71581-71626 
71666-71711 
71615-71660 
71568-71655 
- 
- 
- 
- 
2 UL36 
2 UL36 
2 UL36 
3 UL36 
- 
- 
- 
- 
un1 F 
17 
H129 
KOS 
8966-9147 
9049-9213 
9010-9174 
8997-9161 
34922-35103 
34898-35062 
34804-34968 
34768-34932 
5 TRL (b) 
5 TRL (b) 
5 TRL (b) 
5 TRL (b) 
5 IRL (b’) 
5 IRL (b’) 
5 IRL (b’) 
5 IRL (b’) 
un2 F 
17 
H129 
KOS 
150989-151306 
151064-151381 
150962-151279 
150854-151171 
25157-25474 
25090-25407 
25087-25404 
25009-25326 
9 TRS (c) 
9 TRS (c) 
9 TRS (c) 
9 TRS (c) 
9 IRS (c’) 
9 IRS (c’) 
9 IRS (c’) 
9 IRS (c’) 
un3 F 
17 
H129 
KOS 
93-296/151880-152083 
106-309/151929-152132 
106-333/151771-151974 
118-309/151734-151925 
26047-26250 
25955-26158 
25896-26111 
25889-26080 
8 TRL,8 TRS (a) 
8 TRL,8 TRS (a) 
9 TRL,8 TRS (a) 
8 TRL,8 TRS (a) 
8 IR (a’) 
8 IR (a’) 
9 IR (a’) 
8 IR (a’) 
Table 9 Location and sequence repeats of the selected putative G-quadruplex forming oligonucleotides, in the 
genome of HSV-1, are shown. 
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To note that all identified sequences, apart from un3, were characterized by four GGGG-
tracts, therefore possessing the ability to fold into 4-tetrad stacked G-quadruplex. This kind of 
tetraplex is in principle very stable, as denoted by the high G-scores obtained by these 
oligonucleotides (Table 9). The un3 sequence displayed four GGG-tracts therefore gaining a 
lower G-score. However, three Gs were additionally present in each of the two 6-base-long 
loops. Because increasing evidence demonstrates the possibility that non-sequential G bases 
take part to G-quadruplex formation (Mukundan & Phan, 2013), more options for the building 
of a very stable quadruplex structure are also available for the un3 sequence. 
 
 
Figure 4.1.1 Schematic representation of the HSV-1 genome. G-quadruplex forming regions and their position 
within the genome are indicated. The terminal (TRL and TRS) and internal (IRL and IRS) repeats are shown as 
rectangles. The leading and lagging strands are depicted by a thick and thin line, respectively. 
 
 
4.1.2 Biophysical characterization of selected HSV-1 putative G-4 
sequences 
To determine the possibility of G-quadruplex formation and the likely topology of the HSV-1 
putative QGRS, circular dichroism spectroscopy was carried out.  
Parallel G-4 structure usually shows a strong positive band at 265 nm and a minimum around 
240 nm; CD spectra with a maximum around 295 nm and a negative peak around 260 nm 
typically display an antiparallel conformation; two peaks at both 265 nm and 295 nm are 
characteristic of a mixed-type G-4 structures which indicate the coexistence of distinct 
parallel and antiparallel folded species in solution (Bugaut & Balasubramanian, 2008). 
In the presence of physiological concentrations of K
+
, all tested oligonucleotides displayed 
CD G-quadruplex signatures. In particular, gp054 oligonucleotides exhibited a maximum at 
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290 nm and a shoulder at 260 nm, indicative of a hybrid G-quadruplex (Figure 4.1.2a); un2 
presented two positive peaks at 290 nm and 240 nm and a negative peak at 260 nm, 
characteristic of an antiparallel topology, while un1 and un3 showed a main positive peak at 
260 nm and a negative peak at 240 nm, signature of a parallel conformation (Figure 4.1.2b).  
 
 
Figure 4.1.2 CD analysis of HSV-1 G-quadruplex forming sequences in the absence or presence of K
+
 100 mM. 
CD spectra of the gp054 series oligonucleotides a) in the presence or c) without K
+
. b) CD spectra of the un 
series oligonucleotides with K
+
 100 mM and d) in the absence of K
+
. e) Thermal unfolding analysis of HSV-1 G-
quadruplex sequences. Molar ellipticity at the peak wavelength has been plotted against temperature. 
 
Usually, G-quadruplex folding occurs in the presence of K
+
, while in the absence of this 
monovalent cation oligonucleotides are mostly unfolded. The HSV-1 oligonucleotides, 
however, displayed positive peaks at 290 and 260 nm, characteristic of G-quadruplex 
conformation, even in the absence of K
+ 
(Figure 4.1.2c,d), indicating strong propensity to fold 
into the tetraplex structure. Stability of HSV-1 G-quadruplexes in the presence of K
+
 was 
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assessed by thermal denaturation experiments monitored by CD (Figure 4.1.3) and UV 
spectroscopy (Figure 4.1.2e). As shown in Figure 4.1.2e, 4.1.3 and Table 10, in the presence 
of K
+
, all gp054 series oligonucleotides were stable up to 80°C and unfolded only at higher 
temperature, with Tm values around 90°C. Un2 was even more stable, with Tm above 95°C, 
while un3 showed two transitions with Tm at 65°C and above 95°C, indicating the presence of 
at least two conformations (Table 10). 
 
 
Figure 4.1.3 CD thermal denaturation analysis. Spectra of the indicated oligonucleotides, in the presence of K
+
 
100 mM, during thermal unfolding are shown. Arrows indicate spectra progression during temperature 
increasing. 
 
 
Sequence Tm (UV,  
100 mM K+) 
Tm (CD, 
100 mM K+) 
Tm (CD no K+) ΔTm[100 mM/no K+] 
(CD) 
gp054a 87.4 ± 0.4 88.1±1.3 24.7±0.7/48.0±1.1 63.4/40.1 
gp054b 88.0 ± 0.4 87.5±1.1 25.5±0.4/48.4±1.6 62.0/39.1 
gp054c 92.3 ± 0.8 90.8±0.3 23.2±0.8/51.7±1.3 67.6/39.1 
gp054d 91.5 ± 0.1 90.7±0.3 29.8±0.8/71.3±2.6 60.9/19.4 
gp054e 91.7 ± 0.6 87.5±0.5 23.7±1.2/58.0±0.8 63.8/29.5 
gp054f 88.1 ± 0.1 88.0±0.2 25.2±0.5/51.9±1.4 62.8/36.1 
un1 nd nd 40.8±9.8 nd 
un2 > 95 > 95 50.3±0.9 > 44.7 
un3 64.06 ± 0.68, >95 65.3±1.2, >95 34.7±4.7 30.6/ > 60.3 
Table 10 Stability of HSV-1 G-quadruplex folding sequences measured by UV and CD, and in the 
presence/absence of K
+
. 
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Because of the very low solubility of un1 in the presence of K
+
, Tm values for this sequence 
were not obtained. Tm values obtained by UV thermal unfolding analysis were in very close 
accordance with those obtained by CD (Table 10). In the absence of K
+
, CD-monitored 
unfolding of gp054 oligonucleotides showed two transitions: the first one with a maximum at 
around 290 nm displayed Tm below 30°C; the second one, with a positive peak at 260 nm 
with Tm around 50°C. The only exception was gp054d which reported a second Tm of 71.3°C. 
In the absence of K
+
, un2 was the most stable sequence, followed by un1 and un3 (Table 10).  
The ability of the HSV-1 QGRS to fold into G-quadruplex was further assessed by EMSA 
analysis. After folding in the absence or in the presence of K
+
, oligonucleotides were loaded 
onto native gels lacking or containing K
+
 100 mM, respectively. Even in the absence of K
+
, 
all gp054 sequences run markedly faster than their 22 bp-length control marker, indicating 
folding in these conditions (compare lanes a-f with lane M, Figure 4.1.4a). In particular, 
gp054d displayed the fastest mobility. This oligonucleotide also exhibited the highest Tm 
value (second transition) in the absence of K
+ 
(Table 10), confirming its inherent best aptitude 
to fold into G-quadruplex in the absence of K
+
.  
The 29 bp- and 28 bp-long sequences un1 and un2, respectively, also migrated faster than the 
22-long control marker (compare lanes 1-2 with lane M, Figure 4.1.4a), indicating effective 
folding. In the case of un1, its low solubility was responsible for the lower signal. In contrast, 
the 23 bp-long un3 migrated as an unfolded oligonucleotide (compare lane 3 with lane M, 
Figure 4.1.4a), confirming its lower tendency to fold in the absence of K
+
 (see lower G-score, 
Table 8, and lower stability, Table 10). In the presence of K
+ 
(Figure 4.1.4b), the gp054 
sequences maintained their G-quadruplex conformation as monomolecular species. In 
addition, lower migrating species, ascribable to intermolecular dimeric G-quadruplex forms, 
were also observable (lanes a-f, Figure 4.1.4b). Un1 and un2 remained essentially unvaried 
with respect to no K
+
 conditions (lanes 1-2, Figure 4.1.4b), while un3 in this case run faster 
than the 22 bp-long marker (lane 3, Figure 4.1.4b), indicating effective folding in the presence 
of the monovalent cation.  
The ability of the HSV-1 GQRS to form intermolecular multimeric G-quadruplexes was 
further evaluated by EMSA with increasing concentrations of unlabelled oligonucleotide. As 
shown in Figure 4.1.5, the gp054 sequences only were able to efficiently form dimer 
tetraplexes (Figure 4.1.5a), while un2 and un3 essentially did not fold into dimers even at high 
oligonucleotide concentration (Figure 4.1.5b,c).  
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Figure 4.1.4 Electrophoresis mobility shift analysis (EMSA) of HSV-1 oligonucleotides. Oligonucleotides were 
folded a)  in the absence or b) presence of K
+
 and loaded on native gels lacking or containing K
+
, respectively. 
The identity and length of each oligonucleotide are shown above and below the gel image, respectively. M 
indicate a marker lane loaded with two oligonucleotides with known length and unable to fold into secondary 
structure. 
 
 
 
 
Figure 4.1.5 EMSA analysis of HSV-1 oligonucleotides. Each labelled oligonucleotide was incubated with 
increasing concentrations of the same unlabelled oligonucleotide and loaded on a native polyacrylamide gel. The 
identity of each oligonucleotide is shown above the gel image. M indicate a marker lane, loaded with two 
oligonucleotides with known length and unable to fold into secondary structure. C is a control lane, lacking the 
unlabelled oligonucleotide. The monomeric and dimeric forms are indicated as Mon and Dim.  
 
 
4.1.3 Stabilization of HSV-1 G-4 forming sequences by G-quadruplex 
ligands 
Given the capability of all the HSV-1 selected sequences to form highly stable G-quadruplex 
structures at several conditions, the G-quadruplex ligands BRACO-19 and TMPyP4 were next 
tested by CD analysis for their ability to bind the HSV-1 GQRS in the presence of K
+
.  
BRACO-19 converted the shoulder at 260 nm of the gp054 oligonucleotides into a negative 
peak, therefore shifting the initial hybrid G-quadruplex towards an antiparallel-like 
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conformation (Figure 4.1.6a,b). Differently, a similar peak conversion is induced by TMPyP4 
only in gp054a, gp054b, gp054d and gp054e (Figure 4.1.6b), but not in gp054c (Figure 
4.1.6a) and gp054b.  
 
 
Figure 4.1.6 Biophysical analysis of HSV-1 G-quadruplex forming oligonucleotides in the presence of two G-
quadruplex ligands: spectra of the a) gp054c, b) gp054e, c) un2 and d) un3 oligonucleotides (4 µM) in the 
presence or absence of BRACO-19 or TMPyP4 (16 µM) are shown. 
 
During thermal unfolding, different conformations were sequentially stabilized by both 
BRACO-19 and TMPyP4. The initial antiparallel conformation of gp054 oligonucleotides in 
the presence of both ligands was shifted to a parallel conformation at higher temperatures 
(Figure 4.1.7a,d). In contrast, un2 and un3 maintained their innate antiparallel and parallel, 
topologies, respectively in the presence of the compounds (Figure 4.1.6c,d) and during 
thermal unfolding (un2 in Figure 4.1.7b,e; un3 in Figure 4.1.7c,f). BRACO-19 further 
stabilized all HSV-1 oligonucleotides, increasing Tm to above 95°C. 
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Figure 4.1.7 CD thermal denaturation analysis in the presence of TMPyP4 (a, b, c) or BRACO-19 (d, e, f): 
spectra of the indicated oligonucleotides (4 µM) during thermal unfolding, in the presence of the two G-
quadruplex ligands (16 µM), are shown. Arrows indicate spectra progression during temperature increasing. 
Numbers indicate temporal sequence of spectra variation. 
 
Additional evidence of the intrinsic stability of the identified HSV-1 G-quadruplexes and on 
the possibility of strongly stabilizing them with BRACO-19 was provided by the Taq 
polymerase stop assay. Extended un2, un3, gp054a and g054d sequence templates (Table 4) 
were designed to contain a primer-annealing region. Following primer annealing, the 
templates were treated with Taq polymerase in the absence/presence of K
+
 and with 
increasing concentrations of BRACO-19. As shown in Figure 4.1.8, all G-quadruplex forming 
sequences except un3 did stop the polymerase at the first G-rich region encountered by the 
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enzyme even in the absence of K
+ 
(lanes 1, un2, gp054a, gp054d, Figure 4.1.8). When the 
cation was added, a strong stop was observed in all G-quadruplex templates (lanes 2, un2, 
un3, gp054a, gp054d, Figure 4.1.8). Upon addition of BRACO-19 the intensity of the initial 
stop site dramatically increased (see lanes 3-4, un2, un3, gp054a, gp054d, Figure 4.1.8). 
Moreover, an additional stop site corresponding to a second G-rich region was observed in the 
un2 template, possibly indicating the presence of multiple G-quadruplex structures. In 
contrast, a control sequence devoid of G-tracts that could fold into tetraplex did not show any 
stop site in the presence of K
+
 and BRACO-19 (lanes 1-4, non-G4, Figure 4.1.8), indicating 
that the observed polymerase inhibition was G-quadruplex dependent and specific. 
 
 
Figure 4.1.8 Taq polymerase stop assay on un2, un3, gp054d and gp054a DNA templates in the absence and 
presence of K
+
 10 mM (- and + lanes, respectively) and in the presence of increasing concentration of BRACO-
19 (0.5 µM, 1 µM) (B19 lanes). A non-G-quadruplex template (non-G4 lanes) was also used as negative control. 
P indicates primer. RT pausing sites are indicated by arrows. G clusters are shown aside each gel image.  
 
 
4.1.4 Antiviral property of G-quadruplex ligands against HSV-1 
Once demonstrated that selected putative HSV-1 G-quadruplex forming sequences can 
effectively fold into stable G-quadruplex structures, which are further stabilized by K
+
 and G-
quadruplex ligands, we next assayed the commercially available compounds, BRACO-19 and 
TMPyP4, for antiviral activity. Given the differential effect on HSV-1 replication cycle, the 
two G-quadruplex ligands are discussed individually. 
TMPyP2, a porphyrin derivative which shares chemical features, i.e. a large aromatic surface 
and cationic moieties, with BRACO-19 and TMPyP4, but displays a different G-quadruplex 
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binding mode and markedly lower G-quadruplex binding affinity (Han, et al., 2001), (Le, et 
al., 2013), was used as a negative control.  
 
4.1.5 Antiviral activity of BRACO-19 on HSV-1 
Given the ability of BRACO-19 to recognize and stabilize HSV-1 G-quadruplexes, we tested 
the possibility that it displayed antiviral activity.  
Cytotoxicity of BRACO-19 was assessed on Vero cells, a monkey kidney epithelial cell line 
which sustains HSV-1 infection (Figure 4.1.9).  
 
 
Figure 4.1.9 Cytotoxicity of BRACO-19 and TMPyP2 (µM). MTT assay with a) BRACO-19 (0.04-25 µM) or 
b) TMPyP2 (0.04-125 µM). b), Growth curve analysis, obtained by treating Vero cells with c) BRACO-19 or d) 
TMPyP2 (0.04-25 µM). 
 
BRACO-19 was non-cytotoxic up to 25 µM, the highest tested dose, (cytotoxic concentration 
required to reduce the cell number by 50%, CC50 > 25 μM) (Figure 4.1.9a), whereas TMPyP2 
was non-cytotoxic up to 125 µM (CC50 > 125 μM) (Figure 4.1.9b). In addition, they did not 
impair cell growth up to 5 days of daily-treatments (Figure 4.1.9c,d). Increasing 
concentrations of BRACO-19 or TMPyP2 were added to Vero cells infected with HSV-1 
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strain F (MOI 1), and supernatants were collected at 24 h.p.i. Infectious viruses present in the 
supernatants were quantified by plaque assay.  
As shown in Figure 4.1.10, BRACO-19 demonstrated an effect at 200 nM and its antiviral 
activity increased up to 70% at 25 µM (EC50 = 10 μM). The compound TMPyP2, used as 
reference, was inactive up to 1 µM, while it showed 50% inhibition at the highest 
concentration (EC50 = 25 μM) (Figure 4.1.10).  
 
 
Figure 4.1.10 Plaque assay: infected cells (MOI 1) were treated with increasing concentrations (0.04 M – 25 
M) of BRACO-19 and TMPyP2; supernatants were collected at 24 h.p.i. and the number of plaque forming 
units was determined. 
 
4.1.5.1 Effect of BRACO-19 on viral entry 
It has been shown that HSV-1 fusion to the cells is mediated by interaction of several viral 
glycoproteins, most importantly gB and gC (Herold, et al., 1991), with heparan sulfate, a 
polysaccharide present on the cell surface (Reske, et al., 2007). BRACO-19, as most G-
quadruplex binding molecules, is a polycationic agent, the observed antiviral activity might be 
mediated by the interaction of BRACO-19 with the negatively charged heparin sulfate, thus 
preventing virus attachment to the cells.  
To test this hypothesis, BRACO-19 was added at different times post-infection until the virus 
had completed its fusion to the cell and entry (i.e. 1 h.p.i.) (Sodeik, et al., 1997). In this time 
range we did not observe any difference to the activity obtained by treating the cells 1 h pre-
infection (Figure 4.1.11), indicating that, despite its polycationic nature, BRACO-19 does not 
act by inhibiting virus fusion to the cells. 
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Figure 4.1.11 Effect of BRACO-19 on virus entry into the cells. Cells were treated with BRACO-19 (25 M) at 
various time points (-1, 0, 1, 2 h) relative to infection with HSV-1 strain F at a MOI of 1. After an infection of 1 
h at 37°C, cells were washed and maintained in culture medium. At 30 h.p.i. supernatants were collected and 
titrated by plaque assay. Virus yields are given as % relative to the untreated control. 
 
 
4.1.5.2 Mechanism of action of BRACO-19 against HSV-1 
Because large portions of the viral genome could fold into G-quadruplex structures and could 
be stabilized by BRACO-19, we investigated if compound treatment impaired polymerase 
processing at the viral genome. To test this hypothesis, we extracted HSV-1 DNA from a viral 
stock and treated it with increasing concentrations of BRACO-19 and TMPyP2. The gp054 
sequences (within the UL36 coding region) and the un G-rich tracts (in the TRL region) were 
amplified by standard PCR using Taq polymerase and primers (Table 4) that annealed to the 
relevant G-rich flanking regions. A non-G-rich/non-G-quadruplex forming region (in the 
UL36 coding region) was also amplified as negative control sequence.  
Amplified DNA corresponding to gp054 and un G-quadruplex forming regions decreased in a 
concentration-dependent manner in the presence of BRACO-19 (Figure 4.1.12a, un and 
gp054 with BRACO-19). In contrast, BRACO-19 was not able to disrupt polymerase 
processing in the non-G-quadruplex forming region (Figure 4.1.12a, non-G4 with BRACO-
19) and TMPyP2 had no effect on enzymatic activity both in the G-quadruplex and non-G-
quadruplex forming regions (Figure 4.1.12a, un, gp054 and non-G4 with TMPyP2). For 
quantification purposes, HSV-1 DNA extracted from infected cells treated with increasing 
amounts of BRACO-19 and TMPyP2 were amplified by real-time PCR and quantified by 
SYBR
®
 green. As shown in Figure 4.1.12b, amplification of the G-quadruplex forming region 
(gp054) was inhibited up to 40% (with respect to the non-treated control, 100%) in the 
presence of BRACO-19 (4 μM), while no effect was detected in the non-G-quadruplex 
forming region, confirming lack of activity of the compound against the polymerase enzyme.  
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Figure 4.1.12 Inhibition of HSV-1 DNA replication by BRACO-19. a), b), c) Inhibition of DNA replication in 
G-quadruplex regions in vitro. gp054 and un G-quadruplex regions were elongated using the Taq polymerase 
stop assay, in the presence of increasing concentration of a) BRACO-19 or c) TMPyP2 (2-fold dilutions from 16 
M to 0.25 M). A non-treated sample (lane N) and a sample without DNA (lane C) were used as negative 
controls. M indicates the marker. b) Real-time PCR on a gp054 G-quadruplex sequence and a control non-G-
quadruplex region was performed in the presence of BRACO-19 or TMPyP2 (2-fold dilutions from 4 M to 0.25 
M). Quantification of amplified products was obtained by SYBR® green detection. HSV-1 DNA was extracted 
from HSV-1-infected Vero cells. In all cases, HSV-1 DNA was extracted from HSV-1-infected Vero cells.  
d) Quantification of intracellular DNA amounts obtained from infected cells at 3 h and 20 h.p.i., treated with 
increasing concentration of BRACO-19 (B19) and TMPyP2 (P2), with n ≥ 3, mean ± s.d., Student’s t-test, 
**P < 0.01. RQ are Relative Quantities. DNA was detected using specific IE-gene, E-gene or L-gene primers 
sequences (Table 3). e) Time-of-addition assay of BRACO-19. Vero cells were infected with HSV-1 strain F and 
BRACO-19 was added at different time points after infection. Virus was collected at 30 h.p.i. and quantified by 
plaque assay. The activity of BRACO-19 was compared with that of the negative control (non-treated infected 
cells) and of ACV as reference drugs. Data representative of two independent experiments.  
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As expected, TMPyP2 was also inactive against both G-quadruplex and non-G-quadruplex 
forming sequences. This data demonstrate that BRACO-19 specifically interact with G-
quadruplex forming regions in the HSV-1 genome in vitro and inhibit polymerase processing 
likely due to the steric hindrance caused by multiple tetraplex structures stabilized by the 
ligand.  
We therefore tested whether viral DNA replication was impaired by BRACO-19 in infected 
cells.  HSV-1 infected cells (MOI 1) were treated with different amounts of BRACO-19 or 
TMPyP2 and intracellular viral DNA was extracted post-infection and quantified by real-time 
PCR. DNA extraction was performed at three different time points likely before (3 h.p.i.), 
during (8 h.p.i.) and after (20 h.p.i.) the viral DNA was replicated in cells by the viral 
replication machinery. As shown in Figure 4.1.12d, BRACO-19 reduced intracellular viral 
DNA levels to 50% of the untreated control (100%) at the highest concentration only at 8 
h.p.i. and 20 h.p.i. (Figure 4.1.12d). In contrast, BRACO-19 at 3 h.p.i. and TMPyP2 did not 
affect viral DNA amounts. In addition, BRACO-19 at 8 and 20 h.p.i. did not modify DNA 
amounts of a control cellular gene (Figure 4.1.12d). These results indicate that BRACO-19 
exerts its antiviral activity by acting specifically at the viral DNA level. 
To further define the viral step affected by the compound, a time-of-addition experiment was 
set up (Daelemans, et al., 2011). This experiment determines how long the addition of a 
compound can be postponed before its antiviral activity is lost in a single replication cycle. 
Thus, HSV-1 replication is blocked up to a time point corresponding to the occurrence of the 
last viral step targeted by the drug, which can be revealed comparing the antiviral effect of the 
test compound with that of a reference compound with established mode of action in the time 
frame of replication events. Cells were infected at an MOI of 1, and BRACO-19 was added 
each 2 hours, over 12 h after infection, as indicated in Figure 4.1.12e. Supernatants were 
collected at 30 h.p.i. and virus replication was monitored by plaque assay. ACV was used as 
reference compound targeting viral DNA replication (James & Prichard, 2014). When treating 
infected cells with BRACO-19, a sharp increase in virus amounts (PFU/ml) was observed 
between 8 and 10 h.p.i., indicating that the compound is active at events that occur in this 
time range. Interestingly, ACV showed a similar increase between 8-12 h.p.i.  
Since ACV acts by inhibiting the viral DNA polymerase during DNA replication, these data 
confirm the activity of BRACO-19 during early events of the virus life cycle, including direct 
inhibition of the replication machinery or reduction of functions in trans, such as the activity 
of promoters/genes that are involved in virus DNA replication (Figure 4.1.12e and Figure 
4.1.13). 
Results and Discussion 
84 
 
 
 
Figure 4.1.13 Scheme of the site of action of  BRACO-19 on HSV-1 infected cell. 
  
Results and Discussion 
 
85 
 
4.1.6 Antiviral activity of TMPyP4 on HSV-1 
We investigated the possibility that a second G-quadruplex ligand, TMPyP4, displayed 
antiviral activity against HSV-1.  
Cytotoxicity of TMPyP4 was first assessed on Vero cells with MTT assay. The compound did 
not affect cell viability up to 100 µM, the highest tested dose (CC50 > 100 μM) (Figure 
4.1.14a). Moreover, cell growth was not impaired by this compound up to 5 days, following 
daily-treatment (Figure 4.1.14b). Increasing concentrations of TMPyP4, or TMPyP2, were 
added to Vero cells infected with HSV-1 strain F (MOI 1). Supernatants were collected at 24 
h.p.i. Infectious viruses present in the supernatants were quantified by plaque assay.  
Interestingly, the antiviral activity of TMPyP4 was even higher than that of BRACO-19. 
Similarly to BRACO-19, TMPyP4 demonstrated an effect of 22% at 200 nM (Figure 4.1.14c), 
but its antiviral activity increased up to 90-100% at 1 µM (EC50 = 600 nM). A complete 
inhibition was observed at higher concentrations (5 μM, 25 μM) (Figure 4.1.14c, 4.1.18a).  
 
 
Figure 4.1.14 a) Cytotoxicity of TMPyP4 assayed using MTT assay (0.001-100 µM). b) Growth curve analysis, 
obtained by treating Vero cells with TMPyP4 (0.04-25 µM). c) Plaque assay: infected cells (MOI 1) were treated 
with increasing concentrations (0.2 M – 25 M) of TMPyP4 and TMPyP2; supernatants were collected at 24 
h.p.i. and the number of plaque forming units was determined. 
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4.1.6.1 Entry and viral replication as possible TMPyP4-mediated 
mechanisms of action  
Once proved the antiviral property of TMPyP4 on HSV-1, a number of additional assays were 
carried out to study the mechanism of action exploited by this porphyrin.  
To test whether TMPyP4 influence viral entry, HSV-1 (strain F) infected Vero cells were 
treated with the compound (5, 25 µM) at different times post-infection until the virus had 
completed its fusion to the cell and entry. Similarly to BRACO-19, in this time range we did 
not observe any difference to the activity obtained by treating the cells 1 h pre-infection 
(Figure 4.1.15). The result indicates that TMPyP4 does not affect the attachment of the virus 
to the host cells. 
 
Figure 4.1.15 Effect of TMPyP4 on virus entry into the cells. Cells were treated with TMPyP4 (5 M) at various 
time points (0, 2 h) relative to infection with HSV-1 strain F at a MOI of 1. After an infection of 1 h at 37°C, 
cells were washed and maintained in culture medium. At 30 h.p.i. supernatants were collected and titrated by 
plaque assay. Virus yields are given as % relative to the untreated control. 
 
Second, the hypothesis that TMPyP4 impaired viral replication was examined. As described 
above, HSV-1 DNA was isolated from a viral stock and treated with increasing concentrations 
of TMPyP4 (0.1-3.2 µM). Using Taq polymerase stop assay, we demonstrated that TMPyP4 
was able to prevent the amplification of G-rich regions in a dose-dependent manner in vitro 
(Figure 4.1.16a). The primer sequences used to amplify by standard PCR these regions, gp054 
sequences (within the UL36 coding region) and the non-G-rich/non-G-quadruplex forming 
region (in the UL36 coding region), are listed in Table 4.  
Similarly to the effect observed treating HSV-1 DNA with increasing concentrations of 
BRACO-19 (Figure 4.1.12a,b), TMPyP4 was proved to strongly affect the activity of the Taq 
enzyme in a concentration-dependent manner, during the elongation of the G-4 containing 
regions gp054 (Figure 4.1.16a). A non-G-rich/non-G-quadruplex forming sequence was also 
treated with TMPyP4 and amplified, as a negative control sequence. As previously observed 
with BRACO-19 and TMPyP2 (Figure 4.1.12a,b), TMPyP4 was not capable to disrupt 
polymerase processing in the non-G-quadruplex region (Figure 4.1.16b).  
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Figure 4.1.16 Taq polymerase stop assays on HSV-1 DNA treated with increasing concentrations of TMPyP4 
(0.1-3.2 µM). a) Gradual TMPyP4-induced inhibition of the Taq-enzyme processing. b) Defective amplification 
of a non G-4 region, within the HSV-1 genome, previously treated with increasing concentration of TMPyP4 
(0.1-3.2 µM). 
 
We next tested if viral DNA replication was impaired by TMPyP4 in infected cells, as 
observed with BRACO-19. To assess this hypothesis, HSV-1 infected cells (MOI 1) were 
treated with increasing concentration of TMPyP4 (0.04-25 µM), subsequently intracellular 
viral DNA was extracted at 3, 8, 20 h.p.i. and quantified by real-time PCR. In comparison 
with non-treated infected cells used as control, no decrease of viral DNA was detected after 
TMPyP4 treatment (Figure 4.1.17), thus suggesting that viral DNA replication is not affected 
by TMPyP4.  
 
 
Figure 4.1.17 Quantification of intracellular DNA amounts obtained from infected cells at 3 h and 20 h.p.i., 
treated with increasing concentration of TMPyP4 (0.04-25 µM), with n ≥ 3, mean ± s.d., Student’s t-test, 
**P < 0.01. RQ are Relative Quantities. 
 
4.1.6.2 Mechanism of action of TMPyP4 against HSV-1 
Although the extraordinary inhibitory capability displayed by TMPyP4 on HSV-1, viral entry 
and DNA replication were demonstrated not to be affected by the compound. We, therefore, 
hypothesized that the intracellular HSV-1 DNA was not fully infectious or included in mature 
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virions still entrapped within the cytoplasm of cells. To test this hypothesis, we carried out 
two different types of experiments.  
First, Vero cells were infected with HSV-1 (F strain) at a MOI of 1 PFU/ml, treated with 
increasing concentrations of TMPyP4, as described above. At 24 h.p.i., both supernatants and 
cell content were conserved and analysed in parallel. Cells were lysed with repeated 
freeze/thaw cycles to be tested by plaque assay along with the supernatants (Figure 4.1.18). 
 
 
Figure 4.1.18 Plaque assay: infected cells (MOI 1) were treated with increasing concentrations (1 M – 25 M) 
of a) TMPyP4 and b) TMPyP2, as negative control. Supernatants were collected at 24 h.p.i. and the number of 
plaque forming units was determined (dark grey). In parallel, infected and treated Vero cells were lysed with 
repeated freeze/thaw cycles, and intracellular HSV-1 was titrated (light grey).  
 
As previously mentioned, plaque assay from supernatants showed a TMPyP4-induced 
inhibitory effect of up to 90% at 1 µM, whereas the virus was completely knocked down at 
higher concentrations (Figure 4.1.18a). At the same TMPyP4 concentration (1 µM), on the 
contrary, intracellular HSV-1 levels were approximately equal to untreated cells, used as a 
control (Figure 4.1.18a). However, HSV-1 inhibition within the cells was observed at higher 
concentrations (5, 25 µM), thus suggesting that multiple sites of action on the virus are 
affected by TMPyP4. Moreover, these data suggest that TMPyP4 induced trapping of fully 
infectious HSV-1 particles in the cytoplasm of cells.  
TMPyP2 did not display a pronounced activity on the intracellular HSV-1, in comparison 
with the supernatants in which, once again, it was inactive up to 1 µM but it showed a 50% 
HSV-1 inhibition at 25 μM (Figure 4.1.18b).  
We next performed transmission electron microscopy (TEM) experiments to observe the 
precise location of HSV-1, after the treatment with TMPyP4. Following the standard protocol, 
Vero cells were infected with HSV-1 strain F (MOI 1) and treated with TMPyP4 (0 µM as a 
control, and 1, 5, 25 µM). At 24 h.p.i., cells were fixed in 2.5% glutaraldehyde and pellets 
were appropriately processed for TEM analysis.  
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Figure 4.1.19 Transmission electron microscopy analysis. a) Non-treated/infected Vero cells, and infected cells 
treated with b) 1 µM or c) 25 µM of TMPyP4 are shown. In the cytoplasm of infected/treated cells, HSV-1-
containing vesicles are indicated with solid black arrows. Dashed black arrows indicate the nuclear membrane. 
Two cells for each condition are shown.  
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Compared to non-treated infected sample used as a control (Figure 4.1.19a), large vesicles 
enclosing groups of HSV-1 particles were observed within the cytoplasm of infected/treated 
cells (1 µM in Figure 4.1.19b, 25 µM in Figure 4.1.19c). All these vesicles, characterized by 
their own membrane, were located nearby the nuclear membrane.  
Interestingly, HSV-1 particles appeared properly assembled, a DNA-containing dark was is 
visible as well as capsid and tegument in the nucleus and/or the cytosol area. Nevertheless, 
several immature HSV-1 virions were also observed, some of them with an empty core 
(Figure 4.1.19).  
An analogous experimental approach was employed for TMPyP2 and even BRACO-19, to 
verify whether these compounds were also capable to form such particular vesicular 
formations.  
At 1 µM, TMPyP2 was unable to induce the formation of such HSV-1 aggregates. In addition, 
the principal steps of the viral cycle appeared in compliance with the literature, and both 
extensive nuclear egress and cell egress of mature virions were observed (Figure 4.1.20a). 
However, very few HSV-1 containing-vesicles appeared at 25 µM of TMPyP2. This behavior 
could be ascribable to the partial G-quadruplex binding capability of TMPyP2 (Figure 
4.1.20b). Indeed, as mentioned above, TMPyP2 is a porphyrin derivative, conformational 
isomer of TMPyP4, thus sharing a number of chemical features with BRACO-19 and 
TMPyP4 (Han, et al., 2001), (Le, et al., 2013).  
In 1999, for example, the team of Prof. Lawrence Hurley investigated the interactions of 
TMPyP4 and TMPyP2 with an antiparallel quadruplex DNA ([GGGTTA]4). It was 
discovered that both compounds can bind to G-quadruplex with a differential binding mode. 
TMPyP4 binds to the intramolecular quadruplex DNA by stacking externally to the guanine 
tetrad at the GT step, while TMPyP2 binds predominantly to the same G-4 DNA structure via 
external binding to the TTA loop (Han, et al., 1999). Therefore, even if TMPyP2 acts as a G-
quadruplex ligand, its extremely lower binding affinity towards the G-quadruplex still makes 
it the compound of choice to be used as negative control. However, it must be kept in mind 
that some of the observed effects might be due to the residual G-quadruplex binding activity. 
As a further proof of the differential mechanism of action displayed by TMPyP4 and 
BRACO-19, TEM analysis was performed on infected Vero cells treated with several 
concentration of BRACO-19 (5, 25 µM). BRACO-19 did not showed HSV-1 containing 
vesicles (infected/untreated cells as control in Figure 4.1.21a; infected/treated cells with 
BRACO-19 at 5 µM in Figure 4.1.21b and 25 µM in Figure 4.1.21c). 
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Figure 4.1.20 Transmission electron microscopy analysis. TMPyP2-treated/infected Vero cells, at a 
concentration of a) 1 µM or b) 25 µM, are shown. HSV-1-containing vesicles are indicated with solid black 
arrows (b). Dashed black arrows indicate cell egress, dotted black arrows indicate the nuclear membrane (a).  
 
 
 
Figure 4.1.21 Transmission electron microscopy analysis. a) Non-treated/infected Vero cells, and infected cells 
treated with b) 5 µM or c) 25 µM of BRACO-19 are shown. Solid black arrows indicate the nuclear membrane. 
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Overall, we proved that TEM data are in accordance to plaque assay experiments, for both 
TMPyP4 and TMPyP2. Given the 80-90% HSV-1 inhibition in the supernatants (Figure 
4.1.18a), the treatment of infected cells with TMPyP4 (1 µM) impaired the release of mature 
HSV-1 virions from the cytoplasm of Vero cells. TEM revealed that HSV-1 is detectable 
within multivesicular bodies in the cells (Figure 4.1.19b,c, solid arrows). Consequently, these 
data suggest that TMPyP4 could have a role in the HSV-1 maturation and/or egress (Brown, 
et al., 1994). The similarities of the HSV-1 including vesicles to lysosomal vesicles made us 
further hypothesis the involvement of a defensive cellular mechanism, better known as 
autophagy, which is likely TMPyP4-induced.  
Autophagy is postulated to play a role in antiviral innate immunity. It is an evolutionarily 
conserved process in which the cell packages cytosolic constituents in double-membrane 
vesicles and delivers them to the lysosome for degradation (Orvedahl, et al., 2007).  So far, 
herpesviruses have developed strategies to downregulate autophagy, although the varicella-
zoster virus does not seem to encode any autophagy inhibitors (Takahashi, et al., 2009). 
HSV-1-encoded neurovirulence protein ICP34.5, the viral homologs of bcl-2 of Kaposi's 
sarcoma herpesvirus, murine gammaherpesvirus 68 (γHV-68) (Sinha, et al., 2008) (Pattingre, 
et al., 2005), and the human cytomegalovirus (HCMV) TRS1 protein have all been shown to 
block the formation of autophagosomes through their interactions with the autophagy protein 
Beclin 1.  
 
 
Figure 4.1.22 Schematic representation of PKR/eIF2α pathway in HSV-1 (Lussignol, et al., 2012). 
 
Beclin 1 is a critical component of several highly regulated complexes that control the 
formation and maturation of autophagosomes (Lussignol, et al., 2012). Moreover, the protein 
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kinase RNA activated (PKR) is also known to be activated by many viruses because dsRNA 
is a frequent by-product of viral replication or a product of overlapping transcription from the 
compact genomes of DNA viruses. PKR activation blocks viral protein synthesis and, 
consequently, stifles viral production. HSV-1 protein ICP34.5 interacts with the cellular 
phosphatase-1α (PP1α) to mediate the dephosphorylation of the eukaryotic initiation factor 2α 
(eIF2α), thus antagonizing the PKR signaling pathway and inhibiting its autophagy function 
(Figure 4.1.22) (Orvedahl, et al., 2007), (Radtke, et al., 2013), (Lussignol, et al., 2012). As a 
consequence, lack of the HSV-1 protein ICP34.5 can stimulate autophagy. 
Importantly, the un3 cluster corresponds to the promoter of the gene γ134.5 that encodes the 
ICP34.5 protein (Chou & Roizman, 1986). The γ134.5 gene itself is located in the inverted 
repeats of the b sequence of the L component and it is present in two copies per genome 
(Ackermann, et al., 1986). HSV-1 mutants that fail to express the γ134.5 protein are incapable 
of multiplying and causing encephalitis in experimental animal models (Chou, et al., 1990). 
On the contrary HSV-1 mutants, lacking both copies of the γ134.5 gene, can normally 
replicate in some permissive cell lines as Vero cells (Chou & Roizman, 1994). 
Very interestingly, the DR2 segment present in the a region, which overlaps exactly with our 
un3 sequence, has been shown to form an unwound, nuclease sensitive conformation of non-
B DNA, called anisomorphic DNA (Sarisky & Weber, 1994), that entirely matches with the 
G-quadruplex structure presented in this work. Notably, this region has been shown to 
mediate transcriptional repression only in its anisomorphic DNA conformation (i.e. the G-
quadruplex), which perfectly correlates with the notion that G-quadruplex act as 
transcriptional silencers. Many examples of transcriptional repressors have been provided in 
human cells (Cogoi & Xodo, 2006), (McLuckie, et al., 2011), (Qin, et al., 2010).  
In addition, the DR2 segment (un3) has been shown to be bound by the eukaryotic 
transcription factor SP1 (Chung, et al., 1995), which again has been involved in G-
quadruplex-mediated regulation of transcription in human cells (Todd & Neidle, 2008). 
We have recently demonstrated a G-quadruplex-mediated transcriptional silencing activity in 
a SP1 binding region of the HIV-1 long terminal repeat promoter (Perrone, et al., 2013a). It is 
also interesting to note that the un3 G-quadruplex was inherently less stable than the other 
tested sequences (Table 8, 9). This fact raises the possibility that the DNA in this region is 
processed by proteins that alternately stabilize the G-quadruplex and B-form, which in turn 
function as a switch to activate or turn off transcription. A similar behavior has been reported 
for c-myc and KRAS oncogene promoters where different proteins recognize and stabilize the 
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folded and unfolded sequence (Brooks, et al., 2010), (Paramasivam, et al., 2009), (Cogoi, et 
al., 2008). 
To test the autophagy hypothesis, we infected Vero cells with HSV-1 strain F (MOI 1) and 
co-treated the cells with 3-MA, which is reported as an autophagy inhibitor by inhibiting 
phosphoinositide 3-kinase (PI3K) (Le Sage & Banfield, 2012), (Wu & Brosh, 2010). 
Supernatants were collected as 24 h.p.i. and assayed by plaque assay. As shown in Figure 
4.1.23, the co-treatment of infected Vero cells with TMPyP4 (1-25 µM) and 3-MA (1 mM) 
was able to counteract the antiviral effect of TMPyP4 (at 1 µM) of 20%, thus limiting the 
autophagy process. Due to the total HSV-1 inhibition, an almost undetectable differential 
effect was noticed at the highest TMPyP4 concentrations (5 and 25 µM). The lack of a total 
abolishment of TMPyP4 antiviral effect by co-treating with 3-MA is in accord with the 
hypothesis of a multiple site of action of TMPyP4, which is mainly evident at the highest 
concentrations. 
 
 
Figure 4.1.23 Plaque assay of infected Vero cells treated with both TMPyP4 (1-25 µM) and 3-MA (1 mM). The 
differential effect of TMPyP4/3-MA co-treated and infected cells is given as % relative to the TMPyP4-only 
treated/infected cells (% Δ effect). 
 
Further studies are ongoing to confirm the involvement of autophagy in TMPyP4-mediated 
antiviral effect against HSV-1: quantification of a specific autophagy marker (LC3) and the 
effect of TMPyP4 on Vero cells infected with the ICP34.5 mutant R3616 (Chou, et al., 1990). 
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4.1.7 Effect of G-quadruplex ligands on HSV-1 gene expression 
The HSV-1 QGRS are embedded in genes encoding essential viral proteins (gp054 for UL36 
and ICP0). We thus investigated whether the transcription of HSV-1 late genes was impaired 
by G-quadruplex ligand treatment. We designed primers for the transcripts of two γ genes 
(UL36, UL37) (Table 3). Upon treatment of infected cells (MOI 1) with BRACO-19, both 
UL36 and UL37 transcripts were markedly decreased at 24 h.p.i. up to 50% and 60% 
respectively (Figure 4.1.24, BRACO-19). This effect was specific for HSV-1 transcripts since 
no variation in the control ß-actin transcript was observed (Figure 4.1.25), as well as 
following TMPyP4 or TMPyP2 treatment (Figure 4.1.25). 
The treatment with TMPyP4 caused an even higher inhibition up 90% for UL37 and 80% for 
UL36 (Figure 4.1.24, TMPyP4).  
In contrast, TMPyP2 reduced HSV-1 transcript levels to a much lower extent (100-70%).   
 
 
Figure 4.1.24  mRNA levels of selected HSV-1 late genes: infected cells were treated with BRACO-19, 
TMPyP4 or TMPyP2 (5μM). At 24 h.p.i. total RNA was isolated, retrotranscribed into cDNA, and expression of 
specific genes determined by RT-PCR. Ctrl indicates the non-treated Control, RQ are Relative Quantities. In all 
data sets: n ≥ 3, mean ± s.d., Student’s t-test, **P < 0.01. 
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Figure 4.1.25 cDNA levels of the cellular gene ß-actin, indicated as Ct. Infected cells were treated with 
BRACO-19, TMPyP4 or TMPyP2 (1-25 μM); 24 h post infection total RNA was isolated, retrotranscribed into 
cDNA and expression of ß-actin gene determined by RT-PCR. 
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4.2 HHV-6: RESULTS AND DISCUSSION 
4.2.1 Analysis of human herpes virus-6 genome 
The genomic architecture shared by HHV-6A and HHV-6B is unique among herpesviruses 
(Figure 1.2.10) (Braun, et al., 1997). For the present study, the most interesting feature 
showed by the HHV-6 genome is the presence of several reiterations of the hexanucleotide 
(TTAGGG)n.  These reiterations are located nearby the pac1 and pac2 domains within the 
direct repeats DRL and DRR. More specifically, adjacent to the pac2 sequences are serial 
TTAGGG motifs that are identical to the human telomeric repeat sequence (TRS), while those 
adjacent to pac1 are imperfect and are referred to as het(TTAGGG)n sequences. As described 
above, it is presumed that through homologous recombination between the TRS present 
within the HHV-6 genome and the telomeres, the HHV-6 genome, or part of it, gets integrated 
within human chromosomes (Morissette & Flamand, 2010). Although these hexanucleotides 
are present in both HHV-6A and HHV-6B, the context of the reiterated sequences within the 
DR in HHV-6A and HHV-6B differs (Braun, et al., 1997). 
The genome of the main HHV-6A (GS and U1102) and HHV-6B (Z29 and HST) strains was 
analyzed to determine the precise telomeric motif repeat number at the terminal ends of these 
viruses (Figure 4.2.1).  Moreover, following the parameters previously used to analyze HSV-1 
genome, an extensive analysis of both the leading and lagging strands was achieved to 
investigate the presence of additional putative G-quadruplex forming sequences. 
The highest G-quadruplex folding propensity was observed in correspondence with the DRs 
in the lagging strand (G-score of 42), in which the telomeric motifs are repeated as 
(TTAGGG)n (Figure 4.2.1). However, in HHV-6 the G+C content is ~43%, much lower than 
G+C amount in the HSV-1 genome (~68%) (Gompels & Macaulay, 1995) (Braun, et al., 
1997), therefore no other interesting clusters of repeated putative G-quadruplex forming 
sequences were identified. Considering the leading strand, the strain Z29 of HHV-6B 
displayed the greatest number of TTAGGG units (Figure 4.2.1). In all HHV-6 strains, a single 
TTAGGG repeat was also identified between the two telomeric clusters in both DRs, whereas 
repeated and isolated TTAGGG sequences were identified in the unique region of genomes. 
Although the great number of repeats (33 repeats in the strain Z29, 25 in the strain U1102, 19 
and 18 repeats in GS and HST respectively) (Figure 4.2.1), the presence of wide loop regions 
between them prevents the folding into G-quadruplex. 
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Figure 4.2.1 HHV-6 genome analysis. The number of the telomeric motif (TTAGGG) in the genome of the main 
strains of HHV-6A/6B is shown. U indicates the unique long region of the viral genome, het(TTAGGG)n are 
imperfect telomeric repeated sequences. The scheme refers to as the leading strand (5’→3’). 
 
 
4.2.2 Antiviral activity of G-quadruplex ligands against HHV-6 
The G-quadruplex folding ability of the telomeric sequence has been extensively studied and 
its hybrid G-quadruplex structure has been fully characterized by circular dichroism, UV 
spectroscopy, NMR or mass spectrometry (Parkinson, et al., 2002), (Phan, et al., 2007). 
Therefore, we tested the possibility that the two G-quadruplex ligands BRACO-19 and 
TMPyP4 displayed antiviral activity against HHV-6. The antiviral activity of BRACO-19 and 
TMPyP4 was assayed on the T-lymphoblastic cell line Molt-3, which is permissive to HHV-
6B infection. Differently, TMPyP4 was the only G-quadruplex ligand tested on HSB-2 cells, 
which sustain HHV-6A infection, due to the high cytotoxicity of BRACO-19 on these T-
lymphoblasts. PBMCs were also isolated from blood samples of donors and tested for both 
compounds, following the infection with HHV-6A (GS strain) and B (Z29 strain). In all cases, 
TMPyP2 was used as a negative control. 
Cytotoxicity of the compounds was first assessed on Molt-3, HSB-2 and PBMC with MTT 
assay. Compared to Vero cells, TMPyP4 and BRACO-19, tested from 0.01 µM up to 50 µM, 
revealed very high toxicity on Molt-3 and HSB-2 cells, which constituted the most susceptible 
cell line (Table 11). TMPyP2 cytotoxicity on both these cell lines was almost equal to 
TMPyP4 cytotoxicity (Table 11). PBMCs, on the contrary, were generally less affected by all 
compounds.  
The cytotoxicity critically increased after HHV-6 infection. For this reason, cell growth of 
infected cells treated every 48 h with the small molecules was carefully monitored by cell 
count (Figure 4.2.2), and subsequently the concentration range to test the compounds was 
selected.   
 
Results and Discussion 
 
99 
 
 
 BRACO-19 TMPyP4 TMPyP2 
HSB-2 CC50 ~ 2 µM CC50 ~ 10 µM CC50 ~ 10 µM 
Molt-3 CC50 ~ 6.9 µM CC50 ~ 10 µM CC50 ~ 10 µM 
PBMC CC50 ~ 9.5 µM CC50 > 50 µM CC50 > 50 µM 
Table 11 CC50 values of BRACO-19, TMPyP4 and TMPyP2 on the cell lines HSB-2, Molt-3 and PBMC, 
determined with MTT assay. 
 
 
 
Figure 4.2.2 Cell growth of infected Molt-3, HSB-2 and PBMCs monitored by count, after the treatment with 
TMPyP4, BRACO-19 or TMPyP2. For Molt-3 and PBMCs, compounds were added every 48 h at 4 h.p.i. (day 
1), 48 h.p.i. (day 3 p.i.) and 96 h.p.i. (day 5 p.i.); differently, for HSB-2, TMPyP4 was added at 48 h.p.i. (day 3 
p.i.), 96 h.p.i. (day 5 p.i.) and 144 h.p.i. (day 7 p.i.). Cells were counted at 48 h.p.i. (day 3 p.i.), 96 h.p.i. (day 5 
p.i.), 144 h.p.i. (day 7 p.i.), and also 192 h.p.i. (day 9 p.i.) for HSB-2. Cell count of Molt-3 infected with HHV-
6B (Z29 strain, MOI of 0.5) treated with a) TMPyP4, b) TMPyP2 or d) BRACO-19 is shown. c) HSB-2 infected 
with HHV-6A (GS strain, MOI of 0.5) and treated with TMPyP4. e) PBMCs infected with HHV-6B (Z29 strain, 
MOI of 0.5) and treated with TMPyP4. P4 and P2 mean TMPyP4 and TMPyP2, respectively. B19 is BRACO-
19. 
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Molt-3 cells, as well as PBMCs first isolated from blood samples, were infected with HHV-6 
strain Z29 (MOI 0.2 and 0.5) and, subsequently, increasing concentrations of TMPyP4 (2-fold 
dilutions from 1 M to 0.125 M or 10-fold dilutions from 1 M to 0.01 M), BRACO-19 
(2-fold dilutions from 2 M to 0.25 M) or TMPyP2 (2-fold dilutions from 1 M to 0.125 
M) were added every 48 h. Aliquots of supernatant and/or cells were collected every 48 h, 
from 48 h.p.i (day 3, post infection) up to 144 h.p.i. (day 7, post infection). HHV-6 DNA was 
isolated from both supernatant and cell collected samples and assayed with RT-PCR. Non-
treated infected cells were used as control, the housekeeping GAPDH was used as reference. 
Differently, HSB-2 cells were infected with HHV-6A strain GS at a MOI of 0.5 (or 1), grown 
at 37°C, 5% CO2 for 48 h, then treated with TMPyP4 or TMPyP2 (2-fold dilutions from 1 M 
to 0.125 M or 10-fold dilutions from 1 M to 0.01 M). The differential procedure was due 
to the lower rate of infection. 
 
 
Figure 4.2.3 Antiviral effect determined on Molt-3 cells infected with HHV-6B strain Z29 (MOI of 0.5) and 
treated with TMPyP4 or BRACO-19 every 48 h, from 4 h.p.i. up to 96 h.p.i. (day 5 p.i.). Aliquots of supernatant 
and cell were collected at 48 h.p.i. (day 3 p.i.), 96 h.p.i. (day 5 p.i.) and 144 h.p.i. (day 7 p.i.); DNA was 
extracted and quantified by SYBR
®
 green detection. Non-treated infected cells are used as control, GAPDH as 
reference to normalize data. Intracellular viral DNA levels after treatment with a) TMPyP4 (10-fold dilutions 
from 1 M to 0.01 M) or c) BRACO-19 (2-fold dilutions from 3 M to 0.1875 M) are shown. Viral DNA 
levels from supernatant after treatment with b) TMPyP4 (2-fold dilutions from 1 M to 0.125 M) or d) 
BRACO-19 (2-fold dilutions from 2 M to 0.25 M) are also shown. RQ are Relative Quantities, B19 means 
BRACO-19, whereas P4 indicates TMPyP4. 
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Similarly to HSV-1 study, TMPyP4 displayed the most interesting antiviral effect against 
both HHV-6A and HHV-6B.  
As shown in Figure 4.2.3b, TMPyP4 inhibited HHV-6B of 60% at 0.125 µM up to 70% at 
0.5-1 µM at 48 and 144 h.p.i. (day 3, 7 p.i. respectively) (EC50 ~ 0.125 µM). At 96 h (day 5), 
the antiviral effect of TMPyP4 was up to 60%, at the highest tested concentration 1 µM.  
A stronger TMPyP4 effect was observed on PBMCs infected with HHV-6B: the viral 
inhibition was up to 70% at 1 µM at 48 h.p.i. (day 3 p.i.), whereas up to 80-90% at 0.125 µM 
at 96 and 144 h.p.i. (Figure 4.2.4). 
 
 
Figure 4.2.4 Antiviral effect of TMPyP4 (2-fold dilutions from 1 M to 0.125 M) determined on PBMCs 
infected with HHV-6B strain Z29 (MOI of 0.5). Cells were treated every 48 h, from 4 h.p.i. (day 1 p.i.) up to 96 
h.p.i. (day 5 p.i.). Aliquots of supernatant were collected at 48 h.p.i. (day 3 p.i.), 96 h.p.i. (day 5 p.i.) and 144 
h.p.i. (day 7 p.i.); DNA was extracted and quantified by SYBR
®
 green detection. Non-treated infected cells are 
used as control, GAPDH as reference to normalize data. RQ are Relative Quantities. 
 
 
Figure 4.2.5 Antiviral effect of TMPyP4 (2-fold dilutions from 1 M to 0.125 M) determined on HSB-2 cells 
infected with HHV-6A strain GS (MOI of 0.5). Cells were treated every 48 h, from 48 h.p.i. (day 3 p.i.) up to 
144 h.p.i. (day 7 p.i.). Aliquots of supernatant were collected at 96 h.p.i. (day 5 p.i.), 144 h.p.i. (day 7 p.i.) and 
192 h.p.i. (day 9 p.i.); DNA was extracted and quantified by SYBR
®
 green detection. Non-treated infected cells 
are used as control, GAPDH as reference to normalize data. RQ are Relative Quantities. 
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As shown in Figure 4.2.5, on HHV-6A the treatment with TMPyP4 showed a maximal 
antiviral effect of 60% at 144 and 192 h.p.i. (day 7 or 9, respectively) (EC50 ~ 0.125-300 μM). 
As mentioned above, BRACO-19 was tested only on HHV-6B, due to the high cytotoxicity of 
this G-quadruplex ligand on HSB-2. BRACO-19 inhibited HHV-6B up to 80% at 48 h.p.i. 
(day 3 p.i.) (EC50 ~ 0.450 µM). However, although its inhibitory effect was also maintained at 
96 and 144 h.p.i (day 5 and 7, respectively), the progressive increasing rate of infection 
reduced the antiviral property of this acridine derivative up to 40% at the highest tested dose 2 
µM (Figure 4.2.3d). In fact, after the infection with HHV-6 and simultaneously to an increase 
of virus in the cells, cell growth is temporarily reduced within the first 48 h.p.i., followed by a 
further increase of the cell growth up to a predominant cytopathic effect induced by the virus, 
which normally leads to cell death. To follow whether an adequate progression of the 
infection was occurring all along the assay, Ct and/or HHV-6 copies were monitored at the 
increasing time points after infection (Figure 4.2.7). 
The compound TMPyP2, used as reference, was almost inactive up to 1 µM on both HHV-6A 
(Figure 4.2.6b) and HHV-6B (Figure 4.2.6a), indeed it displayed an inhibition of 20% 
maximum at 1 μM).  
Interestingly, no decreased intracellular HHV-6A (not shown) and HHV-6B (TMPyP4 in 
Figure 4.2.3a and BRACO-19 in Figure 4.2.3c) DNA amounts were observed at the 
investigated time points.  
 
 
Figure 4.2.6 Activity of TMPyP2 (2-fold dilutions from 1 M to 0.125 M) determined on a) Molt-3 infected 
with HHV-6B strain Z29 (MOI of 0.5) and b) HSB-2 cells infected with HHV-6A strain GS (MOI of 0.5) is 
shown. Molt-3 cells were treated with the compound every 48 h, from 4 h.p.i. up to 96 h.p.i. (day 5, p.i.), 
aliquots of supernatant were collected at 48 h.p.i. (day 3, p.i.), 96 h.p.i. (day 5, p.i.) and 144 h.p.i. (day 7, p.i.). 
Differently, HSB-2 cells were treated every 48 h, from 48 h.p.i. up to 144 h.p.i. (day 7, p.i.), aliquots of 
supernatant were collected at 96 h.p.i. (day 5, p.i.), 144 h.p.i. (day 7, p.i.) and 192 h.p.i. (day 9, p.i.). In both 
cases, viral DNA contained in the collected supernatants was isolated and quantified by SYBR
®
 green detection. 
Non-treated infected cells are used as control, GAPDH as reference to normalize data. RQ are Relative 
Quantities, whereas P2 indicates TMPyP2. 
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The function of (TTAGGG)n is not known, but it has been hypothesized to play a role in DNA 
packaging and in the maintenance of viral chromosome as a self-replicating episome in 
latently infected cells. The conserved terminal cis-acting herpesvirus packaging signals, pac1 
and pac2, are present in HHV-6A and HHV-6B, flanked by imperfect and perfect iterations of 
TTAGGG. During DNA replication, a head-to-tail arrangement probably occurs, juxtaposing 
the pac1 and pac2 signals in the correct orientation, creating a favored cleavage site for unit-
length molecules (Braun, et al., 1997). 
Further studies are ongoing to confirm this hypothesis and a role of G-quadruplex in the 
packaging of the virus. 
 
 
 
Figure 4.2.7 Progression of HHV-6 infection. Ct referred to infected/non-treated cells (control) at increasing 
days post infection. Figure shows the infection of Molt-3 and PBMCs with HHV-6b (Z29 strain), and HSB-2 
with HHB-6A (GS strain) 
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4.3 VIRAL G-QUADRUPLEX VISUALIZATION IN INFECTED 
CELLS: RESULTS AND DISCUSSION 
 
As extensively discussed above, comprehensive biophysical and structural studies proved that 
G-rich DNA (or RNA) sequences can spontaneously fold into G-quadruplex in vitro. 
Moreover, the additional G-quadruplex stabilization under near-physiological conditions (K
+
) 
suggests that this non-canonical secondary structure may form in genomic DNA in vivo, 
although this is a topic of some debate (Lipps & Rhodes, 2009). In fact, the visualization of 
G-quadruplex in human cells has always represented a big challenge, and only recently the 
first evidences have started to accumulate for its presence and function in vivo.  
DNA G-quadruplex structures are associated with a number of important aspects of genome 
function, which include transcription, recombination and replication (Figure 4.3.1). Therefore, 
the replication of DNA G-quadruplex motifs requires their unfolding by helicases, such as 
BLM (Sun, et al., 1998), FANCJ (Wu, et al., 2008), WRN, REV1 and ATRX (alpha-
thalassaemia/mental retardation syndrome X-linked) (Law, et al., 2010). 
 
 
Figure 4.3.1 Possible locations of G-quadruplex structures in cells. G-quadruplex formation could occur in G-
rich regions of double-stranded DNA, such as at promoter regions of genes (a) and during replication (b) when 
DNA becomes transiently single-stranded. Telomeric G-overhangs are single-stranded, favoring G-quadruplex 
formation (c). (d) Outside the nucleus, G-quadruplexes could form in mRNA and indeed the 5’-UTRs of 
mRNAs, rich in G-quadruplex forming potential. The red crosses indicate possible impediments caused by G-
quadruplexes to replication, transcription and translation (Lipps & Rhodes, 2009). 
 
In 2012, the research team of Prof. Shankar Balasubramanian was the first to provide 
important evidences for the formation of G-quadruplex structures in the genome of human 
cells, using a G-quadruplex selective antibody named BG4. They also proved that G-
quadruplex formation in DNA is modulated during cell-cycle progression and further 
stabilized by the small-molecule ligand pyridostatin (PDS) (Biffi, et al., 2013). 
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In 2013, following the development of a G-quadruplex selective monoclonal antibody named 
1H6, an additional proof of G-quadruplex formation in mammalian cells was provided by the 
team of Prof. Peter M. Lansdorp (Henderson, et al., 2013). 
We have successfully demonstrated the presence of putative G-quadruplex forming sequences 
in both HSV-1 and HHV-6, their capability to effectively form highly stable G-quadruplex 
structures, which are further stabilized by the addition of K
+
 and G-quadruplex ligands, as 
well as the very promising antiviral activity of some of these G-quadruplex ligands such as 
TMPyP4 and BRACO-19. As a further step, we wondered whether it was possible to visualize 
viral G-quadruplex structures in infected cell lines. To this end, we tested both BG4 and 1H6 
antibodies on HSV-1 infected Vero cells (MOI 0.5) and HHV-6B infected Molt-3 (MOI 1), 
through immunofluorescence.   
 
4.3.1 G-quadruplex structure affinity of BG4 and 1H6 
To evaluate the binding affinity of BG4 and 1H6 for viral G-quadruplex forming sequences 
(Table 7) and their different structural conformations, we performed ELISA assay.  
BG4 was first produced in highly competent cells (BL21DE3-RIL) and cells were next 
sonicated to release the protein. Subsequently, BG4 was purified using an imidazole gradient 
(from 20 mM to 500 mM), dialysized in PBS 1X to remove salts and finally quantified 
through the Bradford assay and a BSA curve. 
Briefly, to perform ELISA 96-well plates were coated with avidin and biotinylated G-
quadruplex folding oligonucleotides (2 pmoles/60 µl) (Table 7), previously denatured by 
heating at 95°C for 10 minutes to favor the folding into G-quadruplex, were bound to the 
plate using the interaction avidin-biotin. Following incubation with BG4 (2-fold dilution from 
6.25 to 200 nM) or 1H6 (2-fold dilution from 0.02 to 40 ng/µl), the binding was detected with 
anti-mouse HRP antibody and TMB solution. Before the incubation with HRP, BG4 required 
a further incubation with an anti-mouse α-flag secondary antibody. Non-treated biotinylated 
oligonucleotides were used as control, ss-DNA as negative control to normalize data (Biffi, et 
al., 2013). Absorbance was determined at λ=450 nm, using a reference wavelength of λ=570 
nm. 
The binding between BG4 and HSV-1 G-quadruplex sequences (gp054a, un2 and un3) is 
shown in Figure 4.3.2, whereas the binding between BG4 and HIV-1 G-quadruplex sequences 
(LTR II+III+IV, LTR III+IV, LTR III+IV M5 and LTR III+IV M4+5) (used as positive 
controls) is shown in Figure 4.3.3. As an additional control of the BG4 specificity for G-
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quadruplex DNA, we also tested several non-G4 forming sequences (Table 7). Non-G4 
folding/G-rich sequences (ss-DNA high G-content), non-G4 folding sequences (ss-DNA, ss-
DNA long), C-rich sequences (TERC DNA, H6 TRS), all used as negative controls, are shown 
in Figure 4.3.4.  
 
 
Figure 4.3.2 BG4 (2-fold dilution from 6.25 to 200 nM) binding affinity for G-quadruplex structures determined 
with ELISA assay on the biotinylated HSV-1 sequences gp054a, un2 and un3 (2 pmoles/60 µl); a non-G4-
forming/non G-rich sequence named ss-DNA was used as negative control, whereas c-myc sequence as 
reference. Plates were read at λ=450 nm, using a  reference wavelength of λ=570 nm. 
 
 
Figure 4.3.3 BG4 (6.25-200 nM, 2-fold dilutions) affinity for the biotinylated HIV G4-forming sequences 
determined with ELISA assay (LTR II+III+IV, LTR III+IV, LTR III+IV M5 and LTR III+IV M4+5; all 2 
pmoles/60 µl); ss-DNA was used as negative control and c-myc sequence as reference. Plates were read at λ=450 
nm, using a  reference wavelength of λ=570 nm. 
 
BG4 showed high affinity for all tested G-quadruplex forming sequences located in the HSV-
1 and HIV-1 genome, despite their different G-quadruplex topology. In fact, BG4 interacted 
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with parallel G-quadruplexes, such as un3 and the reference sequence c-myc (Figure 4.3.2), 
with anti-parallel topologies, such as un2 (Figure 4.3.2), and with mixed-type G-quadruplex 
sequences, such as gp054a (Figure 4.3.2), LTR II+III+IV and LTR III+IV (Figure 4.3.3).  
Surprisingly, BG4 displayed affinity also for the mutated HIV sequences LTR III+IV M5 and 
LTR III+IV M4+5, which were proved to fail the folding into G-quadruplex (Perrone, et al., 
2013a). In addition, it bound non-G4-forming/G-rich sequences, long sequences, a C-rich 
sequence (TERC DNA) and a complementary telomeric sequence (H6 TRS) as well. 
 
 
Figure 4.3.4 BG4 (6.25-100 nM, 2-fold dilutions) affinity for biotinylated non-G4 forming sequences 
determined with ELISA assay (2 pmoles/60 µl); ss-DNA was used as negative control and c-myc sequence as 
reference. Plates were read at λ=450 nm, using a  reference wavelength of λ=570 nm. 
 
All the non-G4-forming sequences were analyzed by circular dichroism to confirm that the 
folding into G-quadruplex did not occur in the test conditions (Figure 4.3.5).  
 
 
Figure 4.3.5 CD spectra of negative control sequences (4 μM) in the presence of K+ 100 mM. un2 was included 
ad positive control. Molar ellipticity has been plotted against wavelength. 
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In comparison to G-quadruplex folding sequences, such as un2 and hTELO, the control 
sequences did not display folding into G-quadruplex (Figure 4.3.5). 
Therefore our data suggested that, apart from G-quadruplex DNA structures, BG4 does not 
efficiently discriminate between a wide range of DNA structures. The binding is influenced 
by several factors such as the length of the DNA sequences, the G-content independently of 
the G4-folding ability, and the presence of alternative DNA secondary conformations, most 
likely random coil conformation. 
Very promising results were obtained with 1H6 antibody. Due to the limited antibody 
availability and the high 1H6 concentration required to carry out ELISA assay, only two G-
quadruplex forming sequences could be tested (gp054a and hTELO), and the negative control 
ss-DNA. As shown in Figure 4.3.6, 1H6 displayed differential affinity depending on the G-
quadruplex topology. This monoclonal antibody showed high affinity especially for the 
telomeric sequence (hTELO) and a lower affinity for gp054a. As expected, no binding was 
observed between 1H6 and ss-DNA.  
Interestingly, during the development and characterization of 1H6 antibody, it showed a high 
selectivity also for the sequence GGGGTTGGGGTTGGGGTTGGGG (i.e. gp054b).  
 
 
Figure 4.3.6 1H6 (0.020-40 ng/µl, 2-fold dilutions) affinity for biotinylated G-quadruplex forming sequences 
gp054a (HSV-1) and hTELO (HHV-6), determined with ELISA assay (2 pmoles/60 µl); ss-DNA was used as 
negative control. Plates were read at λ=450 nm, using a  reference wavelength of λ=570 nm. 
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4.3.2 Visualization of viral G-quadruplex DNA structures 
BG4 and 1H6 were tested on HSV-1 infected Vero cells (MOI 1 or 0.5) and HHV-6 infected 
Molt-3 cells (MOI 1) with immunofluorescence. Briefly, Vero and Molt-3 were infected with 
HSV-1 (F strain or mutant) or HHV-6 (Z29 strain) respectively and incubated at 37°C, 5% 
CO2. At selected time points (2-20 h.p.i.), cells were fixed with 4% paraformaldehyde (Vero) 
or 100% acetone (Molt-3), and eventually permeabilized with 0.5% tween-20. The blocking 
step occurred in 5% FBS at 4°C, for 12 h. Cells were then incubated with BG4 (dilution 
1/100, from a stock concentration of 520 ng/µl) or 1H6 (1 µg/ml). BG4 required a further 
incubation with an anti-mouse α-flag secondary antibody. The detection was achieved by 
incubating with alexa Fluor-488 or 594 for BG4, or alexa Fluor-546 for 1H6. Moreover, 
nuclear staining for DNA was achieved with DAPI (BG4 experiments) or DRAQ5
®
 (1H6 
experiments). 
Although the solvent used to fix the cells did not affect the interaction between antibody and 
G-quadruplex DNA structures, BG4 did not display promising results.  
 
 
Figure 4.3.7 Immunofluorescence assay with BG4. a) mock-infected Molt-3 and b) infected Molt-3 cells (MOI 
of 1) were incubated with BG4 (~5.2 ng/μl), α-flag (1 μg/μl) and subsequently with Alexa-546 1/500 (red 
signal). Nuclear staining for DNA (blue signal) was achieved by incubating with DAPI.  
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A very high background signal was detected using alexa Fluor-488, whereas alexa Fluor-594 
abolished aspecific fluorescence but also highlighted that BG4 is unable to completely cross 
the nuclear membrane. Despite increasing MOI or different time points of investigation, the 
red fluorescence, referred to the binding of BG4 with G-4, was comparable among uninfected 
and infected cells (Figure 4.3.7). 
In contrast, visualization of viral G-quadruplex DNA structures was achieved using the 1H6 
antibody. To carry out immunofluorescence, Vero cells were infected with a recombinant 
HSV-1 (F strain) named V41, expressing VP16 linked to the green fluorescent protein (GFP). 
Infected Vero cells were fixed with 4% paraformaldehyde, crucial solvent for a good 
execution of immunofluorescence with 1H6, at several time points depending on the viral 
cycle step. Given that the folding into G-quadruplex depends on separation of the two 
complementary strands by helicases during important physiological processes, such as 
replication or transcription, the selected time points for investigation are strictly related to the 
HSV-1 replication cycle.  
Therefore, we chose two time points preceding viral replication (2 and 4 h.p.i.), two time 
points corresponding to HSV-1 replication (6 and 9 h.p.i.), and a number of time points 
consecutive to viral replication (14 h.p.i., or 18-20 h.p.i.).  
VP16, product of the UL48 gene, is one of the most-abundant tegument proteins. VP16 is 
essential for HSV-1, because it regulates IE-genes transcription, assembly and egress of 
infectious virions. Moreover, it modulates the activity of several viral components, and it is 
assembled in approximately 1000 to 1500 copies per virion (La Boissière, et al., 2004). This 
recombinant virus replicates with virtually normal kinetics and yields and incorporate the 
fusion protein into the virion, resulting in autofluorescent particles.  
As reported by the group of Prof. Peter O’Hare, no significant fluorescence is visible at the 
earliest stages of infection (up to 3 h.p.i.), whereas between 3 and 5-6 h.p.i VP16-GFP is 
detectable as bright punctate foci, mostly as a diffuse pattern within the nucleus. At 
intermediate times from 7 to 12 h after infection, in which VP16-GFP is observable in a 
homogeneous diffuse cytoplasmic pattern, these nuclear foci expand and coalesce into large 
globular domains within the nucleus, likely representing replication compartments. After 12 
h.p.i., VP16-GFP accumulates in vesicular-like foci mainly in the cytoplasm. Moreover 
increasing in intensity and additional accumulation at the boundaries between cells occur at 
late stages (La Boissière, et al., 2004). 
Recombinant HSV-1 V41, therefore, allowed monitoring of the cell infection state and 
locating HSV-1 within infected cells. 
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Interestingly, a very consistent increase of foci (in red), specific for the binding between G-
quadruplex DNA structures and 1H6, following detection with alexa Fluor-546, was observed 
at the two HSV-1 replication-related time points, 6 and 9 h.p.i. (Figure 4.3.8d,e respectively), 
in comparison with mock-infected Vero cells (Figure 4.3.8a). The highest intensity of red 
fluorescence was recorded at 6 h.p.i., corresponding to the beginning of HSV-1 replication. 
Moreover, in comparison with both mock-infected and infected cells, the red fluorescence 
decreased when treating infected cells with PAA (400 μg/ml) (Zhou & Knipe, 2002), which is 
an inhibitor of viral replication (Figure 4.3.9a, PAA treatment). These evidences suggested 
that 1H6 specifically recognized and interacted with viral DNA G-quadruplexes over cellular 
G-quadruplex structures. 
At the earliest stages of infection, 2 and 4 h.p.i. (Figure 4.3.8b,c respectively), 1H6-related 
signal was comparable to the red fluorescence of uninfected Vero cells (Figure 4.3.8a). In 
fact, between 0-1 h.p.i. and 4-5 h.p.i. earlier steps of the replication cycle, such as HSV-1 
attachment and entry and IE-gene transcription, occur and likely no unfolding of viral DNA, 
from double-stranded DNA to single-stranded DNA, takes place. In accordance with 
literature, GFP-VP16 was barely visible at 2 h.p.i., whereas GFP foci became clearer from 4 
h.p.i. 
At later stages (14 h.p.i. and after), once HSV-1 replication occurred, the fluorescence 
determined by 1H6 binding to G-quadruplex structures gradually decreased (Figure 4.3.8f). 
However, between 14 and 16 h.p.i., red foci mainly localized at the nuclear membrane, most 
likely due to the nuclear egress of nucleocapsids to the cytoplasm of cells. This peculiar 
behavior was not detectable after 16 h.p.i. (Figure 4.3.8f).  
No background was recorded by incubating mock-infected/infected cells with alexa-546 
(1/500) and DRAQ5
®
 1/1000 only, in the absence of the primary antibody 1H6 (Figure 
4.3.9b,c, background). 
The different procedure, used to fix HHV-6B infected Molt-3, made impossible a good 
execution of immunofluorescence in the presence of 1H6, while pure acetone is not suitable 
for this antibody. 
Taken together, data suggested a highly specific interaction between 1H6 and viral G-
quadruplex DNA structures. In fact, the increase of fluorescence occurred at viral replication 
fundamental steps (6-9 h.p.i.), whereas it was inhibited by treating infected cells with 
replication inhibitors. Interestingly, these data constitute the first evidence of virus-related G-
quadruplex formation in infected cells. 
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Figure 4.3.8 Immunofluorescence assay with 1H6 on Vero cells infected with a recombinant HSV-1 strain F 
(MOI 0.5), the GFP-expressing recombinant virus V41, which promotes the release of the GFP-fused VP16. 
Cells were fixed and analyzed at different time points: b) 2 h.p.i., c) 4 h.p.i., d) 6 h.p.i., e) 9 h.p.i., f) 14 h.p.i., 
whereas a) mock-infected Vero cells were used as control. Green fluorescence is the signal of GFP-fused VP16; 
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red fluorescence was achieved by incubating infected and fixed cells with 1H6 antibody (1µg/ml) and, 
subsequently, with an anti-mouse alexa Fluor-546 secondary antibody (1/500). Nuclear staining for DNA, 
highlighted as a blue signal, was achieved by incubating Vero cells with DRAQ5
®
 (1/1000). At the top of each 
figure, merge of signals is on the left side and GFP signal on the right side; at the bottom of each figure, red 
1H6/alexa-546-derived signal is on the left side, while DRAQ5
® 
fluorescence is on the right. e) White arrows 
indicate 1H6 mainly localized at the nuclear membrane. In each panel, pictures at 20X (at the top) and 60X (at 
the bottom) are shown. 
 
 
 
 
Figure 4.3.9 Immunofluorescence assay on a) infected Vero cells treated with PAA to block viral replication; b) 
mock-infected or c) infected Vero cells to test the background of the reagents used to perform experiments. Fort 
the infection, the recombinant V41 HSV-1 was used at a MOI of 0.5. Cells were fixed at 6 h.p.i. and incubated 
with alexa Fluor-546 (1/500) and DRAQ5
®
 (1/1000) only to test a background signal (b, c), or also with the 
primary antibody 1H6 (a). At the top of each figure, merge of signals is on the left side and GFP signal on the 
right side; at the bottom of each figure, alexa-546 signal (referred to 1H6) is on the left side, while DRAQ5
® 
fluorescence is on the right. In each panel, pictures at 20X are shown. 
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4.4 ANALYSIS OF VIRAL PACKAGING SEQUENCES BY 
CIRCULAR DICHROISM 
 
In the present study, we demonstrated the presence of extensive clusters of G-4 forming 
sequences that are able to form highly stable G-quadruplex structures. More specifically, 
some of these clusters, un3 sequences in HSV-1 and tandem repeats of the human telomeric 
sequence in HHV-6, are located nearby the domains pac1 and pac2 needed for viral cleavage 
and packaging. 
HSV-1 encodes six proteins (UL6, UL15, UL17, UL28, UL32, UL33), which are necessary 
for DNA cleavage and packaging, as previously described in detail, and homologs of these 
proteins are also present in HHV-6 (U12, U36, U50, U60, U66).  
For HSV-1, the protein UL28 is required for the cleavage of concatameric DNA into viral 
procapsids. In 2001, it was reported by the group of Prof. Joel D. Baines that G-rich DNA 
fragments, containing the pac1 DNA packaging motif, can be induced by heat treatment to 
adopt “novel” DNA conformations, able to migrate faster than the corresponding duplex in 
non-denaturing gels. Interestingly, it was proved that UL28 protein displayed a very high 
binding-affinity for these novel DNA structures, whereas double-stranded DNA of identical 
sequence composition is not recognized by the protein. They also demonstrated that only one 
strand of the pac1 motif (G-rich strand) is responsible for the formation of these unusual 
DNA structures (Adelman, et al., 2001).  
We hypothesized that these novel conformations are indeed G-quadruplex structures and, 
therefore, we analyzed these reported wild-type (wt) and mutated HSV-1 packaging 
sequences (Table 2) with circular dichroism, in order to verify whether the “novel” reported 
DNA conformations are effectively G-quadruplex structures. In fact, published evidences 
showed that the folding into this particular DNA conformation appears crucial for viral 
cleavage/packaging (Adelman, et al., 2001). For this reason, whether a folding into G-
quadruplex occurs, targeting the viral genome at this level could actually constitute a 
promising G4-related site of action in innovative antiviral strategies.  
We also tested the pac1 motif of HHV-6, which differs in HHV-6A and HHV-6B (Table 6) 
(Thomson, et al., 1994).  
Given the high number of guanosines in HSV-1 packaging sequences, we recorded CD 
spectra in the absence or presence of KCl 50 mM. In the case of HHV-6, pac1 sequences are 
characterized by a lower amount of G bases, therefore CD spectra were recorded in the 
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absence or presence of KCl 100 mM. HSV-1 packaging sequences were also tested in the 
presence of BRACO-19 (16 μM). 
All wt and mutated HSV-1 packaging sequences showed a parallel conformation in the 
absence of K
+
, in physiological conditions and also after the addition of BRACO-19 (Figure 
4.4.1, 4.4.2). However, mutations of some bases strongly affected the stability of these 
sequences during thermal unfolding, especially for mut L-poly G and mut T-rich (Figure 
4.4.2).  
 
 
Figure 4.4.1 CD thermal denaturation analysis in the presence of the wild-type HSV-1 pac1 sequence and a 
mutated form (mut R-poly G sequence). CD spectra of the indicated oligonucleotides (4 µM) were recorded in 
the absence of K
+
 (a, d), in the presence of K
+
 50 mM (b, e), or in the co-presence of K
+
 50 mM and the G-
quadruplex ligand BRACO-19 (16 µM) (c, f). Arrows indicate spectra progression during temperature 
increasing.  
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Figure 4.4.2 CD thermal denaturation analysis in the presence of two mutated HSV-1 packaging sequences, mut 
L-poly G and mut T-rich. CD spectra of the indicated oligonucleotides (4 µM) were recorded in the absence of 
K
+
 (a, d), in the presence of K
+
 50 mM (b, e), or in the co-presence of K
+
 50 mM and the G-quadruplex ligand 
BRACO-19 (16 µM) (c, f). Arrows indicate spectra progression during temperature increasing. 
 
In the absence of K
+
, mut L-poly G displayed the highest Tm (72.11°C) (Figure 4.4.2a), and it 
was further stabilized by K
+
 50 mM and BRACO-19 (Figure 4.4.2b,c) (Table 12). HSV-1 
pac1 showed a Tm of ~41°C, but an incredibly high stabilization was determined by adding 
BRACO-19 (over 60°C) (Table 12). The less stable oligonucleotide is mut L-poly G, thus 
indicating a crucial role of two cytosines followed by four guanines in the first G-tract of the 
HSV-1 pac1 sequence during the folding into G-quadruplex. Given the lower stabilization of 
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mut T-rich induced by K
+
 or BRACO-19 (Figure 4.4.2d,e,f and Table 12), also the T-rich tract 
appeared indispensable for G-quadruplex formation and stability. 
 
HSV-1 (wt/mutated) packaging sequences 
Oligo K
+
 0 mM K
+
 50 mM K
+ 
50 mM+B19 
ΔTm (K+ 
50mM/no K
+
) 
ΔTm (K+ 50 
mM+B19/no K+) 
HSV-1 pac1 40,99 ± 0,94 60,48 ± 0,5 >100 19,5 >59,01 
Mut. L-poly G 32,76 ± 1,7 35,55 ± 1,64 39,42 ± 8,58 2,8 6,7 
Mut. T-rich 53,99 ± 0,76 56,22 ± 0,3 67,07 ± 1,2 2,23 13,1 
Mut. R-poly G 72,11 ± 0,47 91,15 ± 6,9 >100°C 19,04 >27,9 
HHV-6 packaging sequences 
Oligo K
+
 0 mM K
+
 100 mM  
ΔTm (K+ 
100mM/no K
+
) 
 
HHV-6A pac1 67,31 ± 2,79 >100 - >32,9 - 
HHV-6B pac1 55,67 ± 0,94 67,24 ± 3,26 - 11,57 - 
Table 12 Stability of HSV-1 and HHV-6 G-quadruplex folding packaging sequences measured by CD, in the 
presence/absence of K
+
 (50 or 100 mM), and BRACO-19 (B19, 16 μM) in the case of HSV-1 sequences. Values 
are indicated as Tm (°C). 
 
 
 
 
Figure 4.4.3 CD thermal denaturation analysis in the presence of HHV-6A pac1 and HHV-6B pac1 sequences. 
CD spectra of the indicated oligonucleotides (4 µM) were recorded in the absence of K
+
 (a, c) and in the 
presence of K
+
 100 mM (b, d). Arrows indicate spectra progression during temperature increasing. 
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Similarly to HSV-1 packaging sequences, HHV-6A pac1 and HHV-6B pac1 sequences 
exhibited a parallel G-quadruplex topology, characterized by very high molar ellipticities 
(Figure 4.4.3). Although the major stability displayed by the pac1 sequence of HHV-6A 
(U1102 strain), both sequences were very stable in the absence of K
+
, with Tm between 56-
68°C, whereas the addition of K
+
 (100 mM) further stabilized the G-quadruplex structures of 
~12°C for HHV-6B pac1 and over 33°C for HHV-6A pac1 (Figure 4.4.3 and Table12). 
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5 CONCLUSIONS 
 
In this work we have found that the GC-rich HSV-1 genome presents 6 extended repeated 
clusters of G-quadruplex forming sequences, covering 1100 bp on the leading strand and 920 
bp on the lagging strand (Figure 4.1.1 and Table 9). The a sequence, which embedded the un3 
G-quadruplex forming tract, has been shown to sustain multiple essential viral functions: it 
supports recombination with high efficiency (Smiley, et al., 1990), despite being dispensable 
for isomerization (Martin & Weber, 1996); it contains the packaging signal and the cleavage 
site of concatemeric DNA (Smiley, et al., 1992). Importantly, the un3 cluster corresponds to 
the promoter of the gene that encodes the γ134.5 protein (Chou & Roizman, 1986). The γ134.5 
gene itself is located in the inverted repeats of the b sequence of the L component and it is 
present in two copies per genome (Ackermann, et al., 1986). This protein has initially been 
shown to contribute to HSV neurovirulence in vivo. Indeed, HSV-1 mutants that fail to 
express the γ134.5 protein are incapable of multiplying and causing encephalitis in 
experimental animal models (Chou, et al., 1990), (Chou & Roizman, 1994). However, 
collecting evidence suggests that the γ134.5 protein is a multifunctional protein. Among other 
roles, the γ134.5 protein is implicated in HSV-1 DNA replication since its carboxyl-terminal 
domain complexes with PCNA (proliferating cell nuclear antigen), a nuclear protein involved 
in DNA replication and cell cycle regulation (Harland, et al., 2003). In addition, the γ134.5 
protein has been shown to facilitate the initiation of protein translation in infected cells by 
bridging eukaryotic initiation factor eIF2α and protein phosphatase PP1α (He, et al., 1997), 
mechanism by which it blocks autophagy in cascade signal pathway (Lussignol, et al., 2012), 
(Orvedahl, et al., 2007). 
Very interestingly, the DR2 segment present in the a region, which overlaps exactly with our 
un3 sequence, has been shown to form an unwound, nuclease sensitive conformation of non-
B DNA, called anisomorphic DNA (Sarisky & Weber, 1994), that entirely matches with the 
G-quadruplex structure presented here. Notably, this region has been shown to mediate 
transcriptional repression only in its anisomorphic DNA conformation (i.e. the G-
quadruplex).  This conformation perfectly correlates with the notion that G-quadruplex acts as 
transcriptional silencers, in addition it has been shown to be bound by the eukaryotic 
transcription factor SP1 (Chung, et al., 1995), which again has been involved in G-
quadruplex-mediated regulation of transcription in human cells (Todd & Neidle, 2008). 
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The viral functional role of the remaining repeat regions possessing the ability to fold into G-
quadruplex has been less extensively studied than the a sequence. Their complexity and 
importance is however evident: the inverted repeats of the L and S component contain the α 
genes 0 and 4, respectively, in their entirety (Chou & Roizman, 1986), (Perry & McGeoch, 
1988). These genes encode ICP0 and ICP4 proteins, which are fundamental transcriptional 
activators. In addition, two HSV-1 origins of DNA replication (OriS) are localized in the 
TRS/IRS repeated region of the viral genome (Stow, 1982). To note, however, that the 
identified G-quadruplex forming regions were close but not embedded in these functional 
sequences. 
The analyzed G-quadruplex forming sequences in the HSV-1 genome displayed distinctive 
features: for example, the gp054 oligonucleotide series only formed dimers. G-quadruplex 
dimer formation is required in HIV to promote virus recombination by strand transfer 
(Piekna-Przybylska, et al., 2013). Among the gp054 oligonucleotides, gp054d stands out for 
its improved stability. Interestingly, this is the only sequence that presents one C base in the 
loop and displays identical CT loops. It has been reported that C can also be involved in G-
quartet formation (Lim, et al., 2009), therefore it is possible that C bases augment the folding 
stability of this sequence. 
The general remarkably high stability of the HSV-1 G-quadruplex forming sequence is an 
intriguing aspect: in physiological conditions all but one sequence (un3) displayed Tm around 
90°C and were capable of folding into tetraplex even in the absence of K
+
. Therefore, during 
temporary DNA unfolding which occurs in replication and transcription, these sequences in 
their single-stranded form are very likely to fold into G-quadruplex. In eukaryotes and 
prokaryotes, G-quadruplex have been implicated in genetic instability (Ribeyre, et al., 2009), 
genome rearrangements (Cahoon & Seifert, 2009), chromosome end capping (De Cian, et al., 
2008) and control of gene expression. In promoter and gene coding sequences, G-
quadruplexes were proposed to serve as loading platforms for gene regulatory factors 
enabling, for example, rapid activation of gene transcription under stress conditions 
(Helmrich, et al., 2013). In addition, G-quadruplex motifs have been associated with over 
90% of DNA replication origins (Besnard, et al., 2012). It is therefore plausible that the G-
quadruplex forming regions in the HSV-1 genome display multiple yet non-identified 
functions required for the viral biology.  
The porphyrin TMPyP4 (Shi, et al., 2001), (Yamashita, et al., 2005) and BRACO-19, a tri-
substituted acridine (Harrison, et al., 2003) (Read, et al., 2001), both characterized by 
Conclusions 
 
121 
 
excellent G-quadruplex binding properties (Phatak & Burger, 2007), have been employed 
here to check the effect of the stabilization of HSV-1 G-quadruplex forming regions.  
We have shown that TMPyP4 and BRACO-19 stabilized all tested sequences. In particular, 
BRACO-19 was able to arrest viral DNA processing by Taq polymerase in vitro, while in 
infected cells this activity resulted in early inhibition of viral replication (less viral DNA was 
synthesized in treated cells), generalized shut down of late viral mRNA levels and overall, in 
inhibition of viral production. The time of addition assay indicated an early time range of 
activity (within 8 h.p.i.), similarly to ACV which targets viral DNA polymerase. Altogether 
these data indicate that BRACO-19 targets early viral mechanisms, such as viral replication 
by directly inhibiting the replication machinery or by inhibiting functions in trans, like the 
γ134.5 promoter activity. In contrast, no specific inhibition of the UL36 protein was observed 
(Figure 4.1.10, 4.1.12e).  
Very promising results were further provided by TMPyP4, tested on HSV-1 infected Vero 
cells. Data suggested that TMPyP4 exploits its antiviral activity by interfering with the γ134.5 
promoter thought alternative mechanisms of action, in comparison to those of BRACO-19. 
TMPyP4 displayed a strongly significant antiviral activity against HSV-1 in collected 
supernatants, even higher than the inhibitory effect of BRACO-19. However, plaque assay 
showed the presence of infectious HSV-1 particles within treated cells (Figure 4.1.18). TEM 
analysis proved that HSV-1 remains entrapped in vesicles located in the cytoplasm of cells, 
nearby the nucleus. Given the high similarities of these HSV-1-containing vesicles to 
autophagosomes, two TMPyP4-induced mechanisms of action were hypothesized to occur: 1) 
TMPyP4 affects HSV-1 maturation/egress and 2) TMPyP4 acts by stabilizing un3 G-
quadruplex forming sequences, which results in an altered expression of the γ134.5 protein 
and thus in autophagy induction. Indeed, these two mechanism may converge in just one 
common mechanism, since the presence of un3 cluster within the promoter of γ134.5 gene can 
impact on the γ134.5 protein expression, which has been related to HSV-1 maturation/ egress 
regulation (Brown, et al., 1994), and autophagy regulation (Lussignol, et al., 2012), 
(Orvedahl, et al., 2007), (Le Sage & Banfield, 2012).  To this end, the co-treatment of HSV-1 
infected Vero cells with both TMPyP4 and 3-MA counteract the antiviral efficacy of TMPyP4 
of up to 20%, by specifically reducing autophagy process (Le Sage & Banfield, 2012). Further 
experiments, such as the use of a ICP34.5-deleted HSV-1 mutant and quantification of 
ICP34.5 after treatment with TMPyP4, are ongoing to confirm these hypothesis. 
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Interestingly, these differential mechanisms of action of BRACO-19 and TMPyP4 could be 
ascribable to a different interaction between G-quadruplex ligands and G-quadruplex 
topologies. 
The antiviral activity of TMPyP4 and BRACO-19 was compared to that of TMPyP2, a 
molecule which shares similar chemical features but shows a much lower binding affinity 
towards G-quadruplexes (Han, et al., 2001). At the highest concentrations, TMPyP2 displayed 
a moderate HSV-1 inhibitory capability, which might be mediated by G-quadruplex 
interaction as well (Le, et al., 2013). However, based on the observation that TMPyP2 was 
essentially inactive in other assays, it cannot be excluded that TMPyP2 at high doses displays 
anti-HSV-1 activity via a non-G-quadruplex related mechanism, or that the instability of the 
porphyrin derivatives might contribute to the observed differences. 
It has to be noted that only large clusters of G-quadruplex sequences have been considered in 
this work: additional single tetraplexes in key regions of the HSV-1 genome (i.e. promoters of 
early key genes) may be present and participate to the antiviral activity of the compound. 
Since its first introduction in the 1980s, ACV has been the antiviral drug of choice for the 
treatment of HSV-1 infections (Vere Hodge & Field, 2013). However, the emergence of 
resistance to ACV has created an obstacle for the treatment of HSV-1 (Bacon, et al., 2003).  
Moreover, because of the inherent different mechanism of action, G-quadruplex ligands could 
be envisaged as therapeutic options against HSV-1 strains resistant to current anti-herpetic 
drugs. 
This work has provided the first evidence of 1) large clusters of repeated G-quadruplex 
folding sequences in the HSV-1 genome; 2) the possibility to target them with G-quadruplex 
ligands; 3) BRACO-19-mediated antiviral effects during early events of the viral life cycle, 
such as DNA replication or promoter activity/expression of genes that control viral replication 
and transcription (Figure 4.1.10, 4.1.24); 4) TMPyP4-mediated antiviral effects during HSV-1 
maturation/egress events by stimulating autophagy process, due to a minor expression of 
γ134.5 protein as a consequence of the G-quadruplex presence in the promoter of γ134.5 gene.  
The great capacity of TMPyP4 and BRACO-19 to also inhibit both HHV-6A and HHV-6B 
indicates that G-quadruplex can be considered a promising innovative anti-herpetic target. 
The visualization of G-quadruplex structures in cells, which has always constituted an 
ambitious challenge, was recently achieved using specific antibodies able to selectively binds 
to G-quadruplex DNA structures (Biffi, et al., 2013), (Henderson, et al., 2013). 
For the present study, detection of viral DNA G-quadruplexes in infected cells is strongly 
necessary to support and confirm the presence of this particular secondary conformation of 
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DNA in the genome of viruses, as HSV-1. The visualization of viral G-quadruplex, in 
addition, can prove the role of G-quadruplex itself during essential events of the viral 
replication cycle, therefore the importance of targeting it in successful novel antiviral therapy, 
which could be capable to potentially eradicate the virus from the host. As shown, the use of 
the monoclonal antibody 1H6, showing high selectivity for G-quadruplex structures, for the 
first time allowed us to reach this very ambitious goal. A strong increase of red foci, relative 
to the binding of 1H6 with DNA G-quadruplex structures, were observed between 6 and 9 
h.p.i., in which viral DNA is locally unwound to facilitate the replication of HSV-1. The 
increasing fluorescence in such a crucial time point, in comparison with mock-infected cells, 
suggested a specific interaction between the antibody and viral G-quadruplexes, over cellular 
G-quadruplex structures. An additional proof a specific interaction between 1H6 and viral G-
quadruplex structures was provided by treating infected cells with PAA, known to specifically 
improve viral replication. In fact, the treatment reduced the fluorescence raising. 
Therefore, this work provides a proof of concept for the development of selective anti-
herpetic agents with an innovative mechanism of action which could prove useful also in the 
treatment of viral strains resistant to current anti-herpetic drugs. Although data successfully 
propose G-quadruplex as a very promising antiviral strategy, rational design of small 
molecules, able to selectively recognize viral G-quadruplexes versus the eukaryotic structures 
and improve this binding, is undoubtedly necessary.  
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